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Not long after starting the zebrafish work, the opportunity to work on a mouse 
project with a fairly large scope became too enticing, especially when some hiccoughs in 
the zebrafish work hampered my progress. It was in this way that I began my studies of 
mouse muscle.  
We had initiated a project to directly test the hypothesis that myotubular 
myopathy (MTM) was caused by a dysregulation—namely, a buildup—of PtdIns(3)P in 
cells, due to mutations in MTM1. The strategy for manipulating the system seems 
imminently simple on paper: reduce production of PtdIns(3)P on the MTM background, 
and cure the disease. Regulation of PtdIns(3)P is a highly dynamic and integral 
component of many cellular processes, involving many proteins that act as regulators or 
effectors of the lipid. Therefore, there are many targets (proteins) to choose from when 
aiming to shift the balance of PtdIns(3)P synthesis or metabolism.  
This dissertation introduces and explains some of the targets of our manipulations, 
and provides insight in regard to the role of selected regulators of phosphatidylinositol 3-
phosphate in skeletal muscle. The first chapter is an introduction to many of the topics 
covered in my studies, including the (difficult to say) phosphoinositides, or more 
specifically (and more difficult to say), phosphatidylinositol phosphates. The second, 
third and fourth chapters introduce unique lines of mice harboring genetic mutations 
targeted to skeletal muscle: (mainly) Sac3/Fig4, Vps34/Pik3c3 and PI3K-C2β/Pik3c2β, 
respectively. The final chapter proposes work for the future, and some of the challenges 
awaiting future basic research and clinical practice. 
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X-linked myotubular myopathy (MTM) is a severe centronuclear myopathy, 
characterized by profound weakness and hypotonia at birth, early mortality, and 
significant morbidities. MTM results from mutations in the phosphoinositide phosphatase 
myotubularin (MTM1), which dephosphorylates the lipid substrates phosphatidylinositol 
3-phosphate (PtdIns(3)P) and phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). We 
propose that dysregulation of PtdIns(3)P and PtdIns(3,5)P2 leads to the disease state in 
MTM, and that these lipids play a significant role in muscle development and 
homeostasis. To elucidate the effect of PtdIns(3)P dysregulation in MTM, we examined 
several mouse models with targeted inactivation of phosphoinositide phosphatases (Mtm1 
and Fig4) and kinases (Pik3c3 and Pik3c2β).  
Previous studies showed that tissue-specific neuronal rescue of the spontaneously 
occurring Fig4 mutation of pale tremor (plt) mice prevented overt muscle weakness and 
the development of obvious muscle abnormalities. Our studies confirmed that the 
changes in skeletal muscle observed in the plt mice were primarily related to denervation. 
Fig4 deletion had previously been shown to rescue aspects of Mtmr2-dependent 
neuropathy, so we evaluated the effect of Fig4 haploinsufficiency on the myopathy of 
Mtm1-knockout mice. Compared with Mtm1–/Y males, mice with the genotype 
Fig4+/−/Mtm1–/Y displayed no improvement in muscle histology, muscle size, or 
longevity, indicating that reduction of FIG4 does not ameliorate the Mtm1-knockout 
phenotype. 
To further investigate the function of PtdIns(3)P in skeletal muscle, we focused 
on the primary kinase responsible for its production, and created a muscle-specific 
conditional knockout of the class III PI 3-kinase, Pik3c3. This resulted in progressive 
disease characterized by reduced activity and death by two months of age. 
Histopathology demonstrated changes consistent with a murine muscular dystrophy. 
 xx 
Mechanistic evaluations revealed significant alterations in the autophagolysosomal 
pathway with mislocation of known dystrophy proteins to the lysosomal compartment. 
We present the first analysis of Pik3c3 in skeletal muscle, and report a novel association 
between deletion of Pik3c3 and muscular dystrophy. 
In contrast, muscle-specific deletion of Pik3c2β caused no overt physiological 
defects by 11 months of age, other than impaired glucose tolerance. These studies 
demonstrate the critical role of PIK3C3 in muscle physiology and give insight to some of 






The focus of this dissertation is to examine the role of phosphatidylinositol 
phosphates (PtdInsPs)2 and the kinases and phosphatases that regulate them in the context 
of skeletal muscle health. For an introduction to the topic, there is an overview and 
description of PtdInsP, including their structure, regulation and functions. Next, the focus 
shifts to two isoforms in particular, PtdIns(3)-monophosphate and PtdIns(3,5)-
bisphosphate, that are described in detail. The connection of PtdInsPs to muscle disease 
focuses on the X-linked centronuclear myopathy: myotubular myopathy (MTM). Last is 
the introduction to chapters two through four, which describe projects involving the use 
of mice with mutations in specific kinases and phosphatases that regulate the 
phosphorylation of the PtdInsP-isoforms. 
 
1.1 PtdInsPs 
1-(3-sn-Phosphatidyl)-D-myo-inositol, or more simply, phosphatidylinositol 
(PtdIns), is the base for a family of lipid-phosphates, collectively referred to herein as 
PtdInsPs. These molecules participate in a number of signaling pathways and serve 
crucial roles in the organization and trafficking of membranes in cells. PtdInsPs are of 
relatively low-abundance, but are present in almost all cell types across eukaryotic 
species (De Camilli, Emr et al. 1996, Lindmo and Stenmark 2006, Volpicelli-Daley and 
De Camilli 2007, Nicot and Laporte 2008, Balla, Wymann et al. 2012, Falasca 2012, 
Maffucci 2012). Dysregulation of PtdInsPs has been implicated in a number of human 
diseases, including Charcot-Marie-Tooth (CMT) (Bolino, Bolis et al. 2004, Nicholson, 
Lenk et al. 2011), amyotrophic lateral sclerosis (ALS) (Chow, Landers et al. 2009), and 
                                                
2 Nomenclature for phosphatidylinositol phosphates as “PtdInsP” in this dissertation is based on guidelines 
from IUBMB and IUPAC (www.iubmb.org; http://www.chem.qmul.ac.uk/iupac/misc/phos2t8.html#t4). 
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other neuropathies and myopathies (Amoasii, Hnia et al. 2012, Hakim, Bertucci et al. 
2012). 
The synthesis and localization of PtdInsPs are regulated by phosphoinositide (PI) 
kinases and phosphatases that reversibly phosphorylate PtdIns at the 3-, 4- and 5- 
positions of the myo-inositol (Ins)3 head group. This results in a group of seven unique 
and dynamically inter-convertible PtdInsP isoforms (Michell, Heath et al. 2006) (Figure 
1.1). Regulation of PtdInsP metabolism is a highly conserved process with many of the 
genes encoding regulatory enzymes having close homologues across species (Boss and 
Im 2012). In fact, much of the seminal and ongoing work to understand the interactions 
among the various kinases and phosphatases that regulate PtdInsPs come from studies 
using Saccharomyces cerevisiae, as yeast provide a simple representative model of many 
similar processes involved in membrane and vesicle dynamics in mammals (Weisman 
2006, Strahl and Thorner 2007). 
One of the challenges to this line of work is in the detection of these lipids. There 
is a great interest and an ongoing effort to develop new techniques for detecting the 
individual phospho-isoforms of PtdInsP in vivo, but many of the analyses contained 
herein utilize indirect approaches to measure PtdInsPs. Some of these techniques take 
advantage of probes based on the recognition domains of proteins containing specific 
motifs for selecting a PtdInsP isoform. These domains are reviewed in detail (Lemmon 
2003, Maffucci 2012), and allow for proper trafficking of proteins to membranes, and the 
membranes to their destinations.  
While our understanding of the biology of PtdInsPs is constantly expanding, the 
scope of my work focuses primarily on the conversions of PtdIns to Phosphatidylinositol 
3-phosphate (PtdIns(3)P) and of PtdIns(3)P to Phosphatidylinositol 3,5-bisphosphate 
(PtdIns(3,5)P2), with some consideration of Phosphatidylinositol 5-phosphate 
(PtdIns(5)P) (Figure 1.2). The various PtdInsPs, and the mono-phosphorlyated forms, in 
particular, are very short lived, and can be metabolized within minutes under normal 
physiologic conditions (Michell, Heath et al. 2006). Of the PtdInsPs, PtdIns(3,5)P2 is one 
                                                
3 The use of Ins for myo-inositol (Agrinoff’s “turtle”: see Fisher, S. K., J. E. Novak and B. W. Agranoff 
(2002). "Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional 
significance." J Neurochem 82(4): 736-754.) is not meant to diminish the importance of the other eight 
sterioisomers of inositol found in nature. For example, scyllo-inositol is one of the more aesthetically 
pleasing arrangements from a pure symmetry perspective. 
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of the least abundant, comprising only ~0.05% of the total population of PtdInsPs (Shen, 
Wang et al. 2011). Flux between PtdIns(3)P and PtdIns(3,5)P2 regulates processes 
including endocytosis, endosomal trafficking, and autophagy (Itoh and Takenawa 2002, 
Payrastre 2004, Di Paolo and De Camilli 2006, Michell, Heath et al. 2006, Lecompte, 
Poch et al. 2008).  
PtdIns(3)P is critical in the initiation of autophagosome formation, recruiting and 
organizing effectors that elongate and close the membrane (Vergne and Deretic 2010). 
PtdIns(3)P has been shown to be localized to the limiting membranes of early 
endosomes, and is also seen to be internalized in the yeast vacuole (Gillooly, Morrow et 
al. 2000). When individual regulators of PtdIns(3)P are mutated or inhibited, negative 
consequences have been observed including abnormal vacuolization in cells, defective 
autophagy, neurodegeneration, and muscle diseases among others (Vergne and Deretic 
2010, Rommel, Vanhaesebroeck et al. 2011). Some genetic mutations, as in the case of 
Pik3c3, are embryonic lethal in mice (Zhou, Takatoh et al. 2011). 
PtdIns(3)P is created primarily through phosphorylation of PtdIns at the 3 
position by PI 3-kinases (PI3Ks) (Backer 2008, Meijer and Klionsky 2011), or through 
dephosphorylation of PtdIns(3,5)P2 by FIG4 (Jin, Chow et al. 2008). In yeast, there is 
only one kinase known to produce PtdIns(3)P, and that is Vps34, the Class III PI3K 
known as Pik3c3 in mammals. There are three classes of mammalian PI3Ks that are 
capable of producing PtdIns(3)P from PtdIns in vitro, with varying tissue expression and 
substrate specificity (Foster, Traer et al. 2003, Yan and Backer 2007, Vanhaesebroeck, 
Guillermet-Guibert et al. 2010). The Class I PI3Ks contribute specifically to the 
formation of PtdIns(3,4,5)P3 in vivo, while PIK3C3 and the α- and β-forms of the Class 
II PI3Ks are responsible for PtdIns(3)P in mammalian cell types.  
A group of related 3-phosphatases that convert PtdIns(3)P to PtdIns and also 
PtdIns(3,5)P2 to PtdIns(5)P is a subset of the myotubularin related (MTMR) protein 
family, including MTM1, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, 
MTMR8 and MTMR14 (Vergne and Deretic 2010). Mutations in MTM1 result in X-
linked myotubular myopathy, with MTMR14 playing a significant role as a disease 
modifier (Dowling, Low et al. 2010). Mutations in MTMR2 and MTMR13 result in forms 
of CMT neuropathies (Amoasii, Hnia et al. 2012). As the interconversion of PtdIns(3)P 
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to PtdIns(3,5)P2 is highly important in regulating autophagic pathways, MTMRs have 
been shown to play an important role in activation and control of autophagy under both 
normal and starvation conditions (Dowling, Low et al. 2010, Vergne and Deretic 2010). 
Many of the MTMRs are capable of forming dimmers with other family members, 
increasing specificity and activity of the phosphatases (Clague and Lorenzo 2005). 
Additionally, it has been shown that certain MTMRs, such as MTM1 and MTMR2, bind 
with the regulatory subunit (PIK3R4) of the primary 3-kinase responsible for creating 
PtdIns(3)P, and thereby act as an inhibitor of phosphorylation in addition to their function 
as phosphatases (Cao, Laporte et al. 2007, Vergne and Deretic 2010). Extensive studies 
of the relationship between MTM1 and MTMR14 in zebrafish showed a significant 
deleterious effect on skeletal muscle, recapitulating features of the disease state seen in 
humans with MTM1 mutations (Dowling, Low et al. 2010).  
Since its first reports in 1997 (Dove, Cooke et al. 1997, Whiteford, Brearley et al. 
1997), PtdIns(3,5)P2 has gained appreciation for its ever-increasing number of proposed 
roles, including the initiation of autophagy and other processes involved in cellular 
trafficking (Ho, Alghamdi et al. 2012, McCartney, Zhang et al. 2013). One of the most 
consistent phenotypes from PtdIns(3,5)P2 dysregulation is the formation of enlarged 
vacuoles, indicating a failure to properly regulate membrane trafficking between 
endosomes and lysosomes. Deletion of key components that regulate interconversion 
between PtdIns(3)P and PtdIns(3,5)P2 in yeast results in vacuoles with lower acidity than 
in wild type vacuoles (Yamamoto, DeWald et al. 1995, Bonangelino, Catlett et al. 1997). 
PtdIns(3,5)P2 also plays a role in cytosolic assembly of nuclear-translocating factors such 
as Cti6-Cyc8-Tup1 complexes by way of a binding motif in Tup1 (Han and Emr 2011). 
In addition, work from the Xu lab has discovered a very important role for PtdIns(3,5)P2 
in the activation of lysosomal ion channels (Shen, Wang et al. 2011). Several studies 
have also described a role of PtdIns(3,5)P2 in the activation of the ryanodine receptor in 
cardiac (Touchberry, Bales et al. 2010) and skeletal muscle (Shen, Yu et al. 2009).  
PtdIns(3,5)P2 is primarily generated from PtdIns(3)P by the action of PIKfyve, a 
PtdIns 5-kinase that functions in a complex of proteins in yeast that includes the PtdIns 5-
phosphatase, Fig4, and regulatory proteins such as Atg18, Vac14, and Vac7 (Gary, Sato 
et al. 2002, Duex, Tang et al. 2006, Jin, Chow et al. 2008, Zolov, Bridges et al. 2012). 
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PtdIns(3,5)P2 is metabolized by FIG4 (Sac3) to regenerate PtdIns(3)P, and by a family of 
three-position phosphatases, collectively known as myotubularin-related (MTMR) 
proteins, to generate PtdIns(5)P (Robinson and Dixon 2006, Tosch, Rohde et al. 2006, 
Dyson, Fedele et al. 2012, Hakim, Bertucci et al. 2012). Reduced abundance of FIG4 
protein destabilizes PIKfyve, resulting in a threefold reduction of PtdIns(3,5)P2 relative 
to total PtdIns levels (Chow, Zhang et al. 2007). 
 
1.2 PtdInsPs are regulators of muscle development and homeostasis 
Development of proper skeletal muscle mass and function depends on a signaling 
axis involving the insulin like growth factor (IGF), protein kinase B (PKB or Akt), and 
mammalian target of rapamycin complex 1 (mTORC1) (Hamilton, Philp et al. 2010). 
While the exact process of muscle growth is still not completely clear, there is a direct 
pathway from PtdIns(3,4,5)P3 dependent activation of Akt that leads to signaling 
pathways to increase muscle mass (Bodine, Stitt et al. 2001). Inhibition of 
phosphorylation or activity of the kinases in the pathway result in muscle atrophy and 
prevent muscle growth (Bodine, Stitt et al. 2001). 
Muscle atrophy has been shown to be regulated by ubiquitin ligases such as 
MuRF1 and Atrogin-1, which target thick filament components of sarcomeres for 
degradation by the proteasome (Glass 2010). FoxO transcription factors are responsible 
for the activation of these ubiquitin ligases by transcriptional signaling pathways, but 
their activity is neutralized by Akt-dependent phosphorylation, causing the factors to be 
excluded from the nucleus (Glass 2010). This shows that Akt control of muscle growth is 
accomplished through up-regulation of hypertrophy and down-regulation of atrophy 
pathways. 
The FoxO transcription factors also play a significant role in other aspects of 
muscle homeostasis. Following starvation, muscle begins a process of autophagy in order 
to shut down certain elements of the cell to reduce energy expenditure and recycle other 
elements for additional sources of energy. Some of the genes induced in muscle 
following starvation include Bnip3 and Bnip3l, which are directly activated by FoxO3 
binding to enhancers (Mammucari, Milan et al. 2007). Constitutively active Akt is 
 
 6 
sufficient to abrogate the effects of starvation on transcriptional up-regulation of these 
genes, as well as other genes that are central to autophagic pathways, such as Cathepsins, 
Atrogin-1 and LC-3, indicating yet another role for PtdIns(3,4,5)P3 regulated Akt activity 
(Mammucari, Milan et al. 2007). As the network of PtdInsP isoforms is highly 
interconnected, disruption in any of their regulators could potentially have an effect on 
muscle development or homeostasis. 
In addition to regulation of muscle mass, insulin sensitive glucose transport is 
another area that relies upon PtdInsP signaling cascades (Bridges and Saltiel 2012). 
PtdInsP isoforms directly control various aspects including recycling, translocation and 
fusion of GLUT4-containing vesicles that enable the clearing and uptake of blood 
glucose into the muscle (Bridges and Saltiel 2012). Much of this regulation is 
accomplished through PtdIns(3,4,5)P3 activation of Akt and important control of 
exocytosis and endocytosis by PtdIns(4,5)P2 (Di Paolo and De Camilli 2006).  
As GLUT4 continually traffics between the plasma membrane and vesicles that 
are internalized, recycled and pre-exocytic, PtdIns(3)P is also an important isoform in the 
processeses (Bridges and Saltiel 2012). PtdIns(3)P appears to be present in various 
locations within the cell, and numerous studies have shown the presence of accumulated 
pools of PtdIns(3)P at the plasma membrane is co-incident with increased GLUT4 
trafficking and glucose transport in response to insulin (Bridges and Saltiel 2012). 
However, PtdIns(3)P appears to be involved in the localization of GLUT4 to points of 
fusion, and not in the actual process of fusion, which is dependent on other PtdInsP 
isoforms (Bridges and Saltiel 2012). These findings and others suggest that specific 
PtdIns 3-kinases may serve different functions depending on subcellular localization as 
well as other signaling cascades (Maffucci 2012).  
In addition to the PI3Ks’ importance in regards to regulation of insulin signaling, 
another kinase regulating PtdInsP also has a significant impact on insulin regulation: the 
PtdIns 5-kinase, PIKfyve, known as Fab1 in yeast (Duex, Tang et al. 2006). PIKfyve has 
a very complicated relationship with the phosphatase FIG4 (sometimes referred to as 
Sac3 (Sbrissa, Ikonomov et al. 2007)), and the two proteins form a complex with the 
scaffolding protein, VAC14, to regulate the interconversion between PtdIns(3)P and 
PtdIns(3,5)P2 (Duex, Tang et al. 2006). In this way, FIG4 can be thought of as a sort of 
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amphibious enzyme, catalyzing both production and turnover of PtdIns(3,5)P2. 
Nonetheless, mutations in the two genes result in highly deleterious outcomes, with Fig4-
/- resulting in numerous neurological defects in a form of CMT and early mortality and 
Pikfyve-/- resulting in early embryonic lethality (Chow, Zhang et al. 2007, Ikonomov, 
Sbrissa et al. 2011). 
As null mutations in pikfyve are not viable, Shisheva and colleagues created a 
mouse with a muscle-specific deletion using a floxed gene of pikfyve (Ikonomov, Sbrissa 
et al. 2011). These mice exhibited significant glucose intolerance and muscle insulin 
resistance at an early age, followed by increased body weight and adiposity (Ikonomov, 
Sbrissa et al. 2013). Levels of PtdIns(3,5)P2 and PtdIns(5)P were shown to be reduced by 
in vitro lipid kinase activity assays only in skeletal muscle and heart lysates. The 
increases in body weight and adiposity are curious due to the lack of increased fasting 
blood glucose levels by 6 months of age. However, by 10 weeks of age, the knockout 
mice showed significantly increased levels of insulin measured from plasma in fasting 
animals, becoming more prominent by 6 months. Therefore, hyperinsulinemia without 
increased blood glucose could play a role in these observed effects (Ikonomov, Sbrissa et 
al. 2013). 
Studies of myotubularins suggest additional important roles for PtdIns(3)P and 
PtdIns(3,5)P2 in regulation of skeletal muscle health (Laporte, Bedez et al. 2003, Gibbs, 
Feldman et al. 2010, Romero-Suarez, Shen et al. 2010). The mammalian MTMR family 
contains 15 members encoding phosphatases that primarily dephosphorylate PtdIns(3)P 
and PtdIns(3,5)P2 (Hnia, Vaccari et al. 2012). Mutation of MTM1, the canonical member 
of this gene family, causes myotubular myopathy (MTM), a severe congenital onset 
muscle disease associated with altered muscle structure and profound muscle weakness 
(Laporte, Hu et al. 1996). Analyses of lipid content in affected muscle reveals increased 
levels of PtdIns(3)P and possibly PtdIns(3,5)P2 in skeletal muscle (Pierson, Dulin-Smith 
et al. 2012). Mutation of MTM1 compromises multiple aspects of muscle function 
(Amoasii, Hnia et al. 2012), most notably, excitation-contraction (EC) coupling 
(Dowling, Vreede et al. 2009), the process by which neuronal stimulation to muscle is 
translated into calcium dependent muscle contraction. Specifically, MTM1 mutations lead 
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to severe abnormalities in the structure of the EC coupling machinery (Al-Qusairi, Weiss 
et al. 2009, Dowling, Vreede et al. 2009).  
In addition, MTM1 plays a significant role in numerous aspects of muscle 
physiology including regulation of autophagy (Vergne and Deretic 2010), proper function 
of the neuromuscular junction (Dowling, Joubert et al. 2012), desmin intermediate 
filament architecture (Hnia, Tronchere et al. 2011), and other aspects of muscle activity 
such as EC coupling (Dowling, Vreede et al. 2009). Autophagy is robustly induced in 
skeletal muscle following periods of fasting or denervation, and can be maintained at 
much higher levels and longer durations than in many other cell types (Sandri 2010). 
When autophagy is blocked, muscle wasting is accelerated during periods of fasting and 
denervation (Masiero, Agatea et al. 2009).  
Proper function of the neuromuscular junction can be evaluated through tests of 
fatigability and exercise intolerance. Knock-in (KI) of a MTM1 missense mutation 
(p.R69C) in adult mouse skeletal muscle results in significant exercise intolerance and 
fatigable weakness (Dowling, Joubert et al. 2012). Furthermore, treatment with an 
acetylcholinesterase inhibitor, pyridostigmine, reversed the effects of the KI by modest 
gains in grip strength and larger increases in treadmill endurance, suggesting a link 
between disease pathogenesis seen in myotubular myopathy due to the lack of 
phosphatase activity and the overall condition of the neuromuscular junction (Dowling, 
Joubert et al. 2012). 
Another critical role for MTM1 in muscle is found in the interactions between the 
phosphatase and desmin, an intermediate filament essential for positioning and 
movement of organelles, structural support throughout the cytoplasm and nucleus of the 
cell, and a means to reduce mechanical and nonmechanical stress such as during muscle 
contraction (Hnia, Tronchere et al. 2011). MTM1 interacts with desmin in vitro and in 
muscle, and plays a significant role in mitochondrial dynamics and motility, accounting 
for some of the disease characteristics of myotubular myopathy (Hnia, Tronchere et al. 
2011).  
MTMR14 is another myotubularin family member that is important for muscle 
function (Shen, Yu et al. 2009). Loss of MTMR14 in mice results in spontaneous leakage 
of calcium from sarcoplasmic reticulum and causes impaired EC coupling (Shen, Yu et 
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al. 2009). Further studies in zebrafish revealed that unlike mutations in MTM1, loss of 
MTMR14 alters EC coupling without significantly changing the underlying structure of 
the EC coupling machinery (Dowling, Low et al. 2010).  
Direct application of PtdIns(3,5)P2 increases calcium release from microsomes 
containing the intracellular ryanodine receptor calcium release channel (RyR1), a critical 
component of the EC coupling apparatus (Touchberry, Bales et al. 2010). Thus, direct 
regulation of RyR1-dependent stimulated calcium release may represent one important 
role of PtdIns(3,5)P2 and MTMR14. 
 
1.3 Muscle diseases 
Muscle is a highly specialized, highly ordered and highly demanded organ that 
requires precisely coordinated activation. In addition, muscle plays significant roles in 
metabolic processes such as glucose processing and glycogen storage. Due to the 
particular needs of muscle cells, there are many processes that are unique in muscle, in 
terms of structural components and membranes. Furthermore, over the course of 
development, muscle tissue goes through stages of maturation that can be compromised 
by genetic mutations that result in numerous diseases with etiologies deriving from 
neuronal connectivity, extra-cellular matrix components, integral membrane composition 
or any number of signaling pathways (Grounds and Shavlakadze 2011). Some of the 
diseases that affect children include the congenital myopathies and muscular dystrophies, 
which are broad categorizations of numerous disorders, many of which have unknown 
genetic origin (North 2008, Rahimov and Kunkel 2013). 
 
1.3.1 Congenital myopathies 
Congenital myopathies are characterized by a constellation of distinctive 
morphological abnormalities in muscle biopsies that are detected perinatally after 
diagnosis with certain muscle weaknesses, such as in stereotypic facies and respiratory 
difficulties (North 2008). The individual classes of congenital myopathies are primarily 
diagnosed by features in muscle pathology, and there is a great deal of heterogeneity in 
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genetic etiologies (North 2008). Additionally, mutations in the same gene can cause 
multiple pathologies, and in some cases even differences of classification within the same 
individual when biopsied at different ages (Jungbluth, Zhou et al. 2007). This is in 
contrast to muscular dystrophies, which are typically differentiated by gene or 
mechanism of disease (North 2008). The four primary groups by morphology include 
myopathies with centralized nuclei, myopathies with protein accumulation, myopathies 
with cores and myopathies with fiber size variation (North 2008).  
The centronuclear myopathies (CNM) are a subset of congenital myopathies 
classified in accordance with symptoms including early-onset muscle weakness and 
muscle biopsies that reveal extensive internalized or centralized nuclei without evidence 
of degeneration or regeneration (Das, Dowling et al. 2011). The diseases have a range of 
severity, in part due to the heterogeneity of genetic factors, which include autosomal-
dominant forms, such as in mutations of dynamin-2 (DNM2), autosomal-recessive forms, 
such as in amphyphysin-1 (BIN1) and RYR1 mutations, and the X-linked form (MTM), 
due to mutations in MTM1 (Jungbluth, Wallgren-Pettersson et al. 2008, Nance, Dowling 
et al. 2012).  
As previously introduced, MTM is one of the most severe neurologic disorders to 
affect children, characterized by profound weakness and hypotonia at birth, persistent 
life-long disabilities including wheelchair and ventilator dependence, and early mortality 
(Jungbluth, Wallgren-Pettersson et al. 2008, Das, Dowling et al. 2011). The X-linked 
gene MTM1 is a lipid phosphatase that has been shown in vitro to specifically target 
PtdIns(3)P and PtdIns(3,5)P2 for dephosphorylation (Taylor, Maehama et al. 2000). As 
predicted by the preferred substrate for MTM1 being PtdIns(3)P, levels of PtdIns(3)P are 
significantly elevated in animal models of MTM, in which Mtm1 is mutated or deleted 
(Amoasii, Hnia et al. 2012, Pierson, Dulin-Smith et al. 2012).  
 
1.3.2 Muscular Dystrophies 
Unlike the congenital myopathies, muscular dystrophies involve the progressive 
degeneration and weakening of muscle, and are closer tied to specific genes whose 
mutations lead to numerous muscle-wasting and neuromuscular disorders (Rahimov and 
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Kunkel 2013). One of the most common diseases affecting approximately 1 in 3500 boys 
is Duchenne Muscular Dystrophy (DMD), caused by mutations in the gene encoding 
dystrophin, located on the X chromosome (Rahimov and Kunkel 2013). Dystrophin sits 
on the intracellular membrane of muscle, and interacts with other intracellular proteins, 
transmembrane proteins and extracellular proteins, collectively known as the dystrophin-
associated protein complex, to allow the cell to withstand the enormous mechanical stress 
generated by sarcomeres (Rahimov and Kunkel 2013).  
While DMD is the result of a defect in proper connectivity between the 
cytoskeleton and the extracellular matrix, other dystrophies manifest from mutations in 
genes that affect glycosylation of α-dystroglycan, disruption in the extracellular matrix, 
impaired signaling at the sarcolemma, and defective sarcolemmal repair, among others 
(Rahimov and Kunkel 2013). These defects can be recapitulated in vertebrate animal 
models with a high degree of fidelity, and studies involving mutant mice and zebrafish 
are currently being used to examine the disease mechanisms and potential drug 
treatments (Gibbs, Horstick et al. 2013). 
 
1.4 Directed interference of PtdIns3P regulation by gene knockout of selected 
kinases or phosphatases has mixed results 
This dissertation project is focused on understanding the roles and functions in 
skeletal muscle of specific kinases and phosphatases that regulate the phosphorylation of 
PtdIns. The following sections describe the specific aims of this work, and include 
background and rationale for the projects. 
 
1.4.1 Mtm1 knockout mice: a model of human Myotubular myopathy 
Through the use of vertebrate model systems of MTM, the specific function(s) of 
myotubularin in vivo are beginning to be uncovered (Buj-Bello, Laugel et al. 2002, 
Dowling, Vreede et al. 2009, Beggs, Bohm et al. 2010). Of particular interest are two 
mouse models of MTM, the first created by targeted inactivation of the myotubularin 
gene (Buj-Bello, Laugel et al. 2002), and the second by a knockout mouse model (Al-
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Qusairi, Weiss et al. 2009). The first mice exhibited a severe, progressive skeletal 
myopathy reminiscent of the human disease; they also displayed the pathognomonic 
histopathologic changes of MTM. The two major findings to emerge from this initial 
study were as follows: first, that diseased muscle develops normally and develops 
pathologic changes only after myogenesis is complete; and second, that disease 
pathogenesis is muscle cell autonomous (and not due to motor neuron dysfunction). Buj-
Bello and colleagues later confirmed these findings with a knockout mouse model; they 
further uncovered the fact that tubulo-reticular abnormalities precede the formation of 
central nuclei and occur coincident with disease onset (Al-Qusairi, Weiss et al. 2009, 
Dowling, Vreede et al. 2009). Despite such new knowledge acquired from these model 
system studies, much remains to be understood about the function of myotubularin and 
the pathogenesis of MTM.  
 
1.4.2 Aim 1: To determine a muscle specific role for FIG4 
The second chapter is based on continuations in the characterization of a 
spontaneous mouse mutant (‘pale tremor’ or plt) with a homozygous recessive loss-of-
function mutation in the Fig4 gene (Chow, Zhang et al. 2007). The plt mice are 
characterized by severe and progressive neurodegeneration (Chow, Zhang et al. 2007) 
and increased vacuolization due to defective lysosomal function and impaired autophagy 
(Ferguson, Lenk et al. 2009). However, previous studies of FIG4 did not extensively 
examine its direct role in skeletal muscle development and homeostasis.  
Examinations of three distinct lines of mice gave some results that were a bit 
surprising, based on assumptions of the importance of PtdIns(3,5)P2 in muscle. The three 
lines included the original plt mice, which die before 2 months of age due to progressive 
neurodegeneration, as well as plt mice with restored FIG4 expression in neurons (Chow, 
Zhang et al. 2007, Ferguson, Lenk et al. 2012). In addition, we crossed the plt mice with 
mice carrying mutations in Mtm1 to follow up on a previous report that 
haploinsufficiency of Fig4 rescues the neuropathy associated with Mtmr2 mutation 
(Bolino, Bolis et al. 2004, Vaccari, Dina et al. 2011). These studies support the findings 
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that FIG4 is required for skeletal muscle function, but not in a cell-autonomous role in 
either muscle development or activity. 
 
1.4.3 Aim 2: To determine the effects of targeted deletion of Pik3c3/hVps34 in skeletal 
muscle 
The third chapter introduces a line of mice with a mutation in the Class III PI3K, 
Pik3c3, known in yeast as vacuolar protein sorting protein 34 (Vps34). As mice with null 
mutations for Pik3c3 are not viable, it was necessary to design a mouse with the gene 
ablated specifically in skeletal muscle. These mice with conditional knockout of Pik3c3 
in skeletal muscle were generated by combining floxed Pik3c3 (Zhou, Wang et al. 2010) 
and Cre recombinase under the muscle creatine kinase promoter: Tg(Ckmm-Cre) 
(Bruning, Michael et al. 1998). The resulting mice had normal embryonic and early 
postnatal development, but died by 2 months of age, presumably from severe 
cardiomyopathy (Jaber, Dou et al. 2012). Examination of skeletal muscle in knockout 
animals revealed a previously unreported murine muscular dystrophy that we further 
characterized. In all, we report for the first time a requirement for Pik3c3 in skeletal 
muscle homeostasis, and further identify loss of Pik3c3 as a cause of muscular dystrophy 
in the mouse.  
 
1.4.4 Aim 3: To determine the role of PIK3C2β in skeletal muscle  
Mice were developed by crossing a line harboring the muscle creatine kinase 
promoter driving Cre recombinase, Tg(Ckmm-Cre), with a previously described line 
carrying a floxed Pik3c2β to result in skeletal muscle deletion of Pik3c2β (Harada, 
Truong et al. 2005). As reported of the mice having null deletion of Pik3c2β, our mice 
have normal survival and mobility, growth and observed functions. There were no 
apparent abnormalities in muscle strength or development. However, we observed 
significant changes in certain metabolic processes concerning glucose disposal. There are 






In all, here are several approaches to identify the consequences in skeletal muscle from 
dysregulation of the phosphorylation of PtdIns(3)P and PtdIns(3,5)P2. Depending on the 
exact nature of the disruption in PtdInsP metabolism, we witness a variety of effects on 
skeletal muscle. From these studies, it can be inferred that MTM appears to be not a 
direct result of impaired PtdIns3P processing, but possibly something to do with over-
accumulation of PtdIns(3)P or PtdIns(3,5)P2. The link between MTM1 and kinases 
including PIK3C2β remains to be explored in more detail. The potential directions for 








Figure 1.1 Phosphatidylinositol (PtdIns) and its seven phosphorylated isoforms 
PtdInsPs play essential roles in numerous signaling pathways and metabolic 
functions. The individual phosphoisoforms are rapidly interconverted following 
activation of a variety of kinases (green) and phosphatases (red) upon cellular signals 
from sources such as G-protein coupled receptors (Kukkonen 2011), transcription factors 
(Mammucari, Milan et al. 2007), growth factors (Wheeler and Domin 2006) and insulin 






Figure 1.2 Interconversion among PtdIns, PtdIns(3)P and PtdIns(3,5)P2. 
This dissertation focuses on enzymes, both phosphatases (red) and kinases 
(green), that regulate the phosphorylation of phosphatidylinositol (PtdIns). These include 
a phosphatase, FIG4, responsible for converting phosphatidylinositol (3,5)-bisphosphate 
(PtdIns(3,5)P2) to phosphatidylinositol 3-phosphate (PtdIns(3)P), as discussed in chapter 
2; and two kinases, PIK3C3 and PIK3C2β, that use PtdIns as a substrate to form 









Phosphatidylinositol phosphates (PtdInsPs) are low-abundance phospholipids that 
participate in a range of cellular processes, including cell migration and membrane 
traffic. PtdInsP levels and subcellular distribution are regulated by a series of lipid 
kinases and phosphatases. In skeletal muscle, PtdInsPs and their enzymatic regulators 
serve critically important functions exemplified by mutations of the PtdInsP phosphatase 
MTM1 in myotubular myopathy (MTM), a severe muscle disease characterized by 
impaired muscle structure and abnormal excitation–contraction coupling. FIG4 functions 
as a PtdInsP phosphatase that participates in both the synthesis and breakdown of 
phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Mutation of FIG4 results in a 
severe neurodegenerative disorder in mice and a progressive peripheral polyneuropathy 
in humans. The effect of FIG4 mutation on skeletal muscle has yet to be examined.  
Methods 
Herein we characterize the impact of FIG4 on skeletal muscle development and 
function using the spontaneously occurring mouse mutant pale tremor (plt), a mouse line 
with a loss of function mutation in Fig4. 
Results 
In plt mice, we characterized abnormalities in skeletal muscle, including reduced 
muscle size and specific force generation. We also uncovered ultrastructural 
                                                
4 This chapter was published as Reifler, A., G. M. Lenk, X. Li, L. Groom, S. V. Brooks, D. 
Wilson, M. Bowerson, R. T. Dirksen, M. H. Meisler and J. J. Dowling (2013). "Murine Fig4 is dispensable 
for muscle development but required for muscle function." Skelet Muscle 3(1): 21. 
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abnormalities and increased programmed cell death. Conversely, we detected no 
structural or functional abnormalities to suggest impairment of excitation–contraction 
coupling, a process previously shown to be influenced by PtdIns(3,5)P2 levels. 
Conditional rescue of Fig4 mutation in neurons prevented overt muscle weakness and the 
development of obvious muscle abnormalities, suggesting that the changes observed in 
the plt mice were primarily related to denervation of skeletal muscle. On the basis of the 
ability of reduced FIG4 levels to rescue aspects of Mtmr2-dependent neuropathy, we 
evaluated the effect of Fig4 haploinsufficiency on the myopathy of Mtm1-knockout mice. 
Male mice with a compound Fig4+/−/Mtm1–/Y genotype displayed no improvements in 
muscle histology, muscle size or overall survival, indicating that FIG4 reduction does not 
ameliorate the Mtm1-knockout phenotype. 
Conclusions 
Overall, these data indicate that loss of Fig4 impairs skeletal muscle function but 
does not significantly affect its structural development. 
 
2.2 Introduction 
Phosphatidylinositol phosphates (PtdInsPs) are low-abundance phospholipids that 
are implicated as regulators of a range of cellular processes, including cell migration, 
subcellular organelle trafficking and autophagy (De Camilli, Emr et al. 1996, Di Paolo 
and De Camilli 2006). Phosphatidylinositol 3,5-bisphosphate, or PtdIns(3,5)P2, is a low-
abundance PtdInsP whose function has recently come into focus (Ho, Alghamdi et al. 
2012). PtdIns(3,5)P2 is generated by the action of PIKfyve, a five-position 
phosphoinositide kinase (Zolov, Bridges et al. 2012). PtdIns(3,5)P2 is metabolized by 
FIG4 (Sac3), a five-position phosphoinositide phosphatase, to regenerate 
phosphatidylinositol 3-phosphate (PtdIns(3)P), and by myotubularins, a family of three-
position phosphatases to generate phosphatidylinositol 5-phosphate (or PtdIns(5)P) 
(Robinson and Dixon 2006, Tosch, Rohde et al. 2006, Dyson, Fedele et al. 2012, Hakim, 
Bertucci et al. 2012). Of note, maximal function of PIKfyve requires a complex of 
proteins that includes VAC14 and FIG4 (Gary, Sato et al. 2002, Duex, Tang et al. 2006, 
Jin, Chow et al. 2008). Reduced abundance of FIG4 protein destabilizes PIKfyve, 
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resulting in a threefold reduction of PtdIns(3,5)P2 relative to total PtdInsP levels (Chow, 
Zhang et al. 2007). 
We recently identified and characterized a spontaneous mouse mutant (“pale 
tremor” or plt) with a homozygous recessive loss-of-function mutation in the Fig4 gene 
(Chow, Zhang et al. 2007). plt mice exhibit severe and progressive neurodegeneration 
that involves both neurons and glia of the central and peripheral nervous system (Winters, 
Ferguson et al. 2011). The main subcellular phenotype is increased vacuolization due to 
defective lysosomal function and impaired autophagy (Ferguson, Lenk et al. 2009, 
Ferguson, Lenk et al. 2012). In addition, we (the Meisler group) have identified recessive 
FIG4 mutations in patients with hereditary peripheral neuropathy (Charcot-Marie-Tooth 
Disease type 4J) (Ikonomov, Sbrissa et al. 2010, Lenk, Ferguson et al. 2011, Nicholson, 
Lenk et al. 2011) and motor neuron disease (amyotrophic lateral sclerosis, or ALS) 
(Chow, Landers et al. 2009). However, the role of FIG4 in skeletal muscle has yet to be 
extensively examined in detail. 
Studies of myotubularins indicate a potentially important role for PtdIns(3,5)P2 
regulation in skeletal muscle (Laporte, Bedez et al. 2003, Gibbs, Feldman et al. 2010, 
Romero-Suarez, Shen et al. 2010). The mammalian myotubularin gene family contains 
15 members encoding phosphatases that primarily dephosphorylate PtdIns(3)P and 
PtdIns(3,5)P2 (Hnia, Vaccari et al. 2012). Mutation of MTM1, the canonical member of 
this gene family, results in increased levels of PtdIns(3)P, and possibly PtdIns(3,5)P2, in 
skeletal muscle and causes myotubular myopathy (MTM), a severe congenital muscle 
disease associated with altered muscle structure and profound muscle weakness (Pierson, 
Dulin-Smith et al. 2012). Mutation of MTM1 compromises multiple aspects of muscle 
function (Amoasii, Hnia et al. 2012), most notably excitation–contraction coupling (EC 
coupling) (Dowling, Low et al. 2010), the process by which neuronal stimulation to 
muscle is translated into calcium-dependent muscle contraction. Specifically, MTM1 
mutations lead to severe abnormalities in the structure of the EC coupling machinery (Al-
Qusairi, Weiss et al. 2009). 
MTMR14 is another myotubularin family member that is important for muscle 
function (Shen, Yu et al. 2009). Loss of MTMR14 function in zebrafish and mice causes 
aberrant autophagy and impaired EC coupling (Shen, Yu et al. 2009, Dowling, Low et al. 
 
 20 
2010). Unlike MTM1, loss of MTMR14 alters EC coupling without significantly 
changing the underlying structure of the EC coupling machinery. Direct application of 
PtdIns(3,5)P2 increases calcium release from microsomes containing the intracellular 
ryanodine receptor 1 calcium release channel (RyR1), a critical component of the EC 
coupling apparatus. Thus, direct regulation of RyR1-dependent stimulated calcium 
release may represent one important role of PtdIns(3,5)P2 and MTMR14 (Touchberry, 
Bales et al. 2010). 
Given the potential importance of PtdIns(3,5)P2 in skeletal muscle, we sought to 
understand the impact of FIG4 mutation on muscle development and homeostasis. To 
address this issue, we examined skeletal muscle structure and function in the plt-null 
mouse model of FIG4 dysfunction. We examined plt mice, which die before 2 months of 
age as a result of progressive neurodegeneration, as well as plt mice with restored FIG4 
expression in neurons (Chow, Zhang et al. 2007, Ferguson, Lenk et al. 2012). The latter 
mice have no overt phenotype and survive for more than 18 months. Our data reveal that 
Fig4 mutation is associated with skeletal muscle changes (atrophy and increased 
apoptosis) and impaired muscle force generation, but not with abnormalities in the 
structure or function of the EC coupling machinery. The changes are likely the 
consequence of impaired neuronal input because phenotypic rescue is largely provided by 
neuronal expression of FIG4. In addition, we found that haploinsufficiency of Fig4 does 
not ameliorate effects of Mtm1 mutation in muscle, in contrast to a previous report that 
haploinsufficiency of Fig4 rescues the neuropathy associated with Mtmr2 mutation 
(Bolino, Bolis et al. 2004, Vaccari, Dina et al. 2011). Together, our results support a 
requirement for FIG4 in skeletal muscle function, but not a cellular autonomous role in 
either muscle development or EC coupling. 
2.3 Results 
2.3.1 FIG4 is expressed in skeletal muscle 
We wanted to establish that FIG4 protein was present in skeletal muscle. We 
therefore performed Western blot analysis using anti-FIG4 antibody (NeuroMab). We 
first used a premade multitissue Western blot antibody (IMGENEX) and found that FIG4 
was present in most tissues examined, including skeletal muscle (Figure 2.1A). To 
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determine if FIG4 expression was regulated with maturation of skeletal muscle, we 
examined protein extracts from skeletal muscle of various postnatal ages (Figure 2.1B) as 
well as from differentiating C2C12 myocytes (Figure 2.1C). We detected no obvious 
variability in FIG4 levels at different mouse ages or different developmental stages in 
vitro; thus we conclude that FIG4 is a ubiquitously expressed component of skeletal 
muscle. Of note, we verified that FIG4 expression was absent in Fig4-null (that is, plt) 
skeletal muscle as compared to WT littermates (Figure 2.1D). 
2.3.2 Fig4-null myofibers are reduced in size and exhibit ultrastructural abnormalities 
We began our analysis by examining both light and electron microscopic features 
of skeletal muscle from Fig4-null mice. We examined muscle at 5 weeks of age, since 
these mice do not survive beyond 6 weeks of age (Lenk and Meisler 2013). We also 
studied a limited number of animals with expression of a Fig4 cDNA transgene under 
control of the neuron-specific enolase (NSE) promoter (Ferguson, Lenk et al. 2012). 
These animals were examined at 4, 8 and 20 months of age. 
Routine histopathological analysis of quadriceps, gastrocnemius and diaphragm 
using H&E and SDH stains did not reveal any obvious abnormalities in plt skeletal 
muscle compared to the WT (Figures 2.2A through 2.2D). However, the CSA of plt 
myofibers was significantly smaller than that of their WT counterparts. Quantitation of 
cross-sectional fiber area revealed that plt myofibers were 55.3% smaller than WT fibers 
(n = 400 total fibers counted from quadriceps in three mice per condition) (Figure 2.2E). 
This reduction in size corresponds with the observation that overall muscle mass in plt 
animals was similarly significantly reduced compared to that of age-matched WT 
littermates (Figure 2.11). Of note, overall mass of the body (which is largely dictated by 
muscle weight) at 6 weeks of age was also significantly reduced in plt mice (Figure 2.10). 
Ultrastructural analyses were performed on quadriceps muscle from age-matched 
WT and plt mice using transmission electron microscopy (n = 4 per condition). Overall, 
muscle ultrastructure in plt mice resembled that of controls (Figures 2.3A and 2.3B), 
though swollen and enlarged mitochondria were occasionally observed in muscle from 
plt mice (M in Figure 2.3C). We did not, however, detect consistent abnormalities in the 
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triad, the location of the EC coupling machinery, in any plt mouse examined (arrow in 
Figure 2.3B). 
2.3.3 Increased apoptosis in skeletal muscle and primary myocytes from Fig4-deficient 
mice 
The combination of reduced muscle fiber size and ultrastructurally abnormal 
mitochondria led us to examine whether there was increased cell death in plt muscle. 
TUNEL staining of muscle sections revealed few positive cells in the WT tissue but 
several positive cells in the mutant tissue (Figure 2.4A). To better evaluate this finding, 
we studied isolated myocytes from neonatal WT and plt mice. As with primary cells from 
other organ systems of the plt mice, cells derived from plt muscle demonstrated abundant 
vacuolization. We measured cell death in these primary cell cultures using a TUNEL 
assay. We observed a significant increase in TUNEL-positive cells in Fig4-mutant 
myocytes, consistent with decreased cell survival (Figure 2.4B). Of note, despite the 
vacuolization and impaired survival, Fig4-null myocytes were able to successfully 
differentiate into myotubes upon serum withdrawal (data not shown). There was also no 
change in the ability of plt myocytes to proliferate, as determined by bromodeoxyuridine 
(BrdU) labeling of cells (64% of cells BrdU-positive in control (116 of 182 cells counted) 
vs 64% of cells positive in plt (151 of 235 cells counted). 
2.3.4 FIG4-mutant skeletal muscle has impaired force generation 
To determine the potential functional effects of Fig4 deficiency in skeletal 
muscle, we measured force generation from intact muscle fibers. Testing both EDL and 
soleus muscles revealed statistically significant reductions in specific force generation 
(12% to 24% decrease when adjusted for CSA), indicating mild muscle weakness and 
impaired force generation in the plt animals (Figure 2.5). 
2.3.5 FIG4-mutant myocytes have normal intracellular calcium dynamics 
Given the previous association between PtdIns(3,5)P2 and EC coupling and the 
fact that FIG4 is a known regulator of PtdIns(3,5)P2 levels, we interrogated intracellular 
calcium dynamics. We used whole-cell voltage patch-clamping of isolated neonatal 
mouse myocytes to simultaneously measure voltage-gated L-type calcium currents and 
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intracellular calcium transients. We did not detect abnormalities in either orthograde or 
retrograde coupling or in L-type calcium currents in plt myocytes (Figure 2.6 and Table 
2.1). Taken in conjunction with the normal histological appearance of the triad, these data 
suggest that loss of Fig4 is not associated with impaired bidirectional dihydropyridine 
receptor (DHPR)–RyR1 coupling. 
Table 2.1 Parameters of fitted current-voltage and fluorescence-voltage (∆F/F-V) 
curves.a 
 Gmax (nS/nF) VG1/2 (mV) kG (mV) VREV (mV) (∆F/F)max VF1/2 (mV) kF(mV) 
WT (n = 11) 219 ± 14 9.8 ± 1.4 5.0 ± 0.5 65.3 ± 3.0 2.3 ± 0.4 −7.8 ± 1.9 4.4 ± 0.2 
plt (n = 11) 194 ± 15 9.4 ± 1.3 4.0 ± 0.4 66.7 ± 2.7 2.1 ± 0.2 −5.8 ± 1.7 4.6 ± 0.3 
aWT, wild type. 
2.3.6 Neuronal expression of Fig4 in plt mice reduces skeletal muscle pathology 
We previously reported that expression of FIG4 under the NSE promoter in plt 
animals prevents the development of typical phenotypic abnormalities (Ferguson, Lenk et 
al. 2012). In fact, the appearance of the transgenic (Tg) animals is indistinguishable from 
their WT littermates. We examined skeletal muscle in Fig4−/−/TgNSE mice at 4, 8 and 20 
months of age. There was no obvious difference in histological appearance between WT 
and Fig4−/−/TgNSE mice, which is similar to what we observed in the Fig4-null mice. 
Unlike the null mice, however, Fig4−/−/TgNSE mice exhibited only a very slight 
alteration in myofiber size (11% smaller than WT; n = 5 animals examined per genotype, 
P = 0.02) (Figures 2.7A and 2.7B). This reduction was statistically significant and 
occurred despite the fact that overall weight was the same between WT and 
Fig4−/−/TgNSE animals. Fig4−/−/TgNSE muscle did not display any of the ultrastructural 
changes seen in the Fig4−/− mice (Figure 2.7C) and did not exhibit evidence of increased 
apoptosis. 
Last, to determine whether muscle function was altered in Fig4−/−/TgNSE mice, 
we measured maximum isometric force in soleus and EDL muscles of 18-month-old 
animals. There was a small (approximately 10%) but statistically insignificant (P > 0.1) 
decline in force generation between Fig4−/−/TgNSE mice and their WT littermates 
(Additional File 1, Figure S4). Taking all our data together, we conclude that expression 
of Fig4 in neurons is sufficient to correct the development of significant muscle atrophy 
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and programmed cell death in plt skeletal muscle, but not to prevent subtle but 
reproducible changes in myofiber size in vivo. Of note, we verified by both RNA (reverse 
transcriptase polymerase chain reaction) and Western blot analysis that there was no 
appreciable Fig4 RNA or protein in muscle of Fig4−/−/TgNSE mice (data not shown and 
Figure 2.1D). 
2.3.7 Fig4 haploinsufficiency does not improve the Mtm1-knockout mouse phenotype 
There is a complex interplay between the enzymes that regulate 
phosphoinositides. One potential avenue for treatment of diseases related to PtdInsP 
dysregulation is manipulation of other enzyme levels. This point has been demonstrated 
for the neurological abnormalities associated with Mtmr2 mutation (Vaccari, Dina et al. 
2011). Mice with a recessive mutation in Mtmr2 exhibit peripheral neuropathy, and 
aspects of this neuropathy are reversed in the setting of Fig4 haploinsufficiency. Since 
MTM1 and MTMR2 are highly homologous, we evaluated the effect of 
haploinsufficiency of Fig4 (in plt+/− mice) on the severe muscle phenotype in knockout 
mice lacking expression of Mtm1. Generation of Fig4+/−/Mtm1–/Y male mice revealed no 
difference from Mtm1–/Y mice, with comparable impairments of weight gain, motor 
function and survival and no statistically significant difference in weight or survival 
(Figures 2.8A and 2.8B). 
By histopathological analysis, we demonstrated similar alterations between 
Mtm1–/Y mice and Mtm1–/Y/Fig4+/− mice. We quantitated myofiber size because size is 
correlated with disease severity in patients with MTM (Pierson, Agrawal et al. 2007). 
There was no clear difference in this parameter (Figure 2.8B, consistent with the 
observed lack of functional improvement in the Fig4+/–/Mtm1–/Y animals. In all, 
haploinsufficiency of Fig4 did not appear to alter the Mtm1 phenotype in any meaningful 
way. 
2.4 Discussion 
FIG4 exhibits an important role in central and peripheral nervous system 
development and homeostasis. The consequences of FIG4 deficiency on other organ 
systems are less well delineated. In this study, we defined the consequences of Fig4-null 
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mutation on skeletal muscle. We found that (1) global inactivation of Fig4 in the plt 
mouse is associated with myofiber atrophy and/or hypotrophy, increased apoptosis and 
diminished specific force production; (2) loss of Fig4 does not alter the structure, EC 
coupling apparatus or bidirectional DHPR–RyR1 coupling; and (3) reexpression of Fig4 
in neurons significantly reduces all observed muscle abnormalities. The implications of 
these findings are discussed below. 
Perhaps the most striking aspect of this study is the fact that Fig4 mutation did not 
result in a more deleterious direct effect on muscle development and function. In neurons 
and glia, loss of FIG4 results in severe structural and functional consequences. Given the 
previously recognized importance of phosphoinositide regulation in skeletal muscle (Al-
Qusairi, Weiss et al. 2009, Dowling, Low et al. 2010), we predicted that plt mice would 
exhibit pronounced changes in muscle structure and function. However, effects of Fig4 
ablation on muscle were minimal and largely rescued following neuron-specific 
restoration of FIG4 expression (Fig4−/−/TgNSE mice). Muscle alterations found to persist 
in Fig4−/−/TgNSE mice (for example, 11% reduction in fiber size) could be explained by 
either a minor role for FIG4 expression in muscle fiber size determination or a small 
amount of residual neurogenic atrophy. It is of interest to note the dichotomy between the 
relatively normal appearance of adult plt muscle in situ and the extensive vacuolarization 
of plt myocytes in vitro (Figure 2.12). Similar effects of culturing have been observed in 
other cell types, including fibroblasts (Chow, Zhang et al. 2007) and osteoblasts 
(unpublished manuscript, Lenk GM and Meisler MH). The explanation for this difference 
is unclear and requires further experimentation. 
There are several potential explanations for the lack of a more severe phenotype 
in skeletal muscle of Fig4-null mice. First of all, the partial reduction of PtdIns(3,5)P2 
likely caused by loss of Fig4 may not be enough to result in significant consequences for 
muscle development and function. Alternatively, a different PIKfyve protein complex 
may compensate for the loss of FIG4 to provide sufficient levels of PtdIns(3,5)P2 to 
maintain myofiber homeostasis. A third possibility is that PtdIns(3,5)P2 may be generated 
in muscle by a different or complementary pathway. For example, a three-position kinase 
may generate PtdIns(3,5)P2 from PtdIns(5)P. One current barrier to attempting to 
distinguish these possibilities is the lack of suitable approaches to measure PtdIns(3,5)P2 
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in whole tissues such as skeletal muscle. Development of techniques to aid in measuring 
PtdIns(3,5)P2 in situ are required to answer these questions more definitively. 
Regardless of the explanation, the fact that there is little, if any, muscle-cell 
autonomous phenotype in Fig4-null animals indicates that FIG4 mutations are unlikely to 
result in primary muscle disease. However, significant secondary neurogenically 
mediated myopathic features, such as those observed in plt mice, including reduced 
muscle fiber CSA and specific force generation, suggest that skeletal muscle changes 
may contribute to disease pathogenesis. In other words, the myopathic changes described 
herein may influence disease severity in patients with Charcot-Marie-Tooth disease type 
4J and other disorders caused by FIG4 gene mutation. 
The lack of impairment in the structure of the EC coupling apparatus or of 
bidirectional triad coupling in Fig4-null mice was unexpected. Data from the MTMR14-
knockout mice support the hypothesis that increased levels of PtdIns(3,5)P2 impair 
calcium release from the ryanodine receptor (the core component of the EC apparatus), 
though the underlying mechanism is not clear. Our data imply that reduced levels of 
PtdIns(3,5)P2 do not acutely impair voltage-gated triad calcium release. Furthermore, the 
chronic loss of FIG4 from muscle (with the potential implication of chronically reduced 
PtdIns(3,5)P2 levels) does not alter the ultrastructural appearance of the triad (that is, the 
location of the EC coupling machinery). Thus, a requirement for normal levels of 
PtdIns(3,5)P2 for EC coupling seems unlikely, though the present data do not completely 
exclude this possibility. In addition to more direct interrogation of EC coupling in FIG4-
deficient mice, another potential future direction to address this issue would be to assess 
the impact on EC coupling of muscle-specific knockout of PIKfyve, the kinase required 
for PtdIns(3,5)P2 generation. Again, however, this would necessitate confirmation of a 
specific reduction in PtdIns(3,5)P2 levels in skeletal muscle. 
The final significant observation in this study is that reduced Fig4 expression via 
plt haploinsufficiency does not significantly alter the phenotype of Mtm1-knockout mice. 
Of note, the MTMR2 gene encodes a protein that is highly homologous to MTM1 
(Robinson and Dixon 2006). In addition, we previously demonstrated that zebrafish 
mtmr2 functionally compensates (at least in part) for loss of mtm1, suggesting that 
MTMR2 and MTM1 are functionally quite similar (Dowling, Vreede et al. 2009). 
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However, in contrast to our findings in Mtm1-null mice, Bolino and colleagues found that 
plt haploinsufficiency rescued neuropathy in Mtmr2-knockout animals (Vaccari, Dina et 
al. 2011). The reasons why reduction of FIG4 levels improved the MTMR2-related 
neuropathology, but not the muscle pathology, seen in Mtm1-null mice are not clear. This 
distinction may provide another indication of the nonessential role of FIG4 in skeletal 
muscle or may reflect different quantitative requirements for PtdIns(3,5)P2 in neurons 
and muscle or specific differences between mammalian MTMR2 and MTM1. 
2.5 Conclusions 
We present data demonstrating that FIG4 is required for muscle function but is 
dispensable for muscle development. In addition, most abnormalities associated with 
Fig4 mutation appears to be secondary to the severe neuropathy documented in plt mice. 
Our results do not support a role for FIG4 in EC coupling. Future experiments are needed 
to more firmly establish the relationship between PtdIns(3,5)P2 and EC coupling. 
2.6 Methods 
2.6.1 Animal care and husbandry 
All animals were cared for per protocol under the guidance of, and with ethical 
approval from, the University Committee on Use and Care of Animals (UCUCA) and 
with the assistance of members of the University of Michigan’s Unit for Laboratory 
Animal Medicine (ULAM), who carefully monitored the health of the rodent colonies. 
ULAM maintained proper environmental regulation, including temperature and light 
cycles, unlimited access to water, appropriate food supply and clean enclosures. The 
Fig4-null mutation plt is maintained on two congenic lines, C57BL/6J.plt/+ (N14) and 
C3H.plt/+ (N10) (Lenk and Meisler 2013). Experiments were carried out on homozygous 
plt/plt F1 mice obtained from crosses between the two congenic strains. Pups were 
weaned according to standard protocols, and tails were clipped for genotyping. 
2.6.2 Western blot analysis 
Western blot analyses were performed using the following antibodies: FIG4 
(1:1,000 NeuroMab; UC Davis/NIH NeuroMab Facility, Davis, CA, USA) and 
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glyceraldehyde 3-phosphate dehydrogenase (1:1,000 GAPDH; Millipore, Billerica, MA, 
USA). Mouse multitissue Western blot antibody was obtained from IMGENEX (San 
Diego, CA, USA). Protein extracts were established from flash-frozen mouse skeletal 
muscle and brain using T-PER tissue protein extraction reagent and a Dounce tissue 
homogenizer (Pierce Biotechnology, Rockford, IL, USA). Approximately 50 µg of 
protein were loaded per sample, resolved by polyacrylamide gel electrophoresis on 11% 
gels, and transferred to polyvinylidene fluoride. Secondary antibodies were used at 
1:2,000 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), blots were developed using 
electrochemiluminescence reagent (GE Biosciences, Pittsburgh, PA, USA), and bands 
visualized using the Bio-Rad ChemiDoc XRS+ System illuminator (Bio-Rad 
Laboratories, Hercules, CA, USA). 
2.6.3 Histopathology 
Animals were killed by anesthetic injection, which was followed by cervical 
dislocation. Tissues were then isolated using sterile surgical methods without the use of 
laminar flow hoods. Muscle tissue from quadriceps and tibialis anterior muscles was 
dissected and mounted onto small balsa wood pieces that had previously been frozen with 
drops of Tissue-Tek O.C.T. compound (Sakura Finetek USA, Torrance, CA, USA) and 
then semithawed with light friction. The mounted muscle tissue was immediately 
submerged in a −55°C isopentane bath cooled by liquid nitrogen for flash-freezing. 
Muscles were cut into 12-µm cross-sections and mounted on Superfrost Plus 
slides (Thermo Scientific, Waltham, MA, USA) using a Leica cryostat (Leica 
Biosystems, Buffalo Grove, IL, USA) at −20°C and dried at room temperature before 
storage at −80°C. Slides were stained with Mayer’s hematoxylin and eosin (H&E) or 
succinate dehydrogenase (SDH) following standard protocols and mounted with 
Permount mounting medium (Thermo Scientific). Apoptotic fibers were visualized with 
the ApopTag Plus Peroxidase In Situ Apoptosis Kit (S7101; Chemicon 
International/EMD Millipore, Billerica, MA, USA). Photomicrographs were captured 
using an INFINITY1 digital camera with eponymous software (Lumenera Corp, Ottawa, 
ON, Canada) visualized through an Olympus BX43 light microscope (Olympus America, 
Center Valley, PA, USA). 
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2.6.4 Ultrastructural analysis 
Immediately following dissection, quadriceps and gastrocnemius muscles were 
carefully cut into approximately 1-mm × 2-mm fragments and incubated in Karnovsky’s 
fixative overnight at 4°C. Fixed tissue was brought to the Microscopy and Imaging 
Laboratory (MIL) Core facility at the University of Michigan for processing. Ultrathin 
sections were analyzed for orientation, and grids were prepared for use on the Philips 
CM-100 transmission electron microscope (Koninklijke Philips N.V., Amsterdam, The 
Netherlands). 
2.6.5 Myocyte isolation 
Muscle was dissected from the shoulders and legs of dead mice and placed 
immediately into sterile phosphate-buffered saline. Muscle was then minced finely with a 
sterile razor, fully dissociated with a mixture of collagenase type I (0.1%) and trypsin 
(0.1%) in Ham’s F-12 medium, then incubated at 37°C for approximately 1 h with 
periodic trituration. Cells were pelleted and resuspended in 1:1 Dulbecco’s Modified 
Eagle Medium:Ham’s F-12 Nutrient Mixture (DMEM/F-12) (Gibco/Life Technologies, 
Grand Island, NY, USA) with 20% fetal calf serum (HyClone Laboratories, Logan, UT, 
USA), then filtered through 70- and 40-µm meshes and plated onto collagen-coated 
dishes (BD Biosciences, San Jose, CA, USA). Media were changed after a 1-h incubation 
at 37°C, and recombinant human fibroblast growth factor–basic (AA 10-155, Publication 
PHG0026; Gibco/Life Technologies) was added to a final concentration of 10 ng/ml. 
Cells were maintained at 37°C in a 5% CO2 atmosphere with daily changes of fresh 
media. Cells were visualized using Hamamatsu ORCA-R2 camera and software 
(Hamamatsu Photonics, Hamamatsu-shi, Japan) on a Leica inverted microscope (Leica 
Microsystems). All experiments were performed on passages 2 through 4 myocytes. 
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) 
staining was performed per the manufacturer’s recommendations on myocytes grown on 
coverglass coated with fibronectin and fixed with 4% paraformaldehyde prior to staining. 
2.6.6 Muscle force measurement 
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Extensor digitorum longus (EDL) and soleus muscles were carefully isolated and 
removed from anesthetized mice. Muscles were immediately placed into a bath of Krebs 
mammalian Ringer solution with 0.25 mM tubocurarine chloride maintained at 25°C and 
bubbled with 95% O2 and 5% CO2 to stabilize pH at 7.4. Using 5-0 silk suture, the distal 
tendon of the muscle was attached to a servomotor (model 305B; Aurora Scientific, 
Aurora, ON, Canada), and the proximal tendon was attached to a force transducer (model 
BG-50; Kulite Semiconductor Products, Leonia, NJ, USA). Muscles were stimulated by 
square pulses delivered by two platinum electrodes connected to a high-power biphasic 
current stimulator (model 701B; Aurora Scientific). A personal computer running 
custom-designed software (LabVIEW 7.1; National Instruments, Austin, TX, USA) 
controlled electrical pulse properties and servomotor activity and recorded data from the 
force transducer. Stimulation voltage and optimal muscle length (Lo) were adjusted to 
give maximum twitch force (Brooks and Faulkner 1988). While held at Lo, muscles were 
subjected to trains of pulses 300 ms in duration for EDL muscles and 900 ms for soleus 
muscles, with increasing stimulation frequency until maximum isometric tetanic force 
(Po) was achieved (Brooks and Faulkner 1988). Lo was measured with digital calipers, 
and muscle fiber lengths (Lf) were determined by multiplying Lo by previously 
established Lf-to-Lo ratios of 0.44 for EDL muscle and 0.71 for soleus muscle (Brooks 
and Faulkner 1988). Total muscle fiber cross-sectional area (CSA) was estimated by 
dividing the mass of the muscle by the product of Lf and 1.06 g/cm3, the density of 
mammalian skeletal muscle. Po was normalized by CSA to give specific Po. 
2.6.6 Simultaneous measurement of macroscopic L-type Ca2+ currents and voltage-gated 
Ca2+ transients in myotubes 
Primary cultures of skeletal myotubes were generated from myoblasts derived 
from wild-type (WT) and plt mice as previously described (Avila, O'Brien et al. 2001). 
The whole-cell voltage-clamp technique in conjunction with a Ca2+-sensitive dye (fluo-4) 
was used to simultaneously measure voltage-gated L-type Ca2+ currents (L-currents) and 
intracellular Ca2+ transients on individual myotubes from 8- to 11-day-old myotube 
cultures (Avila and Dirksen 2001, Avila, O'Brien et al. 2001). All voltage-clamp 
experiments were carried out after an approximately 5-min period of dialysis following 
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establishment of the whole-cell configuration. The external recording solution consisted 
of 145 mM tetraethylammonium chloride, 10 mM CaCl2 and 10 mM 2-[4-(2-
hydroxyethyl)piperazine-1-yl]ethanesulfonic acid (HEPES) (pH 7.4). The internal patch 
pipette solution consisted of 145 mM Cs-aspartate, 10 mM CsCl, 0.1 mM Cs2-ethylene 
glycol tetraacetic acid, 1.2 mM MgCl2, 5 mM Mg-ATP, 0.2 mM K5-fluo-4 and 10 mM 
HEPES (pH 7.4). A 1-s prepulse to −30 mV delivered immediately before each test pulse 
was used to inactivate voltage-gated Na+ and T-type Ca2+ channels without producing 
significant L-channel inactivation. L-currents and Ca2+ release were subsequently elicited 
by 200-ms test depolarizations from −50 mV to +70 mV in 10-mV increments and a 10-s 
interval between each test pulse. Capacitative currents were minimized to about 10% 
using the capacitance cancelation feature of the patch-clamp amplifier. Remaining linear 
components were leak-subtracted using a P/3 protocol delivered from a holding potential 
of −80 mV before each test pulse. Peak L-current magnitude was normalized to cell 
capacitance (pA/pF), which was plotted as a function of membrane potential (Vm) and 
fitted as I = Gmax (Vm – Vrev)/(1 + exp[(VG1/2 – Vm)/kG]), where Gmax is the maximal L-
channel conductance, Vm is test potential, Vrev is extrapolated reversal potential, VG1/2 is 
the voltage for half-maximal activation of Gmax, and kG is a slope factor. Relative changes 
in intracellular Ca2+ during each test depolarization were measured following dialysis 
with K5-fluo-4 salt. Fluo-4-dialyzed myotubes were excited at 480 nm and fluorescence 
emission measured at 535 nm was digitized at 10 kHz. A computer-controlled shutter was 
used to eliminate dye illumination during intervals between each test pulse. Relative peak 
changes in intracellular Ca2+ were expressed as ∆F/F ([Fpeak – Fbase]/Fbase) at the end of 
each test pulse, plotted as a function of Vm, and fitted according to equation 2.1: 
  
 
 (Equation 2.1) 
 
 
where (∆F/F)max is the calculated maximal change in fluorescence, VF1/2 is the voltage for 
























V) and fluorescence-voltage (∆F/F-V) data were expressed as means ± s.e.m. Statistical 
significance was determined using a two-tailed Student’s t-test. 
2.6.6 Statistical analyses 
GraphPad Prism software (GraphPad Software, La Jolla, CA, USA) was used to 
calculate the significance of fiber size differences and TUNEL staining results with 
unpaired Student’s t-tests and one-way analysis of variance with Tukey’s post hoc 





Figure 2.1 FIG4 is expressed in skeletal muscle. 
Western blot analysis was performed to establish FIG4 expression using anti-
FIG4 antibody. (A) Mouse multitissue Western blot reveals expression of FIG4 in a 
variety of tissues (Br = brain, Ht = heart, SmI = small intestine, Kid = kidney, Liv = liver, 
Lg = lung, SkM = skeletal muscle, St = stomach, Spl = spleen, Ov = ovary, Tes = testis). 
(B) FIG4 is expressed at multiple mouse ages in brain and skeletal muscle. Ages of mice 
tested were 1, 3, 6, 9 and 20 months. Left lanes are from brain, and right lanes are from 
quadriceps. The top blot was probed with anti-FIG4, and the bottom blot (loading 
control) was probed with glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (C) 
Western blot of protein extracts from C2C12 cells at various stages of differentiation. 
Differentiation was induced by serum withdrawal. Cells were differentiated until long 
myotubes were obviously present (day 8 = D8). (D) Analysis of wild-type littermate and 




Figure 2.2 Histopathological analysis of pale tremor (plt) skeletal muscle. 
Hematoxylin and eosin staining (A,B) and succinate dehydrogenase staining 
(C,D) of cryosections from quadriceps of control (wild type (WT)/littermate (LM)) and 
plt animals. Scale bars = 50 µm. (E) Quantitation of myofiber size from quadriceps 
muscle of 4-week-old plt and WT animals. There were significant reductions in myofiber 





Figure 2.3 Ultrastructural analysis of pale tremor (plt) skeletal muscle. 
Representative photomicrographs from transmission electron microscopic 
analysis of wild-type/littermate (WT, A) quadriceps and plt (B,C) quadriceps. Muscle 
ultrastructure was generally normal in plt muscle (B) with evidence of normal triads 
(arrow). There were infrequently observed areas of abnormalities that particularly 




Figure 2.4 Increased apoptosis in plt skeletal muscle and skeletal myocytes. 
(A) Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling 
(TUNEL) staining was performed on sections from wild-type (WT) and plt skeletal 
muscle. Arrows point to TUNEL-positive nuclei. There was a qualitative increase in 
TUNEL-positive fibers in plt muscle (experiment repeated with sections from three 
different mice per condition). (B) TUNEL staining was performed on myocytes. There 
was a significant increase in TUNEL-positive cells in plt myocytes vs WT myocytes. 
Data reflect fraction of 4′,6-diamidino-2-phenylindole-positive nuclei that were also 
TUNEL-positive. Numbers were 0.28 ± 0.06 for plt and 0.17 ± 0.05 for WT (P = 0.006). 
One hundred cells per experiment were counted, and each experiment was repeated five 





Figure 2.5 Diminished force production in pale tremor (plt) skeletal muscle. 
Specific force (normalized to muscle and body weight) was measured for wild-
type/littermate (WT) and plt (mutant) skeletal muscle (left panel = extensor digitorum 
longus, or EDL) (right panel = soleus). Normalized force was significantly reduced in plt 





 Figure 2.6 L-currents and voltage-gated Ca2+ release are unaltered in pale tremor 
(plt) myotubes. 
(A) Representative whole-cell L-type Ca2+ currents (ICa) and intracellular Ca2+ 
transients (ΔF/F) obtained following 200-ms depolarizations to the indicated membrane 
potentials in myotubes derived from either wild-type (WT) mice (upper panel) or plt mice 
(lower panel). (B,C) Average (± s.e.m.) voltage dependence of peak L-type Ca2+ current 
density (B) and intracellular Ca2+ transients (C) for myotubes derived from either WT 




Figure 2.7 Transgenic (Tg) neuronal rescue of FIG4 expression largely restores plt 
myofiber size. 
(A) Hematoxylin and eosin–stained sections of gastrocnemius muscle from wild-
type (WT) and Fig4−/−/NSE-FIG4 (that is, plt with transgenic expression of Fig4 driven 
by the neuron-specific enolase (NSE) promoter). The plt muscle is essentially 
indistinguishable from WT, with the exception of mild reduction in fiber size. (B) 
Quantification of myofiber size from quadriceps muscles of 8-month-old Fig4−/−/NSE-
FIG4 and WT animals. There was a small but significant reduction in total fiber area in 
transgenically rescued plt muscle: 2,799 µm2 ± 165 for WT vs 2,322 µm2 ± 121 for plt (n 
= 60, P = 0.02). (C) Transmission electron photomicrographs from tibialis anterior 





Figure 2.8 Fig4 haploinsufficiency does not improve the Mtm1-knockout phenotype. 
(A) Hematoxylin and eosin stain of quadriceps muscle from wild-type (WT; 
plt+/−) (top), Mtm1-knockout (Mtm1-KO) (SM, middle) and plt+/−/Mtm1-KO (DM, 
bottom) animals. There was no obvious difference in the appearance of the muscle or in 
the number of abnormal fibers (arrows). (B) Distribution of fiber area. Fiber area was 
measured from WT; plt+/−), single-mutant (SM; Mtm1-KO) and double-mutant (DM; 
plt+/−/Mtm1-KO) skeletal muscles. Thirty fibers from each animal were measured (n = 4 
for SM and DM, n =2 for WT). (C) Terminal body weight (measured in grams). There 
was significant reduction in the Mtm1-KO body weight compared to WT. There was no 
improvement in body weight in plt+/−/Mtm1-KO animals. Average values were as 
follows: 17.8 ± 0.6 g for WT (n = 8), 11.4 ± 0.7 g for Mtm1-KO (n = 9, P < 0.0001 
compared to WT) and 10.5 ± 0.9 g for plt+/−/Mtm1-KO (n = 5, P = 0.48 compared to 
Mtm1-KO). (D) Haploinsufficiency of Fig4 did not provide any survival benefit. Average 








Figure 2.9 Myofiber size is reduced in plt skeletal muscle. 
 (Left panel) Quantitation of myofiber size from quadriceps muscle of 4 week of 
plt and wild type (WT) animals. There was significant reductions in the size of both type 
I and type II fibers. SDH staining was used to distinguish fiber types. 
(Right panel) Quantification of myofiber size from quadriceps muscle of 8 month 
old TgNSEplt and wild type animals. There was a small but significant reduction in total 







Figure 2.10 Body mass is reduced in plt animals. 
Wild type (WT) and plt (mutant) animals were weighed just prior to muscle force 





Figure 2.11 Muscle mass is reduced in plt animals 
Muscle from wild type (WT) and plt (mutant) animals was weighed just prior to 
muscle force measurements. There was a significant reduction in average muscle mass in 






Figure 2.12 Vacuoles form in primary cultures from isolated muscle cells.  
Muscle specific knockout of FIG4 results in the formation of vacuoles in isolated 




Conditional knockout of PIK3C3 causes a murine muscular dystrophy 
3.1 Abstract 
Abnormalities in phosphoinositide metabolism are an emerging theme in human 
neurodegenerative disease. Myotubular myopathy (MTM) is a prototypical disorder of 
phosphoinositide dysregulation that is characterized by profound muscle pathology and 
weakness and that is caused by mutations in MTM1, a phosphatase that targets 3-position 
phosphoinositides (PIs), and particularly phosphatidylinositol 3-phosphate (PtdIns(3)P). 
While the association between MTM1 and muscle disease has become more clarified, the 
normal role(s) of PtdIns(3)P metabolism in muscle development and homeostasis remain 
poorly understood. To begin to address the function of PtdIns(3)P in skeletal muscle, we 
focused on the primary kinase responsible for its production, and created a muscle-
specific conditional knockout of the class III PI 3-kinase, Pik3c3 (VPS34). Muscle 
specific deletion of Pik3c3 did not disturb embryogenesis or early postnatal development, 
but resulted in progressive disease characterized by reduced activity and death by two 
months of age. Histopathological analysis demonstrated changes consistent with a murine 
muscular dystrophy. Examination for cellular mechanism(s) responsible for the 
dystrophic phenotype revealed significant alterations in the autophagolysosomal pathway 
with mislocation of known dystrophy proteins to the lysosomal compartment. In all, we 
present the first analysis of Pik3c3 in skeletal muscle, and report a novel association 
between deletion of Pik3c3 and muscular dystrophy.  
3.2 Introduction 
Phosphatidylinositols (PtdIns) comprise a group of low-abundance lipids with 
hydroxylated inositol head groups that are capable of receiving phosphates at any of the 
three outer positions. Dynamic phosphorylation of the inositol ring influences many 
cellular and metabolic processes including endocytosis, endosomal trafficking, and 
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autophagy (Itoh and Takenawa 2002, Payrastre 2004, Di Paolo and De Camilli 2006, 
Michell, Heath et al. 2006, Lecompte, Poch et al. 2008). The quantity and localization of 
different PtdInsPs are regulated by a group of phosphoinositide kinases and phosphatases 
that function as key regulatory gene products and that have been implicated in a number 
of human diseases, including especially oncologic and neurodegenerative diseases (De 
Camilli, Emr et al. 1996, Lindmo and Stenmark 2006, Volpicelli-Daley and De Camilli 
2007, Nicot and Laporte 2008).  
Myotubular Myopathy (MTM) is a severe childhood onset disease of skeletal 
muscle caused by mutations in the phosphoinositide phosphatase myotubularin (MTM1) 
(Laporte, Bedez et al. 2003, Dowling, Vreede et al. 2009). MTM is characterized by 
profound weakness and hypotonia at birth, persistent life-long disabilities including 
wheelchair and ventilator dependence, and early mortality (Das, Dowling et al. 2011). As 
predicted by the fact that MTM1 has been shown in vitro to be responsible for 
dephosphorylation of PtdIns(3)P, levels of PtdIns(3)P are significantly elevated in animal 
models of MTM (Dowling, Vreede et al. 2009, Pierson, Dulin-Smith et al. 2012, 
Amoasii, Hnia et al. 2013). Despite growing knowledge of disease pathogenesis, there are 
currently no available treatments for MTM. One significant barrier toward therapy 
development for MTM is the fact that the normal function(s) of PtdIns(3)P in skeletal 
muscle are unknown.  
PtdIns(3)P is created through phosphorylation of PtdIns at the 3 position of the 
inositol ring by PtdIns 3-kinases (Backer 2008, Meijer and Klionsky 2011), or through 
dephosphorylation of PtdIns(3,5)P2 by FIG4 (Jin, Chow et al. 2008). There are three 
classes of PtdIns 3-kinases that produce PtdIns(3)P in mammals, with varying tissue 
expression and substrate specificity (Yan and Backer 2007, Vanhaesebroeck, Guillermet-
Guibert et al. 2010). In skeletal muscle, the primary sources of PtdIns(3)P are 
hypothesized (based on gene expression) to be the class III kinase, Pik3c3 (hVPS34), and 
the class II kinase Pik3c2β, with PIK3C3 considered the major enzymatic regulator of its 
production (Herman and Emr 1990, Backer 2008, Meijer and Klionsky 2011). Previous 
studies of PIK3C3 have identified it as a regulator of several intracellular processes 
including endosome-to-golgi membrane traffic (Lindmo and Stenmark 2006), 
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endocytosis (Futter, Collinson et al. 2001, Johnson, Overmeyer et al. 2006), mTOR-S6K1 
signaling (Nobukuni, Kozma et al. 2007, Nishida, Arakawa et al. 2009), and autophagy.  
A homologue for the gene product of Pik3c3 was initially discovered and 
characterized in yeast as vacuolar protein-sorting 34 (Vps34), with mutants exhibiting 
defective partitioning of the vacuolar membrane between mother and daughter cells 
(Herman and Emr 1990). It was later found to be present in a number of complexes with 
other kinases and regulatory proteins such as Vps15 (known as PIK3R4 in mammals) 
(Stack, Herman et al. 1993), Beclin1 (Furuya, Yu et al. 2005), and the GTPase, Rab7 
(Stein, Cao et al. 2005). Early in the studies of Vps34/Vps15 in yeast, there were already 
suggestions of multiple complexes forming under circumstances promoting either 
autophagy or carboxypeptidase Y (Kihara, Noda et al. 2001), that eventually became 
known as complex I (Vps34, Vps15, Vps30/Atg6, and Atg14) and complex II (Vps34, 
Vps15, Vps30/Atg6, and Vps38), regulating autophagy and vacuolar protein sorting, 
respectively (Itakura, Kishi et al. 2008). Mammalian homologues were characterized 
forming similar complexes, with Vps34 known as hVps34 or PIK3C3, Vps15 known as 
PIK3R4, Vps30/Atg6 known as Beclin1, Atg14 known as Atg14l, and Vps38 known as 
UV irradiation resistance-associated gene (UVRAG) (Itakura, Kishi et al. 2008). Perhaps 
its best-studied function is in autophagy, where PIK3C3 and its regulatory subunit 
PIK3R4 form multiple complexes with other autophagy genes to regulate several steps of 
autophagosome formation and maturation (Funderburk, Wang et al. 2010, Miller, 
Tavshanjian et al. 2010, Jaber, Dou et al. 2012, Nemazanyy, Blaauw et al. 2013). 
The goal of this study is to begin understanding the role of PtdIns(3)P in skeletal 
muscle by evaluating the function of PIK3C3. As previously reported, whole animal gene 
knockout of Pik3c3 in the mouse results in early embryonic lethality (Zhou, Wang et al. 
2010, Zhou, Takatoh et al. 2011). Therefore, to study PIK3C3 specifically in muscle we 
have utilized the Cre-lox system. Cre-lox mediated knockout of Pik3c3 has been 
performed in kidney (Bechtel, Helmstadter et al. 2013), liver and heart (Jaber, Dou et al. 
2012), sensory, cortical and hippocampal neurons (Zhou, Wang et al. 2010, Wang, 
Budolfson et al. 2011), and T-cells (Willinger and Flavell 2012), but Pik3c3 has yet to be 
examined in skeletal muscle. We generated mice with conditional knockout of Pik3c3 in 
skeletal muscle by combining floxed Pik3c3 (Zhou, Wang et al. 2010) and Cre 
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recombinase under the muscle creatine kinase promoter: Tg(Ckmm-Cre) (Bruning, 
Michael et al. 1998). The resulting mice had normal embryonic and early postnatal 
development, but died by 2 months of age, presumably from severe cardiomyopathy 
(Jaber, Dou et al. 2012). Somewhat surprisingly, examination of skeletal muscle in 
knockout animals revealed a murine muscular dystrophy. We present the comprehensive 
characterization of this dystrophic phenotype. In all, we report for the first time a 
requirement for Pik3c3 in skeletal muscle homeostasis, and further identify loss of 
Pik3c3 as a cause of muscular dystrophy in the mouse.  
3.3 Results 
3.3.1 Generation and verification of muscle specific Pik3c3 knockout mice 
We generated muscle specific Pik3c3 knockout mice by breeding mice harboring 
a conditional null mutant allele, in which exons 17 and 18 of Pik3c3 are flanked by LoxP 
sites (Pik3c3flox/+) (Zhou, Wang et al. 2010), with previously characterized transgenic 
mice expressing Cre recombinase under the muscle creatine kinase (Ckmm) promoter 
(TgCkmm-Cre) (Bruning, Michael et al. 1998). Heterozygous animals 
(Pik3c3flox/+;TgCkmm-Cre+) were intercrossed to produce Pik3c3 muscle specific 
knockout mice (TgCkmm-Cre+; Pik3c3flox/flox), referred to as Pik3c3-cKO or simply KO, 
and sibling mice, referred to as littermate controls or wild type (WT). An example of 
PCR based genotyping, using previously published primers (Zhou, Wang et al. 2010), 
from a representative cross is presented in Figure 3.1A. 
To verify that we successfully achieved knockdown of Pik3c3 expression, we 
compared both transcript and protein levels from skeletal muscle of knockout mice and 
age-matched littermates. Quantitative RT-PCR (qPCR) revealed an average reduction in 
skeletal muscle of (mRNA) Pik3c3 levels of 82 ± 31% (s.e.m.) in knockout mice 
compared to wild types (n = 4, p = 0.038) (Figure 3.1B). Western blot analysis of extracts 
from quadriceps muscle demonstrated an average reduction of PIK3C3 protein levels to 
11 ± 4% (s.e.m.) of wild type (n = 3, p < 0.001) (Figure 3.1C, D).  
PIK3C3 is hypothesized to be the primary kinase that generates PtdIns(3)P. To 
determine the consequence of reduced PIK3C3 levels on PtdIns(3)P levels, we next 
examined PtdIns(3)P levels from quadriceps muscle of knockout animals and wild type 
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littermates. We did this using an established PtdIns(3)P ELISA (Pierson, Dulin-Smith et 
al. 2012). ELISA based analysis revealed a reduction of PtdIns(3)P levels in skeletal 
muscle of knockout animals to 50% of controls (n = 9) (Figure 3.1E). This level of 
reduction is in keeping with (though less than) the reduction of amount of PIK3C3 
protein, and supports the previous assumption that PIK3C3 is the primary (but not sole) 
kinase responsible for PtdIns(3)P production in skeletal muscle. 
3.3.2 Muscle specific knockdown of Pik3c3 resulted in premature lethality 
Pik3c3-cKO animals appeared normal at birth, and are qualitatively similar to 
littermates through the first month of extra-uterine life (Figures 3.2A,B). This was 
revealed subjectively through animal appearance and activity, and objectively by analysis 
of body weight of gender-matched animals, as comparisons did not show significant 
differences (Figure 3.2A-C). In addition, skeletal muscle tissue taken from animals 
sacrificed within the first month appeared histologically normal (Figure 3.9).  
However, between 40 and 60 days of age, KO animals began to exhibit an overt 
phenotype consisting mainly of reduced voluntary activity. The youngest animal 
observed in our cohort to demonstrate overt phenotypic changes did so at age 42 days (n 
= 27 KO animals). Shortly after first signs of disease, the Pik3c3-cKO animals displayed 
progressively reduced mobility as well as early mortality. The youngest age of death was 
42 days old, while the oldest living knockout animal survived only to 62 days (Figure 
3.2D). The exact cause of death in KO animals was not precisely known, though we 
strongly suspect it is related to cardiac disease (see below).  
3.3.3 Pik3c3 knockout causes a severe dilated cardiomyopathy 
Because the Ckmm promoter expresses in cardiac and skeletal muscle, we next 
examined the hearts of Pik3c3-cKO animals. We first analyzed levels of Pik3c3 transcript 
from heart tissue by qPCR (Figure 3A), and showed an average reduction of 87±3% 
(s.e.m.). We next examined the gross anatomic phenotype of the hearts, and observed a 
dramatic increase in heart size, with the average knockout heart to body mass ratio 
measuring 250% of aged matched controls: (Figures 3.3B,C). Low magnification 
histopathologic analysis corroborated this anatomic observation, revealing qualitative 
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enlargement and thickening of both atrium and ventricle (n = 3) (Figure 3.3D). In 
addition, echocardiography showed evidence of significant cardiac hypertrophy and 
severe cardiac dysfunction (Table 3.1). While B-mode measurements of chamber 
dimensions were largely unchanged, all measurements of septal and posterior left 
ventricular wall thickness by M-mode were significantly increased in Pik3c3-cKO mice 
(Figure 3.3D), with estimated ventricular mass consistent with the morphological 
findings in isolated hearts. Indices of systolic function including ejection fraction and 
stroke volume and cardiac output were all decreased in Pik3c3-cKO, while resting heart 
rate was unchanged. Diastolic function was also impaired as indicated by an increase in 
isovolumic relaxation time and ratio of mitral valve E blood velocity to E’ tissue Doppler 
velocity at the septal annulus. In all, our analysis supports a conclusion that Pik3c3 
deletion in the heart causes a severe cardiomyopathy. Of note, our results are consistent 
with a previously published study using cre-lox knockout of Pik3c3 (Jaber, Dou et al. 
2012). 
3.3.4 Pik3c3 knockout results in a murine muscular dystrophy 
As our primary interest in creating conditional knockouts of Pik3c3 was to 
examine its requirement for skeletal muscle development and homeostasis, we focused all 
subsequent studies on skeletal muscle. We began our analysis by performing routine 
histopathology studies from quadriceps, gastrocnemius, and tibialis anterior muscles. 
Hematoxylin and eosin staining of fresh frozen, cryosectioned muscle from 42-60 day old 
animals revealed clearly abnormal areas with features that included inflammatory 
infiltrates (small blue cells, indicated by arrows), and degenerating and regenerating 
fibers (arrowheads) (Figure 3.4). Within these areas of abnormal muscle, there was a 
significant increase in myofibers with internalized nuclei (Figure 3.10A), consistent with 
muscle regeneration (Figure 3.4A,B). In total, the histopathological changes 
(inflammatory cells, increased internal nuclei and degenerating fibers) were consistent 
with a murine muscular dystrophy. These changes were seen in all muscle groups 
evaluated and in multiple different animals (n=5).  
Of note, there were as well areas of relatively unaffected muscle next to areas 
with dystrophic changes. In addition, muscles harvested from older knockout animals had 
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more areas of aberrant fibers, while (as mentioned above) muscle analyzed before 1 
month of age appeared normal (Figure 3.9). Also, average fiber size was not significantly 
different between knockouts and their littermates (Figure 3.10B). Lastly, we did not 
observe an increase in fibrosis in dystrophic muscle areas of the knockout animals 
(Figure 3.11).  
To corroborate the histopathologic observation of dystrophic muscle in Pik3c3 
knockout mice, we used two additional strategies (Figure 3.5). The first was to measure 
serum creatine phospho-kinase (CK) levels. We obtained blood samples from the 
saphenous vein of animals that were not previously exposed to strenuous exercise or diet 
modifications. CK levels were significantly and highly elevated (p = 0.0062). The 
average level in 45 day-old mice was almost 20-fold higher in conditional knockout 
animals (5450 ± 1260, n=4) as compared to their littermate controls (230 ± 66, n=4, 
Figure 3.5A). 
The second measure of muscular dystrophy was assessment of Evans blue dye 
uptake in skeletal muscle (Figure 3.5B). After systemic injection of Evans blue dye, 
damaged/dystrophic fibers demonstrate dye uptake, while healthy fibers do not. As 
compared to wild types, there was a visible increase in EBD positive fibers, indicating 
damaged muscle in the knockouts. Importantly, there was only a slight increase in EBD 
in the hearts of knockout animals (Figure 3.12), suggesting that the elevated CK levels 
found in the knockouts are most likely from skeletal (and not cardiac) muscle breakdown. 
In all, based on histopathology, serum CK levels, and EBD studies, we concluded that 
reduction of Pik3c3 expression resulted in a murine muscular dystrophy.  
3.3.5 Ultrastructural analysis reveals aberrant membrane structures  
We performed analysis of skeletal muscle ultrastructure to look for clues related 
to muscle disease pathogenesis. Despite elevated CK levels and abnormal EBD uptake, 
no obvious membrane discontinuities or tears were observed in Pik3c3 cKO muscle. 
However, there were widespread and striking abnormalities in several subcellular 
structures (Figure 3.6). Specifically, among the various abnormalities we observed, we 
detected frequent swellings associated with internal sarcolemmal membranes (Figure 
3.6B, arrows) as well as aberrantly appearing mitochondria (Figure 3.6B, arrow-heads). 
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We also observed degradation compartments surrounded by double membranes, a finding 
consistent with aberrant autophagy (Figures 3.6C,E, arrows). Overall, these changes were 
consistent with a defect in membrane turnover (Millay, Maillet et al. 2009), and resemble 
changes seen in skeletal muscle with defective autophagy (Nishino 2003). 
3.3.6 Autophagy genes had aberrant expression and localization in cKO animals 
One of the functions of PIK3C3 in vitro is in the initiation of autophagy. Given 
that the ultrastructural changes were reminiscent of defective autophagy, we examined 
Pik3c3 cKO muscle for evidence of aberrant autophagy. We examined autophagy using 
three approaches: (1) measurement of autophagy related gene expression changes by 
qPCR, (2) examination of autophagic markers by Western blot analysis, and (3) study of 
markers by immunocytochemistry. qPCR revealed significant increases in transcripts 
associated with autophagy, including upregulation of p62 (4.5 ± 0.97 fold change) and 
LC3 (3.3 ± 0.53 fold change) (Figure 3.7A). We also detected increased expression of 
gene products associated with muscle atrophy, such as ubiquitin ligases atrogin-1 (7.0 ± 
1.7 fold change) and MuRF1 (3.1 ± 0.71 fold change). Similarly, we observed significant 
increases in levels of the lysosomal proteinase, cathepsin L (9.1 ± 1.8 fold change). While 
other reports (Mammucari, Milan et al. 2007) on muscle wasting have shown 
upregulation in Bnip3 and Bnip3l, levels of these transcripts were unaffected by the 
Pik3c3 knockout: Bnip3 had a 0.92 ± 0.2 fold change and Bnip3l gave a 0.86 ± 0.23 fold 
change when normalized to WT animals. This is consistent with the fact that we did not 
detect any corresponding alterations in overall muscle size or in the size of individual 
fibers (Figure 3.10).   
We next examined autophagy by looking at protein markers of the pathway. 
Western blot analysis showed significant increases in total protein levels of LC3 and p62: 
LC3-I increased 604% ± 137% and LC3-II by 420% ± 118%, while ratios of LC3-I:LC3-
II remained not significantly different (147% ± 12%) (Figure 3.7B-E); p62 antibody 
showed increases in KO muscle to 1593% ± 137% that of WT controls, using β-actin as 
internal control (n=3). These changes are consistent with defective autophagic flux and 
with the measurements of transcript levels. We performed immunocytochemical analysis 
using an antibody to p62, a protein associated with the initiation of autophagy that 
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accumulates when autophagic flux is impaired. We observed significant accumulation of 
p62 with fibers of KO animals, as compared to basically absent staining in age-matched 
control siblings (Figure 3.7F-H). In total, Pik3c3-cKO resulted in upregulation of markers 
of autophagy, but rather than showing turnover of key proteins, we witnessed an 
accumulation of the markers of autophagosome formation, consistent with an overall 
impairment in the initiation of autophagy. 
3.3.7 Loss of PIK3C3 causes impairment in lysosomal function 
Because aberrant autophagy alone is unlikely to explain the histopathologic 
changes we observed, we sought to uncover additional potential causes for dystrophic 
muscle pathology in the KO mice. Because elevated CK levels and increased EBD uptake 
were suggestive of compromised integrity of the muscle’s external membrane, we 
analyzed expression and localization of integral membrane proteins using 
immunohistochemistry. We observed striking changes in the localization of both 
dystrophin and caveolin-3. In numerous muscle fibers from KO (but not wild type) 
animals, these proteins, while still present at the membrane, also accumulated within the 
myofiber (Figure 3.8B,C,E,F). The mislocalization of these proteins occurred without a 
change in their overall levels, as determined by western blot analysis (Figure 3.13). 
Internal accumulation of membrane proteins has been previously reported in the 
setting of abnormal lysosomal function (Nemazanyy, Blaauw et al. 2013). We therefore 
sought to interrogate lysosomal function in our knockout animals. We examined LAMP1 
staining, and found two important changes as compared to wild types (Figure 3.8A,D): 
accumulation of LAMP1 staining within myofibers as well as increased intensity of 
LAMP1 staining around the plasma membrane. Both findings have been observed in 
other models of lysosomal dysfunction (Malicdan and Nishino 2012). In order to 
quantitate a possible abnormality in lysosomal function, we looked at cathepsin-D 
processing by western blot analysis. Cathepsin-D processing is used as a marker for the 
normal functioning of the lysosome. We found a significant decrease in the mature forms 
of cathepsin-D, suggesting a significant abnormality in the ability of the lysosome to 
cleave cathepsin to its mature, active form (Figure 3.8G,H). Taken together with the 
immunostaining results for LAMP1, dystrophin and caveolin-3, these results are 
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consistent with impaired lysosomal function and suggest aberrant lysosomal processing is 
the cause of membrane protein mislocalization.  
3.4 Discussion 
In summary, we have generated muscle-specific knockout mice of Pik3c3 
(Vps34) and provided the first phenotypic description of the role of PIK3C3 in skeletal 
muscle. Knockout mice had reduced levels of Pik3c3 mRNA and protein in striated 
muscle, and had significantly reduced levels of PtdIns(3)P, the phospholipid generated by 
PIK3C3. Using both morphological and functional analyses, we identified significant 
changes in skeletal and cardiac muscle structure and function and in the overall health of 
the animals, including premature lethality in the second postnatal month. Our results 
specifically identify PIK3C3 as a gene product required for normal muscle structural 
integrity and for the regulation of basal autophagy and lysosome function in skeletal 
muscle.  
One of the most significant findings in our study was the appearance of 
dystrophic muscle pathology in affected mice. This observation was in contrast to our pre 
experiment prediction that loss of Pik3c3 would be associated with abnormalities similar 
to those observed with myotubularin dysfunction, as both over expression and knockout 
of Mtm1 cause significant disruption of the sarcotubular network and (at least for Mtm1 
knockout) a centronuclear myopathy phenotype. Pik3c3-cKO mice clearly did not have a 
centronuclear myopathy, but instead had changes consistent with a muscular dystrophy. 
The presence of a dystrophy was established based on histopathology, CK levels, and 
Evans blue dye staining, and our study thus provides a connection between dysfunction in 
PtdInsP regulation and dystrophic muscle pathology. Of note, a recent study described 
the muscle specific knockout of Vps15, which functions as a co-factor of PIK3C3 
required for many aspects of its function. These mice similarly manifested a murine 
muscular dystrophy, a finding that corroborates the data from the present manuscript 
(Nemazanyy, Blaauw et al. 2013).  
The appearance of dystrophic pathogenesis gives insight into the involvement of 
PIK3C3 in pathways other than canonical Beclin-complex-mediated autophagy. Based on 
previous knockout mice studies, it is unlikely that the defects in autophagy we observed 
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in Pik3c3 KOs are sufficient to explain the severe muscular dystrophy seen in these 
animals. Specifically, disruption the essential components of autophagic machinery Atg7 
and Atg5 does not result in dystrophic pathology, but instead a mild myopathy 
characterized by reduced myofiber size (Raben, Hill et al. 2008, Masiero, Agatea et al. 
2009). Instead, we postulate that abnormalities in lysosomal function are more likely to 
be the cause of the dystrophic animals. This assertion is supported by two major 
observations. The first is that mutations in the lysosomal proteins LAMP2 and GAA both 
result in skeletal muscle disease (Danon Disease (Malicdan and Nishino 2012) and 
Pompe Disease (Raben, Roberts et al. 2007), respectively) with dystrophic features. The 
second is that lysosomal function (and in particular lysosomal exocytosis) has been 
implicated in the regulation of membrane repair (Chakrabarti, Kobayashi et al. 2003), and 
defective membrane repair is a well-established trigger for the development of muscular 
dystrophy (Shin, Tajrishi et al. 2013). Additional experimentation will obviously be 
necessary to specifically establish why the loss of PIK3C3 function causes a muscular 
dystrophy, and to parse out which of the many potential functions of the protein are 
responsible for regulating membrane integrity in skeletal muscle. 
Of note, there are several independent studies of mice with conditionally deleted 
alleles of Pik3c3 in neurons (Zhou, Wang et al. 2010), in T-cells (Willinger and Flavell 
2012), in podocytes (Bechtel, Helmstadter et al. 2013), and in heart and liver (Jaber, Dou 
et al. 2012). Consideration of these studies reveals several common features of organs 
lacking PIK3C3 that are seen as well in our muscle-specific deletion. These include 
aberrant autophagy, disrupted cellular homeostasis, and overall degeneration of tissues. 
Also, there are some specific differences when comparing studies of different cell types, 
including controversy over which stages of autophagy are most affected by loss of 
PIK3C3 function (Jaber, Dou et al. 2012, Nemazanyy, Blaauw et al. 2013). It should be 
noted that there are still many aspects of autophagy initiation and regulation that are not 
well understood, such as the extent of non-canonical pathways (sans Beclin-1), and cells 
use multiple processes for sequestering and/or delivering targets to the lysosome 
(Codogno, Mehrpour et al. 2012), and future studies of the various knockout strains of 
PIK3C3 may help illuminate these issues.  
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Lastly, it should also be noted that PIK3C3 is not the only means for generating 
PtdIns(3)P in skeletal muscle. This assertion is supported by the fact that we observe a 
50% reduction in PtdIns(3)P levels in the muscle of knockouts, despite achieving much 
higher levels of PIK3C3 reduction. One candidate for generating a fraction of PtdIns(3)P 
in skeletal muscle is PIK3C2B, a class II PI 3-kinase that is expressed in skeletal muscle 
and whose function is poorly understood. Experimentation addressing the role of 
PIK3C2B in muscle, and its interplay with the functions of PIK3C3, will obviously be 
important to best understand the role of PtdIns(3)P and its regulation in skeletal muscle.  
3.5 Conclusions 
To summarize, muscle-specific conditional knockout of PIK3C3 revealed a novel 
murine dystrophy with aberrant autophagy and lysosomal function. These novel knockout 
mice provide a useful animal model for the study of degradation pathways and their 
association to the pathogenesis of muscular dystrophy.  
3.6 Materials and Methods 
3.6.1 Care and treatment of animals 
All care and treatment of animals was implemented through protocols carefully 
monitored by the University Committee on Use and Care of Animals (UCUCA). The 
University of Michigan’s Unit for Laboratory Animal Medicine (ULAM) carefully 
monitored the health of the rodent colonies. ULAM maintained proper environmental 
regulation including temperature and light cycles, unlimited access to water, appropriate 
food supply, and clean enclosures. Pups were weaned from their mothers according to 
standard protocols, and tails were clipped for genotyping, as described. 
3.6.2 Generation of mutant mouse strains 
Floxed Pik3c3 mice were a gift from Fan Wang lab, described in Zhou et al. 
(Zhou, Wang et al. 2010). Cre mice are of the strain: B6.FVB(129S4)-Tg(Ckmm-
cre)5Khn/J, obtained from Jackson labs. Mice were crossed to make Pik3c3fl/+; Cre+ 
heterozygous mice, and in-crossed to produce the double floxed allele: Pik3c3fl/fl, 
resulting in the muscle-specific conditional knockout animals. 
 
 57 
3.6.3 Genotyping of mutant mouse strains 
Protocols and primers for genotyping mice were described previously (Zhou, 
Wang et al. 2010). 
3.6.4 Quantitative PCR 
Total mRNA was isolated from muscle homogenates using QIAGEN RNeasy 
kits, and qPCR was performed using cDNA reverse-transcribed by iScript (BioRad) on 
ABI equipment using SybrGreen reagents. Analysis was done by using the ΔΔCt method. 
Primers for transcripts analyzed were previously described (Mammucari, Milan et al. 
2007). 
3.6.5 Western blots 
Protein was isolated from tissue from KO and littermate mice by mincing and 
homogenizing in T-PER buffer (Thermo) with proteinase inhibitors (Roche), with brief 
sonication on ice. Loading buffer was added to protein and run on 10%-15% acrylamide 
gels, followed by transfer to PVDF blots. Primary antibodies were applied overnight at 
4˚C at 1:1000 dilution in 3%BSA, 0.5% TritonX-100, NaF. 
Indirect analysis of protein expression was performed in ImageJ following 
procedures outlined by http://lukemiller.org/index.php/2010/11/analyzing-gels-and-
western-blots-with-image-j/. 
3.6.6 Histology 
Animals were sacrificed by anesthetic injection followed by cervical dislocation, 
and tissues were isolated using sterile surgical methods without the use of laminar flow 
hoods. Muscle tissue from quadriceps and tibialis anterior was dissected and mounted 
onto small balsawood pieces that were previously frozen with drops of O.C.T. (Optimal 
Cutting Temperature, Tissue-Tek) and then semi-thawed with light friction. The mounted 
muscle tissue was immediately submerged in a -55˚C isopentane bath cooled by liquid 
nitrogen for flash freezing. 
Muscles were cut in 12 µm cross-sections and mounted on SuperFrost Plus slides 
using a Leica cryostat at -20˚C, and dried at room temperature before storage at -80˚C. 
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Micrographs were captured with an Infinity1 camera with eponymous software 
visualized through an Olympus BX43 light microscope. Images were cropped in Adobe 
Photoshop and arranged for figures with Adobe Illustrator. 
Standard techniques for indirect fluorescent immunohistology were used: 
Snap-frozen tissues were cryosectioned and collected on superfrost slides. After 
allowing slides to dry, residual O.C.T. from mounting tissue on cryo-chuck was washed 
away with PBS. Slides were blocked for more than 30 minutes at room temperature in a 
solution of 0.25M KCl, 0.20mM HEPES with 1% BSA, 0.1% gelatin, 0.02% NaN3 and 
0.1% Triton X-100, pH 7.9. Slides were incubated overnight at 4˚C in Progen p62 anti-
guinea pig, diluted 1:100 in blocking solution. After three washes in PBS, secondary 
antibodies (Alexa Fluor® 488 conjugated with goat anti-guinea pig IgG, Life 
Technologies) were applied for one hour at room temperature, diluted 1:1000 in blocking 
solution. Slides were washed several times to remove excess secondary and then mounted 
with ProLong® Gold (Life Technologies). 
3.6.7 Bright-field imaging and fiber size analysis 
Slides were stained with Mayer’s Hematoxylin and eosin (H&E) following 
standard protocols, and mounted with Permount. 
Post-capture analysis, including tests of statistical significance, was performed 
using Microsoft Excel 2008 and Graphpad Prism 5 for MacOSX. 
3.6.8 TEM 
Immediately following dissection, tips of quadriceps were carefully cut into 
~1x2mm fragments, and incubated in Karnovsky’s fixative overnight at 4˚C. 
The fixed tissue was brought to the Microscopy and Imaging Laboratory (MIL) 
Core facility at the University of Michigan for processing. Ultrathin sections were 
analyzed for orientation, and grids were prepared for use on the Phillips CM-100 
transmission electron microscope (TEM). 
3.6.9 Measurements of serum CK 
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Serum was collected from the saphenous vein of restrained animals and stored at 
−80°C. Creatine kinase activity was measured in duplicate using CK NADP Reagent 
(Cliniqa, San Marcos, CA, USA). 
3.6.10 Evans Blue Dye uptake assay 
Evans Blue Dye was injected intraperitoneally, and allowed to infiltrate tissues 
over the course of 24 hours before mice were sacrificed and tissues sectioned as 
described above. 
3.6.11 Echocardiographic analysis 
Echocardiograms were taken of the mice as described previously. 
3.6.12 PtdIns(3)P ELISA 
Lipid analysis was performed by indirect analysis of whole muscle lysates using 
Echelon’s PtdIns(3)P Mass ELISA kit (K-3300), as previously described (Pierson, Dulin-







Figure 3.1 Muscle specific Pik3c3 knockout causes significant decrease in PIK3C3 
and PtdIns(3)P levels. 
Muscle specific knockout of Pik3c3 was confirmed through direct (DNA, mRNA, 
protein) and indirect (PtdIns(3)P levels) measures. Samples were obtained from 
quadriceps muscle isolated from 6-8 week old mice, with age-matched littermate 
controls, unless otherwise noted. (A) Genotyping of mice harboring homozygous floxed 
(fl/fl), heterozygous (fl/+), or wild-type (+/+) alleles. (B) As measured by quantitative 
RT-PCR, a significant decrease in Pik3c3 transcript levels (17.7% ± 4.7%, n=4) was 
detected in skeletal muscle from knockout (KO) animals. Values were normalized to 
Gapdh transcript levels, with wild type (WT) average value set at 100% (± 31%, n=4). 
(C) Western blot analysis confirmed reduction of PIK3C3 levels in skeletal muscle from 
KO animals. (D) Quantitation of PIK3C3 protein levels as determined by densitometric 
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analysis, using β-actin protein levels as a loading control, showed a decrease from WT 
levels (100% ± 5.4%) to 11.0% ± 1.0%. (E) PtdIns(3)P levels are reduced in KOs, as 
determined by using a PtdIns(3)P ELISA kit (purified lipid (pmol)/mass (g) of muscle 
tissue) (WT: 3967 ± 225; n=9, KO: 1982 ± 334; n=8). Error bars are presented as s.e.m. 






Figure 3.2 Muscle specific Pik3c3-cKO animals have reduced lifespan. 
The disease phenotype of knockout (KO) mice develops after one month, and 
affected mice die rapidly after onset of symptoms. (A) Despite abnormal levels of 
activity, KO mice are difficult to distinguish by overall appearance from wild type (WT) 
littermates even at 6 weeks of age (KO is on the left). (C) Body mass of KO animals was 
not significantly different (slope p=0.21) than that of WTs, though weights trended 
smaller than age matched WT littermates towards the end of KO disease progression 
(lines represent linear regression WT n=3, KO n=4). (B) Terminal body mass of WT 
(22.7 ± 0.57 g for males and 17.7 ± 0.24 g for females) and KO animals (21.4 ± 0.38 g 
for males and 17.4 ± 0.29 g for females) are not significantly different (unpaired t-tests 
for males, p=0.075, n=9; for females, p=0.45, n=5). (D) KO mice die between 6 and 8 
weeks of age, with median survival of 54 days (KO n=11, equal number of WT 







Figure 3.3 Pik3c3-cKO animals display cardiac abnormalities. 
 (A) As measured by qPCR, Ckmm driven cre expression in the heart leads to an 
87% reduction in levels of Pik3c3 transcript in KO (13.4 ± 1.2%) as compared to WT 
controls (100 ± 2.9%) (n=2, p<0.001). (B) Obvious cardiomegaly was observed in KO 
animals (scale bar = 50 mm). (C) Hearts in KO animals are 2-3 times the size of WT 
littermates. Increases in heart mass to body mass ratios are consistent in affected males 
(254 ± 16.1%) and females (234 ± 16.9%). (***, p<0.001). (D) Cross-sectional histology 
of hearts with sirius red stain demonstrates increased thickness of walls with no 
observable fibrosis (age = 45 days). (E) Representative M-mode echocardiograms from 
the left ventricle of KO mice show marked left ventricular wall hypertrophy compared to 




Table 3.1 Echocardiographic analysis of VPSKO mice. 
  WT Pik3c3-cKO P-value 
BW (gm)  22.2 +/- 4.5 18.7 +/- 3.0 0.152 
HR (bpm)  494 +/- 42 486 +/- 46 0.788 
Chamber morphology     
LVDd (mm2)  27.6 +/- 6.0 25.49 +/- 3.8 0.47 
LVDs (mm2)  17.6 +/- 3.5 19.2+/- 3.4 0.42 
LVd length (mm)  7.36+/- 1.0 8.0 +/- 0.7 0.21 
LVs length (mm)  6.25 +/- 0.9 7.2 +/- 0.7 0.06 
LV Wall thickness     
IVSd (mm)  0.73+/-0.05 1.19 +/- 0.15 <0.001 
IVSs (mm)  0.99 +/- 0.08 1.47 +/- 0.26 0.001 
PWd (mm)  0.68 +/- 0.04 1.2- +/- 0.16 <0.001 
PWs (mm)  1.00 +/- 0.10 1.32 +/- 0.18 0.004 
LV mass (gm)  0.11 +/- 0.02 0.19 +/- 0.03 <0.001 
Systolic function     
SV (ul/beat)  46.4 +/- 17.1 25.1 +/- 4.7 0.016 
CO (ml/min)  18.6 +/- 4.3 12.3 +/- 1.5 0.025 
EF (%) (B-mode)  51.7 +/- 5.9 37.0 +/- 5.1 0.002 
EF (%) (M-mode)  48.2 +/- 5.7 31.7 +/- 11.9 0.013 
Diastolic function     
IVRT (ms)  17.58 +/- 2.83 30.05 +/- 10.7 0.021 
E/E'sa  40.52 +/- 6.32 55.98 +/- 10.2 0.011 
     
     
 
Data are mean +/- SD, n=5 each genotype. Data in bold are statistically significant 
by Student’s T-test. Abbreviations: BW, bodyweight; HR, heart rate; LVD left 
ventricular dimension; LV, left ventricular, IVS; intraventricular septum; PW, posterior 
wall; SV, stroke volume; CO, cardiac output; EF, ejection fraction; IVRT, isovolumic 
relaxation time; E/E’Sa, ratio of mitral valve E blood velocity to E’ tissue Doppler 






Figure 3.4 Pik3c3-cKO animals have aberrant histology.  
Histological analysis of Pik3c3-cKO skeletal muscle shows signs of muscular 
dystrophy. Sections were taken from gastrocnemius muscle of 60-day-old wild type (WT) 
and knockout (KO) animals and stained with Hematoxylin and Eosin. (scale bar = 100 
µm) (A) Low magnification images reveal inflammatory infiltrate (arrows) and changes 
consistent with degeneration and regeneration (arrowheads). (C-F) Higher magnification 
micrographs show changes as in (A,B) but also better reveal abundant internal nuclei. 






Figure 3.5 Pik3c3-cKO mice exhibit dystrophic muscle by independent measures. 
(A) Creatine phosphokinase (CK) measurements of serum obtained from the 
distal saphenous vein showed increases of nearly 50 fold in excess when KO (avg = 5452 
± 1263 mU/mL, n=4) are compared to wild type littermates (avg = 233.3 ± 65.51 
mU/mL, n=4). Significance: ***, p<0.001. (B) Evans Blue Dye (EBD) is taken up by 
dystrophic fibers after 24 hours of incubation following pertitoneal injection. EBD is 
shown in red and counterstained against the extracellular membrane protein Laminin in 





Figure 3.6 Ultrastructural analyses by TEM show aberrant features in Pik3c3-cKO 
mice. 
Tissue from tibialis anterior muscle of six-week-old mice was prepared, mounted 
on slotted grids and imaged on a Phillips CM-100 transmission electron microscope. 
Analysis of TEM micrographs of wild type (WT) littermate controls (A) and Pik3c3-cKO 
(B-E) reveals numerous defects in muscle ultrastructure including sarcoplasmic swellings 
in addition to aberrant vacuoles (arrows) and mitochondria (arrowheads). Scale bar for 








Figure 3.7 Pik3c3-cKO mice exhibit aberrant markers of basal autophagy. 
(A) Transcript levels were measured from mRNA isolated from quadriceps of 
two-month-old Pik3c3-cKO (KO) and wild type (WT) littermates. Results using primers 
for (Map1-)Lc3 (3.3 ± 0.53 fold change), p62 (4.5 ± 0.97 fold change), Murf1 (3.1 ± 0.71 
fold change), Atrogin1 (7.0 ± 1.7 fold change), CathepsinL (9.1 ± 1.8 fold change), Bnip3 
(0.92 ± 0.2 fold change) and Bnip3l (0.86 ± 0.23 fold change) were normalized to Gapdh 
internal controls. y-axis indicates fold increase normalized to littermate controls for ΔΔCt 
(n=3). (B, C) Protein was isolated from quadriceps of two-month-old KO and WT 
littermates for analysis by Western blot with antibodies against MAP1-LC3 and p62. (D) 
Densiometric analysis of LC3-I/II was performed using GAPDH as internal control 
(n=2), showing increases in LC3-I (604% ± 137%) and LC3-II (420% ± 118%), while 
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ratios of LC3-I:LC3-II remained not significantly different (147% ± 12%). (E) 
Densiometric analysis of blot probed with p62 antibody showed increases in KO muscle 
to 1593% ± 137% that of WT controls, using β-actin as internal control (n=3). Sectioned 
gastrocnemius muscle from 60-day-old animals stained using immunochemistry shows 





Figure 3.8 Aberrant accumulation of membrane-associated proteins indicates 
trafficking dysfunction. 
Sectioned gastrocnemius muscle from 60-day-old animals stained using 
immunochemistry shows accumulation of LAMP1 (A and D), Caveolin-3 (B and E) and 
Dystrophin (C and F) in knockout (KO) animals compared to littermate controls. (G) 
Western blot of Cathepsin D reveals alterations in the processing of mature form in KO 
animals from Procathepsin D (Pro), Preprocathepsin D (Pre), and Cathepsin D heavy 
chain (HC) isoforms. (H) Densiometric analysis reveals significant decreases (p<0.01) in 
the levels of Pre and HC isoforms, demonstrated as overall levels normalized to β-actin at 
left, and as total fraction of Cathepsin D at right. 
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3.8 Additional Figures 
 
 
Figure 3.9 Muscle of young Pik3c3 cKO animals appears normal by histological 
analysis.  
Tibialis anterior muscle from animals harvested at 1 month of age appears 
normal. Top panels are from age matched littermate (WT) control. Bottom panels are 
from a Pik3c3 knockout (KO) animal. Left panels are stained with H&E. Right panels are 




Figure 3.10 Cross-sectional muscle analysis is typical of a dystrophic phenotype. 
(A) Concentrated areas of aberrant fibers contained elevated numbers of 
internalized nuclei in knockout (KO) animals (49 ± 11, n=4) compared to control 
littermates (WT) (1 ± 1, n=4). (B) Muscle fiber area distribution in knockout animals 






Figure 3.11 Fibrosis abnormalities are absent from muscle samples. 
Representative level 3 tibialis anterior muscle of 48-day-old mice—control 
littermate (A), knockout (B)—stained with Gomori Trichrome as a test for fibrosis. There 






Figure 3.12 Hearts have limited loss of muscle integrity, as measured by Evans Blue 
Dye uptake. 
48-day-old animals were injected with Evans Blue Dye (EBD) and sacrificed 24 
hours later. Hearts were cryoprotected and sectioned at level 3. Pik3c3 knockout (KO) 
animals showed sparse fibers containing EBD, counterstained with anti-laminin for 




Figure 3.13 Overall levels of integral membrane proteins are unaffected by Pik3c3 
knockout. 
Integral membrane proteins showed no appreciable differences in overall 








Mice with conditional muscle knockout of Pik3c2β  show glucose 
intolerance and loss of muscle integrity 
4.1 Abstract 
Phosphoinositide metabolism plays a role in many of the pathways responsible for 
a variety of human neurodegenerative diseases. One such prototypical disorder of 
phosphoinositide dysregulation is Myotubular myopathy (MTM), characterized by 
profound muscle pathology and weakness, and caused by mutations in MTM1, a 
phosphatase that primarily targets PtdIns(3)P. While the association between MTM1 and 
muscle disease has become more clarified, the normal role(s) of PtdIns(3)P metabolism 
in muscle development and homeostasis remain poorly understood. Following up on our 
recent study of muscle-specific conditional knockout of the class III Phosphatidylinositol 
3-kinase, Pik3c3 (hVps34), we generated mice with conditional muscle deletion of a class 
II Phosphatidylinositol 3-kinase: Pik3c2β. Muscle specific deletion of Pik3c2β caused no 
overt physiological defects or decreased survival by 11 months of age. Histopathological 
analysis of skeletal muscle from knockouts appeared normal. Exploration for aberrant 
cellular mechanism(s) revealed potential roles for PIK3C2β in glucose trafficking and 
cell membrane dynamics. Of note, blood glucose levels were significantly elevated in 
knockout animals at time points following injection of glucose, but not following insulin. 
There were significant increases in resting serum CK in KO animals. In all, we present 
the first analysis of PIK3C2β in skeletal muscle, and report significant changes in some 




The regulation of phosphatidylinositol phosphates (PtdInsPs) by its dynamic 
phosphorylation plays a significant role in cellular signaling pathways and membrane 
trafficking (Di Paolo and De Camilli 2006, Maffucci 2012). Mutations in several of the 
phosphatases that regulate PtdInsPs have been implicated in neurological diseases 
(Amoasii, Hnia et al. 2012). One such disease is myotubular myopathy (MTM), an X-
linked centronuclear myopathy (CNM) that is characterized by significant disability and 
early mortality in boys carrying mutations in the gene myotubularin (MTM1) (Jungbluth, 
Wallgren-Pettersson et al. 2008, Das, Dowling et al. 2011). MTM1 is a PtdInsP 3-
phosphatase, that primarily targets PtdIns(3)P (Taylor, Maehama et al. 2000) as well as 
PtdIns(3,5)P2 (Tronchere, Laporte et al. 2004). Levels of these particular PtdInsPs are 
elevated in animal models of the disease (Dowling, Vreede et al. 2009, Pierson, Dulin-
Smith et al. 2012). 
PtdIns(3)P is created primarily through phosphorylation of PtdIns at the 3 
position by PI 3-kinases (PI3Ks) (Backer 2008, Meijer and Klionsky 2011), or through 
dephosphorylation of PtdIns(3,5)P2 by FIG4 (Jin, Chow et al. 2008). There are three 
classes of PI3Ks that are capable of producing PtdIns(3)P in mammals, with varying 
tissue expression and substrate specificity (Yan and Backer 2007, Vanhaesebroeck, 
Guillermet-Guibert et al. 2010). The PI3Ks include eight specific isoforms containing a 
PI3K core with C2, helical and catalytic domains (Vanhaesebroeck, Guillermet-Guibert 
et al. 2010). The Class I PI3Ks primarily phosphorylate PtdIns(4,5)P2 to form 
PtdIns(3,4,5)P3, and so the primary sources of PtdIns(3)P in muscle are PIK3C3 and the 
class II PI3Ks: PIK3C2α and PIK3C2β. PIK3C3 is considered the major enzymatic 
regulator of its production (Herman and Emr 1990, Arcaro, Volinia et al. 1998, Backer 
2008, Meijer and Klionsky 2011).  
There is a single Class III PI3K (PIK3C3/hVps34), discussed in the previous 
chapter, that is associated with PIK3R4/hVps15, and forms numerous complexes with 
other regulatory proteins (Backer 2008). It has been extensively reviewed in the context 
of autophagy, vesicular trafficking and nutrient signaling (Workman and van Montfort 
2010, Bechtel, Helmstadter et al. 2013, Chen 2013). Studies in muscle have shown that 
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PIK3C3 is essential for muscle integrity and proper trafficking in the endo-lysosomal 
pathways (see Chapter 3). 
The Class II PI3Ks function as monomers, and have a higher molecular weight 
compared with other members of the PI3Ks (Falasca and Maffucci 2007). In vitro, the 
class II isoforms preferentially target PtdIns and PtdIns(4)P, and not PtdIns(4,5)P2 
(Arcaro, Volinia et al. 1998), and further studies have shown that PIK3C2α and 
PIK3C2β generate PtdIns(3)P at the plasma membrane of muscle following stimulation 
by insulin (Maffucci, Brancaccio et al. 2003). However, there remains a bit of 
controversy in regards to the specific contributions of the Class II PI3Ks in insulin 
signaling pathways (Soos, Jensen et al. 2001, Falasca, Hughes et al. 2007). 
The different members of the Class II PI3Ks have unique expression patterns and 
different cation specificity in vitro (Arcaro, Volinia et al. 1998). Cell processes that are 
affected by levels of the Class II PI3Ks include cell mobility and adhesion (Domin, 
Harper et al. 2005), immune responses of T-cells through Ca2+-activated K+ channels 
(Srivastava, Di et al. 2009), and even malignant progression of human cancers through 
RhoA and Rac activation (Blajecka, Marinov et al. 2012).  
The Class II γ isoform is not well characterized, and has low expression patterns 
(Rozycka, Lu et al. 1998), but one study has shown a link between PIK3C2γ and type 2 
diabetes in humans, based on single-nucleotide polymorphism (SNP) analyses (Daimon, 
Sato et al. 2008). The primary differences between the Class II α and II β forms have to 
do with their sensitivity to inhibition by wortmannin (Soos, Jensen et al. 2001), and also 
differences in receptivity to insulin and other signals (Falasca and Maffucci 2007, 
Leibiger, Moede et al. 2010).  
Previous studies of PIK3C2β have identified it as a target of epidermal growth 
factor (EGF), leading to nuclear translocation based on a C-terminal motif (Banfic, 
Visnjic et al. 2009). In vitro studies in A-431 cells have demonstrated that PIK3C2β 
forms an association with a multi-protein complex containing Shc, Grb2, Eps8 and Abi1 
to allow stimulation through EGF receptors (Katso, Pardo et al. 2006). PIK3C2β also 
contributes to lysophosphatidic acid (LPA)-mediated cell migration, suggesting a specific 
signaling molecule for activation of PIK3C2β (Maffucci, Cooke et al. 2005).  
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The experiments described in this manuscript follow up on a mouse created by 
Khavari and colleagues that was null for Pik3c2β by means of a germ-line deletion with 
Cre recombinase (Harada, Truong et al. 2005). Their study of that mouse focused 
primarily on the epidermis, and they detected no effect on epidermal growth, 
differentiation, wound healing or barrier function. Likewise, the mice were viable and 
fertile, indicating that PIK3C2β is dispensable for viability and epidermal homeostasis, 
and likely for most vital functions. The goal of the present study is to understand the role 
of PIK3C2β and PtdIns(3)P in skeletal muscle by evaluating a muscle-specific PIK3C2β 




4.3.1 Pik3c2β muscle conditional knockout mice are verified by molecular analyses. 
Conditional knockout mice were generated that lack PIK3C2β in skeletal muscle, 
using Cre driven by the promoter/enhancer for muscle creatine kinase (Ckmm) to 
specifically excise a floxed allele of Pik3c2β, with loxP sites flanking exons 3-5. Mice 
were genotyped using primers described previously (Harada, Truong et al. 2005), and 
crossed to produce homozygous knockout animals. The animals are bred on the common 
BL/6 background. The Pik3c2β conditional knockout (KO) animals have no overt 
phenotypes to distinguish them from their wild-type littermates (WT), even by the end of 
their first full year of life. 
In order to verify the knockdown of PIK3C2β from the Cre recombinase excision, 
we tested levels of Pik3c2β transcript and PIK3C2β protein by qPCR (Figure 4.1A) and 
Western blot (Figure 4.1C,D) respectively. We show a 63% reduction (p < 0.01) in levels 
of Pik3c2β transcript in the knockout mice (KO), normalized to wild type littermate 
controls (WT, Figure 4.1A).  
The primary substrate for PIK3C2β is PtdIns, based on in vivo and in vitro 
analyses (Arcaro, Volinia et al. 1998), and activity of the kinase results in the production 
of PtdIns(3)P. Therefore, we measured PtdIns(3)P of rested animals by a Mass ELISA kit 
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(Echelon), and determined levels to be 951 ± 699 pmol/mg (n=4) for KO animals, 
compared with 5530 ± 1370 pmol/mg (n=7) for WT littermates (Figure 4.1B). This 
further confirmed the effectiveness of the knockout in our animals.  
To assay protein levels of PIK3C2β, lysates were obtained from quadriceps 
muscles of the mice and the protein was analyzed by Western blots (Figure 4.1C). The 
predicted size of PIK3C2β should result in a band at approximately 180 kDa, and this 
band is reduced in the samples from knockout muscle lysates. Quantification of western 
blot by densitometry shows significant reduction (85.2% ± 20.0%, n=3, *:p=0.013) in the 
intensity of the bands at 180 kDa. PIK3C2β is normalized internally to Actin, and the KO 
animals are normalized to WT levels (Figure 4.1D). 
 
4.3.2 Physiological tests show no overt muscular weakness in Pik3c2β knockout mice. 
The transgenic Ckmm-Cre specifically targets the muscle, so we designed 
experiments to test for defects that might not be apparent by observation in 11-month-old 
KO mice and their littermates. For example, average body mass for the two groups of 
animals was not significantly different between KO (26.1 ± 1.0 g, SD, n=5) and WT 
littermates (27.4 ± 1.1 g, SD, n=5) (Figure 4.2A). Mice that had heterozygous deletions 
of Pik3c2β were included in WT groups for body weight, and analyses comparing the 
three groups (WT vs Het vs KO) also showed no significant differences among groups.  
Next, tests of physical strength were performed to detect any weaknesses or subtle 
defects in the health of the muscle. We chose to use a test of grip strength and the rotorod 
test as basic physiological tests of muscle strength and balance. The KO mice performed 
equally as well as their WT littermates on both tests. Measurements of peak grip strength 
were measured to be 0.115±.028g (SD, n=5) for WT, and 0.104±0.020g (SD, n=5) for 
KO mice (Figure 4.2B). The results were not significantly different based on student’s t-
tests.  For the rotorod test, KO mice achieved an average maximum speed of 6.5 ± 1.6 
r.p.m. (SD, n=5) on the first day, while WT littermates reached 8.5 ± 2.4 r.p.m. (SD, 
n=5). On the second day of testing, KO mice improved to 10.5 ± 3.4 r.p.m. (SD, n=5), 
and WT averaged 9.9 ± 3.5 r.p.m. (SD, n=5) (Figure 4.2C). Results for rotorod 
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performance were not significantly different between any two groups, based on multiple 
student’s t-tests or ANOVA. 
In order to obtain better clarity of muscle force, we used more refined tests by 
isolating soleus and extensor digitorum longus (EDL) muscles from 11-month-old KO 
mice and WT littermates. The muscles were attached to force transducers while being 
maintained ex-vivo, and force was measured upon electrical stimulation directly to the 
muscles. We measured absolute force (Figure 4.2F,K), specific force (Figure 4.2G,L), 
and force deficit following lengthening contractions (Figure 4.2H,M) in both soleus 
(Figure 4.2D-H) and EDL (Figure 4.2I-M) muscles, normalizing to muscle mass of the 
individual muscles (Figure 4.2D,E,I,J). None of the measurements were significantly 
different between groups based on statistical analyses.  
 
4.3.3 Muscle histology appears normal in knockout mice. 
In order to assess the muscle for any histological indications of muscle disease, 
cross-sectional samples were examined from a selection of skeletal muscle to compare 
the Pik3c2β KO muscle fibers to that of WT littermates (Figure 4.3). Hematoxylin and 
eosin (H&E) stains enable visualization of nuclei and defects associated with muscle 
disease such as muscular dystrophy (Figure 3.4). There were no observable differences in 
the staining of gastrocnemius (Gast), tibialis anterior (TibA), or quadriceps (Quad) 
between the two groups, as shown in representative samples in Figure 4.3. 
Succinate dehydrogenase (SDH) activity was used as a correlate of oxidative 
capacity, indicating the abundance of ER and mitochondria (Figure 4.3C,D,G,H,K,L). As 
with H&E stains, SDH activity did not appear to be different between KO and WT 
groups. Glycolytic activity was tested using a periodic acid-Schiff (PAS) stain and there 
were no differences when comparing KO to WT samples . 
 
4.3.4 Pik3c2β KO mice have elevated serum levels of creatine kinase. 
After the animals in the study were tested for muscle strength, serum levels of 
muscle creatine kinase (CK) were measured by drawing several drops of blood from the 
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saphenous vein. KO animals showed a small but significant increase in level of CK (258 
± 38 mU/mL, n=4) compared to WT animals (150 ± 18 mU/mL, n=4) (Figure 4.5A). This 
indicates mild muscle damage even in resting mice, independent of stress by exercise on 
treadmill. However, these numbers do not approach those of severely dystrophic muscle, 
which can be above 5000 mU/mL (Figure 3.5A).  
 
4.3.5 Glucose metabolism is abnormal in Pik3c2β knockout mice. 
PI3Ks play a significant role in insulin action and diabetes, through trafficking of 
the glucose transporter, GLUT4, and Akt pathways (Bridges and Saltiel 2012). The Class 
II PI3K, Pik3c2α, is highly regulated by insulin in skeletal muscle, and has a unique role 
in signaling, independent of pathways affected by wortmannin (Soos, Jensen et al. 2001). 
Pik3c2β, however, has not yet been examined in the context of glucose regulation. In 
order to determine the role of Pik3c2β in metabolic processes including glucose disposal, 
we administered a series of experiments to examine glucose levels and other lipids in the 
blood of Pik3c2β knockout mice. The mice were administered acute doses of glucose or 
insulin following a four-hour period without access to food, and drops of blood were 
taken from scratches to the tail.  
KO animals had normal levels of glucose following the fast (185 mg glucose per 
dl blood) compared to WT (177 mg/dl), however there was a significant deficiency in 
their ability to dispose of blood glucose 30 minutes following acute injection (390 mg/dl 
KO compared to 216 mg/dl WT, n=2). Other time points suggested a trend towards 
significantly increased levels of blood glucose through two hours post injection (Figure 
4.5B).  
In order to determine whether the increase in blood glucose in KO animals was 
due to insulin resistance, we tested blood glucose levels of the mice following acute 
injection of 0.75U insulin per kg. Using a very small number of animals (n=2), we saw 
no significant differences in the response to insulin (Figure 4.5C).  
Lastly, we sent blood samples to be tested for lipid analysis, including 
triglycerides, cholesterol and HDL/LDL levels, and we are awaiting results of those 
analyses as of the writing of this manuscript.  
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Table 4.1 Experimental mice 




55 8/24/12 ♀ PIK3C2Bfl/fl; Cre+ KO 
 RR, Gp, 
MF, P3, qP, 
W, HE, 
SDH 
56 8/24/12 ♀ PIK3C2Bfl/+; Cre- WT 
 RR, Gp, 
MF, P3, qP, 
W, HE, 
SDH 
58 (“60”) 9/1/12 ♀ PIK3C2Bfl/+; Cre+ Het 
 RR, Gp, 
MF, P3, qP, 
W, HE, 
SDH 
59 9/1/12 ♀ PIK3C2Bfl/fl; Cre- WT 
 RR, Gp, 
MF, P3, qP, 
W, HE, 
SDH 
60 (“6X”) 9/1/12 ♀ PIK3C2Bfl/fl; Cre+ KO 25.4 
RR, Gp, 
MF, P3, qP, 
W, GTT 
61 9/1/12 ♀ PIK3C2Bfl/+; Cre+ Het 26.3 RR, Gp, MF, P3 




63 9/1/12 ♀ PIK3C2Bfl/fl; Cre+ KO 25.1 
RR, Gp, P3, 
qP, W, GTT, 
ITT, BL 
97 10/22/12 ♀ PIK3C2Bfl/+; Cre+ Het 24.6 BL, ITT, P3, BL 
98 10/22/12 ♀ PIK3C2Bfl/+; Cre- WT 25.4 
RR, Gp, 
MF, P3, qP, 
W, GTT 
100 10/22/12 ♀ PIK3C2Bfl/+; Cre- WT 26.3 
RR, Gp, P3, 
GTT, BL, 
ITT  
MPC 44 5/19/13 ♀ PIK3C2Bfl/fl; Cre+ KO  MC 
MPC 45 5/19/13 ♀ PIK3C2Bfl/+; Cre+ Het  MC 
MPC 46 5/19/13 ♀ PIK3C2Bfl/+; Cre+ Het  MC 







In summary, we have generated muscle-specific Pik3c2β knockout mice and 
provided the first phenotypic description of the role of PIK3C2β in skeletal muscle. 
Knockout mice had reduced levels of Pik3c2β mRNA and (protein) in striated muscle, 
and had significantly reduced levels of PtdIns(3)P, the phospholipid generated by 
PIK3C2β. Using both morphological and functional analyses, we examined potential 
changes in skeletal muscle structure and function and in the overall health of the animals, 
including significant defects in glucose metabolism.  
One of the most significant findings in our study was the discovery of glucose 
intolerance in affected mice. Elevated levels of blood glucose and insulin intolerance are 
some of the main diagnostic criteria for type 2 diabetes or pre-diabetes. Although the 
connection between PIK3C2β and glucose transporter protein 4 (GLUT4) trafficking has 
not previously been reported, one potential mechanism for this elevated blood glucose is 
through a failure of skeletal muscle to properly dispose of glucose. Another Class II 
PI3K, Pik3c2α, has previously been shown to play a role in insulin signaling through 
GLUT4 translocation (Falasca, Hughes et al. 2007, Dominguez, Raimondi et al. 2011). 
Reduction in PtdIns(3)P through overexpression of MTM1 also results in deficiencies in 
GLUT4 trafficking and activation in response to insulin (Chaussade, Pirola et al. 2003). 
These studies and ours would suggest that such a disruption in the PtdInsP pathway result 
in this condition. 
Potential future directions that would address the role of PIK3C2β in metabolic 
disorders could involve altering exercise or dietary regimes, such as food restriction or 
high fat diets. Increased risk of obesity or mortality might indicate a predisposition for 
many of the complications of diabetes. Also, time course measurements of various 
signaling cascades following acute exposure to insulin or growth factors such as EGF 
could determine the role of PIK3C2β in other pathways. Much more will need to be 
learned about the exact effects from loss of PIK3C2β and PtdIns(3)P in regards to 
GLUT4 function and processing. 
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Finally, the relationship between PIK3C2β and MTM1 has been explored 
previously in cell culture studies (Razidlo, Katafiasz et al. 2011). Simultaneous 
knockdown of both genes seemed to alleviate some detrimental signaling pathways in the 
cells. In order to test the hypothesis that reduction in pools of PtdIns(3)P by elimination 
of PIK3C2β may counteract the effects seen from MTM1 knockout, we propose to cross 
knockouts of both genes in a single line of mice.  
4.5 Conclusions 
We present the first study of a mouse with conditional deletion of Pik3c2β in 
muscle. While these mice appear outwardly healthy and viable, we detected significant 
defects in important metabolic processes. Namely, muscle cells in these animals are 
deficient in their ability to dispose of extracellular glucose, indicating complications 
similar to those seen in diabetic and pre-diabetic individuals. Body weight and muscle 
mass relative to body, and specific force of individual muscles showed no significant 
differences in knockout animals from control littermates. We tested the strength and 
endurance of the affected mice, and saw no measurable deficiencies. Elevated levels of 
CK detected in blood serum from resting animals indicate defects in muscle integrity that 
will require further analysis. In all, these mice reinforce the importance of PtdIns(3)P 
regulation in metabolic homeostasis. 
 
4.6 Materials and Methods 
4.6.1 Care and use of animals 
All animals were cared for under the guidance of the University Committee on 
Use and Care of Animals (UCUCA) protocols and assistance by the University of 
Michigan’s Unit for Laboratory Animal Medicine (ULAM), who carefully monitored the 
health of the rodent colonies. Proper environmental regulation including temperature and 
light cycles, unlimited access to water, appropriate food supply, and clean enclosures 
were maintained for the duration of the study. Pups were weaned according to standard 
protocols, and tails were clipped for genotyping. 
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4.6.2 Generation and screening of transgenic lines 
Generation of the mice with the floxed allele of Pik3c2β, obtained from Jackson 
labs (strain 005702), was described previously (Harada, Truong et al. 2005). The Cre 
mice are of the strain: B6.FVB(129S4)-Tg(Ckmm-cre)5Khn/J, obtained from Jackson 
labs (strain 006475). Mice were crossed to make Pik3c2βfl/+; Cre+ heterozygous mice, and 
in-crossed to produce the double floxed allele: Pik3c2βfl/fl, resulting in the muscle-
specific conditional knockout animals. Primers used for verification of genomic 
incorporation of the transgenic cassettes were also described previously (Harada, Truong 
et al. 2005). 
4.6.3 qRT-PCR 
Total mRNA was isolated from muscle homogenates using QIAGEN RNeasy 
kits, and qPCR was performed using cDNA reverse-transcribed by iScript (BioRad) on 
ABI equipment using SybrGreen reagents. Analysis was done by using the 2^-(ΔΔCt) 
method. Primers for Pik3c2β transcripts analyzed include 
AACAAGGACACCTCTGGGAAACCT and GTCGGTTATTGCCAGGTGTTGCAT; 
and for Rpl4 include ACAACAGACAGCCCTATGCC and 
CGTCCCCCACGACACATATT. 
. 
4.6.4 Protein isolation and western analysis 
Protein was isolated from tissue from KO and littermate mice by mincing and 
homogenizing in T-PER buffer (Thermo) with proteinase inhibitors (Roche), with brief 
sonication on ice. Loading buffer was added to protein and run on 10%-15% acrylamide 
gels, followed by transfer to PVDF blots. Primary antibodies were applied overnight at 
4˚C at 1:1000 dilution in 3% BSA, 0.5% TritonX-100, NaF: Anti-PIK3c2β - 
#WH0005287M2 Sigma monoclonal mouse, Immunogen: NP_002637 αα1~111 GST 
tagged (total 185kDa). Anti-Class I PIK3 (p170) complex BD, #611046 mouse IgG1 170 
kDa. Anti-Class II PIK3 type α (H-300): sc-67306 Santa Cruz, Rabbit polyclonal 




Indirect analysis of protein expression was performed in ImageJ following 
procedures outlined by http://lukemiller.org/index.php/2010/11/analyzing-gels-and-
western-blots-with-image-j/. 
4.6.5 Lipid isolation and PtdIns(3)P analysis 
Lipid analysis was performed by indirect analysis of whole muscle lysates using 
Echelon’s PtdIns(3)P Mass ELISA kit (K-3300), as previously described (Pierson, Dulin-
Smith et al. 2012). A Labscan Multiskan Ascent 96-well plate reader was used to 
measure optical readings of color change at 450 nm. 
4.6.6 Histology 
Animals were sacrificed by anesthetic injection followed by cervical dislocation 
and tissues were isolated using sterile surgical methods without the use of laminar flow 
hoods. Muscle tissue from quadriceps and tibia anterioralis was dissected and mounted 
onto small balsawood pieces that were previously frozen with drops of O.C.T. (Optimal 
Cutting Temperature, Tissue-Tek) and then semi-thawed with light friction. The mounted 
muscle tissue was immediately submerged in a -55˚C isopentane bath cooled by liquid 
nitrogen for flash freezing. 
Muscles were cut in 12 µm cross-sections and mounted on SuperFrost Plus slides 
using a Leica cryostat at -20˚C, and dried at room temperature before storage at -80˚C. 
Slides were stained with Mayer’s Hematoxylin and eosin (H&E) following standard 
protocols, and mounted with Permount. Standard protocols were used for succinate 
dehydrogenase reactions to show oxidative staining patterns. Sigma-Adlrich protocol for 
Periodic Acid-Schiff (PAS, procedure no. 395) was followed using the microwave 
procedure for tissue sections. Micrographs were captured with an Infinity1 camera with 
eponymous software visualized through an Olympus BX43 light microscope. Images 
were cropped in Adobe Photoshop and arranged for figures with Adobe Illustrator. 
4.6.7 Rotorod test 
Animals were tested using an accelerating rotorod (Economex, Columbus 
Instruments, Columbus, OH, USA). Mice were placed on the rod which remained 
stationary for 10 s, after which the speed was set at 5 r.p.m. After rotating at a constant 
 
 88 
speed for 60 s, the rod began accelerating at a rate of 0.1 r.p.m./s and continued until the 
animal was unable to remain on the rod. Total time spent on the rod was recorded starting 
from the time the rod began rotating. Mice were given three trials daily for two 
consecutive days. In between daily trials, animals were returned to their cage for a 
minimum of 15 min. A total of five animals were tested for each genotype.  
4.6.8 Measurements of serum CK 
Analyses of CK activity were performed as previously reported (Gumerson, Davis 
et al. 2013). Briefly, serum was collected from the saphenous vein of restrained animals 
and stored at −80°C. CK activity was measured in duplicate using CK NADP Reagent 
(Cliniqa, San Marcos, CA, USA). 
4.6.9 Muscle force measurements 
Extensor digitorum longus and soleus muscles were carefully isolated and 
removed from anesthetized mice. Following the removal of all muscles, mice were 
euthanized with an overdose of anesthetic and induction of a pneumothorax. Muscles 
were immediately placed in a bath of Krebs mammalian Ringer solution with 0.25 mM 
tubocurarine chloride maintained at 25°C and bubbled with 95% O2 and 5% CO2 to 
stabilize pH at 7.4. Using 5-0 silk suture, the distal tendon of the muscle was attached to a 
servomotor (model 305B, Aurora Scientific, Aurora, ON) and the proximal tendon to a 
force transducer (model BG-50, Kulite Semiconductor Products, Leonia, NJ). Muscles 
were stimulated by square pulses delivered by two platinum electrodes connected to a 
high-power biphasic current stimulator (model 701B, Aurora Scientific). A personal 
computer running custom-designed software (LabVIEW 7.1, National Instruments, 
Austin, TX) controlled electrical pulse properties and servomotor activity and recorded 
data from the force transducer. Stimulation voltage and optimal muscle length (Lo) were 
adjusted to give maximum twitch force (Brooks and Faulkner 1988). While held at Lo, 
muscles were subjected to trains of pulses, 300 ms in duration for EDL muscles and 900 
ms for soleus muscles, with increasing stimulation frequency until maximum isometric 
tetanic force (Po) was achieved (Brooks and Faulkner 1988). Lo was measured with 
digital calipers and muscle fiber lengths (Lf) were determined by multiplying Lo by 
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previously established Lf-to-Lo ratios of 0.44 for EDL and 0.71 for soleus muscles 
(Brooks and Faulkner 1988). Total muscle fiber cross-sectional area (CSA) was estimated 
by dividing the mass of the muscle by the product of Lf and 1.06 g/cm3, the density of 
mammalian skeletal muscle. Po was normalized by CSA to give specific Po. 
4.6.10 Blood Glucose Measurements and Insulin Tolerance Tests 
Blood spots were taken from the extreme distal end of the tail and blood glucose 
content was measured using a hand-held glucometer. Immediately following an initial 
baseline reading, either 1 mg/g D-glucose in saline or 0.75 U/kg insulin was injected 
intraperitoneally. Blood glucose (in mg/dl) was measured with AlphaTRAK2 glucometer 
and test strips (Abbott) from venous blood samples, and recorded at each of the time 
points noted. 
4.6.11 Blood Lipid Analysis 
Plasma was isolated by centrifugation from blood taken immediately post 
mortem, and frozen in liquid nitrogen before being shipped on dry ice to Vanderbilt for 
analyses. 
4.6.12 Statistical analysis 
GraphPad Prism 6 was used for calculating significance of fiber size differences 
and TUNEL staining results with unpaired student’s T-tests and one-way ANOVA with a 








Figure 4.1 Pik3c2b knockout in muscle lysates is verified by molecular analyses. 
(A) As measured by quantitative RT-PCR, a significant decrease in Pik3c2β 
transcript levels (37.4% ± 14.8%, n=3) was detected in skeletal muscle from knockout 
(KO) animals. Values were normalized to Rpl4 transcript levels, with wild type (WT) 
average value set at 100% (± 16%, n=3). *:p=0.008. (B) PtdIns(3)P levels are reduced in 
KOs, as determined by using a PtdIns(3)P ELISA kit (purified lipid (pmol)/mass (mg) of 
muscle tissue) (WT: 5528 ± 1367, n=7; KO: 951 ± 699, n=4). *:p=0.017. (C) Evidence of 
reduction in expression of PIK3C2β by western blot. A band at the expected size of 
PIK3C2β can be seen at 180 kDa. (D) Quantification of western blot by densitometry 
shows significant reduction (85.2% ± 20.0%, n=3, *:p=0.013) in the intensity of the 
bands at 180 kDa. PIK3C2β is normalized internally to Actin, and KO normalized to 




Figure 4.2 Physiological measurements of knockout animals show no differences 
from littermates. 
(A) Pik3c2β knockout animals (KO, lighter bars) maintained stable growth and 
normal body mass compared with wild type littermate controls (WT) (n=4 WT; 4 KO). 
(B) Peak grip strength was measured in adult animals and was found to be very similar in 
WT and KO groups. (C) Animals (n = 4 per group) were placed on a stationary rod that 
rotated at a constant speed of 5 r.p.m. for 60 s and began accelerating at a rate of 0.1 
r.p.m./s. The time each animal was able to stay on the rod beginning at rotation onset was 
recorded for three daily trials over 2 days. (D-M) Force measurement readings of isolated 
soleus (D-H) and EDL (I-M) muscles showed no significant differences between KO and 
WT groups regarding muscle mass (MM), muscle mass per body weight (MM/BW), 




Figure 4.3 Basic histological analyses of Pik3c2β-cKO skeletal muscle show no 
aberrant features. 
Representative cross-sectioned muscle from gastrocnemius (Gast, A-D), Tibialis 
anterior (TibA, E-H), and quadriceps (Quad, I-L) of adult female mice are shown above. 
Hematoxylin and eosin stains (H&E; left two columns) and succinic dehydrogenase 
reactivity (SDH; right two columns) show no patterns of aberrant or diseased muscle 





Figure 4.4 Analyses of Pik3c2β-cKO skeletal muscle show no aberrant glycogen 
accumulation. 
Periodic Acid Schiff (PAS) staining of Tibialis anterior muscle in Pik3c2β 
knockout animals (KO) and wild type (WT) littermate controls reveals normal 
distribution of mucopolysaccharides. (A,B) Staining pattern of pararosaniline from 
Schiff’s reagent (pink) is counterstained with hematoxylin (dark purple). (C,D) Prior to 
performing PAS stain, Diastase (α-Amylase) is used to clear polysaccharides as a 





Figure 4.5 Metabolic processes  
(A) Levels of serum creatine kinase were significantly elevated in rested animals. 
Animals were tested at 11 months of age, and PI3C2β knockout (KO) animals averaged 
258 ± 38 mU/mL (n=4), compared with wild-type littermates (WT) that averaged 150 ± 
18 mU/mL (n=4) *:p=0.04. (B) Blood glucose levels were measured over the course of 
time following acute injection of glucose (B) and 0.75 U/kg insulin (C), as a glucose 
tolerance test (GTT) and an insulin tolerance test (ITT), respectively. (B) Blood glucose 
was measured at 0, 5, 15, 30, 60 and 120 minutes following injection of glucose to 
measure disposal rates. There was a significant difference between the groups at 30 
minutes post injection, KO = 390 ± 69 compared to WT = 216 ± 2 (*:p=0.018). Time 
points at 15 minutes (KO = 446 ± 87, WT = 311 ± 3) and 60 minutes (KO = 286 ± 48, 
WT = 160 ± 9) following glucose injection approached significance with p=0.056 and 
p=0.074, respectively (KO n=3, WT n=2). (C) Blood glucose levels following insulin 
injection dropped at approximately the same rate, starting at 189 ± 16 for KO and 150 ± 7 
for WT (p=0.03, n=2), and ending at 85 ± 16 for KO and 94 ± 1 for WT after one hour. 






Conclusions and Future Directions 
 
There is still much to be learned about the role of phosphatidylinositol (PtdIns) 3-
phosphates in skeletal muscle, and the contributions of PtdIns3P kinases, phosphatases 
and effectors during development and muscle activity. The main premise of the work 
described in this dissertation is that the proper regulation of inter-conversion among the 
different PtdInsP isoforms in muscle, particularly between PtdIns(3)P and PtsIns(3,5)P2, 
is important for maintaining muscle function and structural integrity, as deficiencies in 
the process result in diseases such as myotubular myopathy (MTM) and dystrophy, as 
seen in the Pik3c3 conditional knockout mice. While this appears to be true in various 
contexts, dysregulation of the process can manifest in many outcomes. 
 
5.1 Conclusions and future directions for knockout of Fig4 
Null mutations of Fig4 in mice (plt) cause numerous defects that ultimately result 
in rapidly progressive paralysis, including significant muscle atrophy, and early mortality 
(Chow, Zhang et al. 2007). Neuronal rescue of Fig4 results in a correction of this disease, 
not only in the neurons in which FIG4 is present, but also results in rescue of phenotypes 
relating to glia and skeletal muscle, implying that the disease is primarily caused by 
impaired neuronal function (Figure 5.1) (Ferguson, Lenk et al. 2012). Results from the 
work outlined in chapter 2 (Reifler, Lenk et al. 2013) show a restoration of survival, 
muscle fiber size, muscle force, and overall health of animals. 
The connection between FIG4 and the myotubularin protein family, specifically 
MTMR2, had previously been explored as a potential means of counterbalancing adverse 
effects from disruption of the interconversion between PtdIns(3)P and PtdIns(3,5)P2 
(Vaccari, Dina et al. 2011). Measurements of PtdIns(3)P in fibroblasts revealed no 
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significant differences among the different mutant groups. However, levels of 
PtdIns(3,5)P2 from fibroblasts were significantly reduced relative to PtdIns(4,5)P2 in plt 
mice, but had significant increases in Mtmr2 KO mice (Vaccari, Dina et al. 2011). 
Fibroblasts from the plt mice had independently been demonstrated to have significant 
reduction in PtdIns(3,5)P2 relative to total PtdInsP without significant changes to levels 
of PtdIns(3)P (Chow, Zhang et al. 2007). Muscle from Mtm1 KO animals appeared to 
have significant increases in PtdIns(3)P based on measurements from ELISA, although 
PtdIns(3,5)P2 was not examined in those samples (Pierson, Dulin-Smith et al. 2012). The 
key piece of information that hinted that Fig4 KO might counteract effects seen in Mtm1 
mutations came from the Vaccari et al. paper. They showed that relative levels of 
PtdIns(3,5)P2 were significantly reduced in fibroblasts from double knockout animals 
compared to levels in cells from Mtmr2 KO mice, while mice heterozygous for one gene 
and null for the other had levels similar to Mtmr2 KO levels. At the same time, they 
argued that perhaps the effect on levels of PtdIns(3,5)P2 from haploinsufficiency of FIG4 
would be below detection, because Mtmr2-/-Fig4+/- animals showed reductions in myelin 
outfoldings compared with Mtmr2-/- mice. If features of MTM were due primarily to the 
buildup of PtdIns(3)P and/or PtdIns(3,5)P2, then a double knockout of Mtm1 and Fig4 (or 
at least haploinsufficiency of Fig4) might have a positive effect on the Mtm1 mutant 
phenotype. Our results did not confirm this hypothesis, although we were unable to 
measure levels of PtdIns(3,5)P2 in muscle tissue to determine whether we had truly hit 
our intended target (Reifler, Lenk et al. 2013). Also, we did not have data from full 
double knockouts of Fig4 and Mtm1. 
It is possible that MTM1 functions in a different location within the cell than 
FIG4, or at least that the myopathy caused by the mutations is the result of enzymatic 
activity independent of FIG4/PIKfyve/VAC14. The very fact that neural rescue of Fig4 
results in healthy muscle tissue reveals at least that its dysregulation does not affect 
membrane integrity or triad formation. 
There is one unexplored possibility that the mutational insertion in the Fig4 gene 
of plt mice creates some alternately expressed form of Fig4 in muscle, and that another 
product may be able to compensate for the loss of the full length protein in muscle and 
other cells, but not in neurons. This comes from preliminary observations of differential 
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expression in the levels of transcript able to be amplified by qRT-PCR using primer sets 
that target different parts of the message. Furthermore, some antibodies against FIG4 
antigens reveal multiple bands that may represent the protein products of the alternate 
splicing. Of course, the existence of such products must be confirmed before any 
mechanistic conclusions are drawn. 
Taking into account the results of muscle specific knockout of Pikfyve, it would 
be interesting to examine the affect of muscle specific knockout of Fig4 (or Tg-NSE-
Fig4 rescued plt) on glucose tolerance and GLUT4 trafficking (Ikonomov, Sbrissa et al. 
2013). As PIKfyve and FIG4 function in a tight complex, and elimination of FIG4 alone 
can alter the activity of PIKfyve, the Fig4 KO animals could reinforce the importance of 
the equilibrium between PtdIns(3)P and PtdIns(3,5)P2 as a regulator of glucose disposal 
through trafficking of GLUT4 in skeletal muscle (Ikonomov, Sbrissa et al. 2002, 
Berwick, Dell et al. 2004, Duex, Tang et al. 2006, Ikonomov, Sbrissa et al. 2007). 
 
5.2 Conclusions and future directions for conditional knockout of Pik3c3 
In our study of mice with conditional knockout of Pik3c3/Vps34, we determined 
that skeletal muscle of the mice resembled models of autophagic vacuolar myopathies 
and dystrophy. By the end of the second postnatal month, mice became sick and died, 
with highly elevated blood serum levels of creatine kinase (CK) along with defects in 
cardiac and skeletal muscle. Muscle membrane integrity was compromised based on the 
CK readings as well as Evans Blue dye (EBD) uptake and appearance of damaged muscle 
fibers from histological analyses. EBD was not as highly apparent in cardiac muscle, 
indicating that the dystrophic phenotype primarily manifested in skeletal muscle.  
The analyses of cardiac disease matched previous studies of a similar knockout 
animal with targeted deletion of Pik3c3 by another mutation, but with the same 
expression (using the Ckmm promoter to drive Cre recombinase) (Jaber, Dou et al. 2012). 
Both our results and theirs demonstrated significant hypertrophy in cardiac muscle, and 
accumulation of markers of autophagy, such as p62 and LC3. It is believed that the main 
cause of death in these animals is due to heart failure.  
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Our study expanded on the work done previously, and explored the defects seen 
in skeletal muscle. Another study that paralleled our own explored the effects of 
conditional knockout of the regulatory subunit of PIK3C3: PIK3R4/Vps15 (Nemazanyy, 
Blaauw et al. 2013). They used a Human Skeletal Actin promoter driving cre 
recombinase (Acta1-Cre) to selectively delete Pik3r4 in skeletal muscle of mice. Their 
knockout mice reduced levels of PIK3C3, as well as PIK3R4, possibly by destabilizing 
the enzyme, to undetectable levels, or else eliminating auto-activation of the components 
of the complex. As seen in our mice, there was significant induction of p62 and LC3 
(Figure 3.7).  
Due to the fact that mice with deletions of autophagy genes such as Atg7 do not 
present the same type of muscle disease, the question of whether complications from 
Pik3c3 deletion arise from defective autophagy may be partially answered (Nemazanyy, 
Blaauw et al. 2013). The muscle from our knockout animals exhibited similar patterns of 
protein accumulation as seen in lysosomal trafficking diseases, termed autophagic 
vacuolar myopathies (AVMs) (Malicdan and Nishino 2012), also seen in the Pik3r4 
knockout mice (Nemazanyy, Blaauw et al. 2013). 
One of the avenues that we were unable to follow to a satisfactory answer regards 
the specific mechanism for the loss of membrane integrity. We hypothesized that a mouse 
with extremely high serum CK readings would have some sort of defect in membrane 
repair. Therefore, we designed experiments to test the extent of membrane repair, by 
tracking the rate of fluorescent dye into isolated myofibers following injury from high 
intensity focal radiation. Unfortunately, results from the experiments did not adequately 
address the questions we wished to answer, as we had many technical complications, 
such as our difficulty in measuring levels of Pik3c3 expression in any given cell (or 
ability to visualize the presence of Cre) in culture. There was high variability in responses 
to damage from some preparations, and we were unable to satisfactorily complete our 
investigations.  
The search for a definitive mechanistic picture must work to identify the cause 
and disease mechanism of the high CK readings. One step that we have taken is to 
rederive the knockout line on a mouse background expressing Cre recombinase under the 
human skeletal actin (HSA or Acta1) promoter. This produces a mouse much more 
 
 99 
similar to the one studied by Pende and colleagues, and may result in longer-lived mice 
with more identifiable deficiencies in skeletal muscle (Nemazanyy, Blaauw et al. 2013).  
In regards to the Pik3r4 mutant mouse, it would be of great interest to see whether 
effects of mutations in that line are caused by disturbances in physical interactions and 
associations between PIK3C3 and its regulatory subunit, or by direct interference in 
kinase activity. This could be accomplished by expressing constructs of Pik3c3 in the 
knockout mice that contain point mutations in important domains of the protein. 
 
5.3 Conclusions and future directions for mice with conditional knockout of 
Pik3c2β 
I showed in my studies of the muscle specific Pik3c2β knockout mouse that it is 
possible to decrease levels of PtdIns(3)P in muscle without causing structural defects, 
and with only a minor impact on quality of life. These mice were not subjected to 
rigorous exercise or extreme dietary modification, and had free access to standard food 
rations. The major findings from my work showed modest increases in resting serum CK 
levels, and a deficiency in the ability of the mice to dispose of blood glucose. While basal 
levels of the glucose transporter type 4 (GLUT4) transcript and overall protein were 
unaffected as measured by qRT-PCR and Western blot analyses, there are more 
sophisticated assays available to test additional effects on the process. Some of the 
outstanding questions include the following: 
If PtdIns(3)P is significantly reduced, is it only in a particular pool, or are levels 
changed only in a particular subcellular location? What could we learn through isolation 
of a portion of the internal membranes and analyses of the lipid composition, such as 
through fractionation experiments (Andrew, Roses et al. 1973, Smith and Appel 1977)? 
Do the different PI3Ks truly act on different pools of PtdIns to form PtdIns(3)P? Looking 
at comparisons with other animal models, was there any effect from knockout of Pik3c3 
on glucose transport?  
In the continuation of this work, it would be interesting to see the effect of 
Pik3c2β cKO in regards to trafficking of GLUT4 to outer membranes by labeling the 
transporter and monitoring distribution over time following stimulation. Muscle is the 
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primary tissue responsible for postprandial glucose disposal. Previous work has shown 
that PIKfyve knockout in muscle causes impairment in glucose disposal in both oxidative 
(soleus) and glycolytic (EDL) muscles (Ikonomov, 2013). Specifically, basal glucose was 
normal, but insulin-stimulated blood glucose was significantly impaired. Inositol 
isoforms have been shown to generally cause an increase in plasma membrane trafficking 
of GLUT4 (Yamashita 2013). Since the muscle seems to be fairly healthy, it of utmost 
importance to have a clear picture of the overall PtdInsP dynamics.  
In a previous study of Pik3c2β knockout, a null mutant of Pik3c2β was generated, 
and did not display any major disease phenotype, but the emphasis of the study was on 
epidermal cell development (Harada, Truong et al. 2005). It would be interesting to see 
whether metabolic defects are more apparent in another line that does not rely on the 
Ckmm promoter to produce targeted deletion of the gene. Finally, based on results from 
previous research (Razidlo, Katafiasz et al. 2011), one of the more interesting avenues of 
discovery will be the impact of Pik3c2β mutations on human disease, specifically, MTM.  
Their study focused on phosphatases, myotubularin (MTM1) and the MTMR 
family, and the PI3Ks that regulate the equilibrium of PtdIns(3)P in HeLa cells and 
primary cultures of skeletal muscle myotubes (Razidlo, Katafiasz et al. 2011). Their 
findings indicated that MTM1 and PIK3C2β have a unique connection in the regulation 
of caspase 9 and PARP activation through Akt signaling, for while co-knockdown of 
MTM1 with PIK3C2β abrogated apoptotic effects, co-knockdown of other kinases with 
MTM1, including PIK3C2α and PIK3C3, did not have the same effect (Razidlo, 
Katafiasz et al. 2011). These data and others suggested a potential importance of 
PIK3C2β in muscle health, and characterization of an animal model with tissue-specific 
deletion of Pik3c2β on the background of MTM mice. 
 
5.4 Future directions for the study of MTM1 
In order to address the interactions between MTM1 and the other effectors, 
kinases and phosphatases targeting the same substrates and products, my first 
experiments with the Mtm1 mutant mice focused on the potential of Fig4 null or halplo-
insufficiency to abrogate the deleterious effects of the disease (Reifler, Lenk et al. 2013). 
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While the results were not encouraging, we had begun a path with potentially high 
rewards. If we could restore the balance of PtdIns(3)P in the muscle, that might be 
enough to correct the features that are pathognomonic for MTM.  
Therefore, we began crossing lines of mice that possessed Mtm1 knockout with 
PI3K knockouts to attempt to rescue the MTM phenotype. Exciting preliminary data 
show that Pik3c2β KO may improve the disease phenotype of Mtm1-/Y by the following 
standards: The double knockout animals showed increases in survival, with mice 
heterozygous for Pik3c2β on the Mtm1-/Y background surviving slightly longer than 
Mtm1-/Y single knockouts; the double knockout animals showed an amelioration in 
appearance based on early histological analyses. 
Assuming that deletion of Pik3c2β may provide some relief to skeletal muscle 
with mutations in Mtm1, it would be necessary to examine the time course of disease 
progression for treatment. If there is something like a critical window in muscle 
development in which cells rely on MTM1 activity to regulate accumulation of 
PtdIns(3)P, then it may be that inhibition of PI3 kinases would only be required 
temporarily, before their own activity drops to non-pathogenic levels on the Mtm1-/o 
background. 
Pharmacologically targeted inhibition of PIK3C2β without inhibition of 
PI3K/AKT/mTOR pathway may be difficult, as many of the current small molecules 
have low specificity for individual PI3Ks, but it would be highly interesting to see the 
effects (Rodon, Dienstmann et al. 2013). If such an inhibitor could be developed, it would 
be important to test metabolic effects of diet as well, as there is a probability of 
complications similar to diabetes with impaired glucose disposal. Still, if the choice was 
between mortality within the first year of life or diabetic complications, diagnoses of 
Mtm1 mutations may have a very plausible option for treatment. 
 
5.5 Complications in the study of phosphatidylinositol phosphates 
One of the great barriers in our understanding of PtdInsPs is the lack of sufficient 
tools for labeling and visualizing the dynamic inter-conversion among the 
phosphoisoforms. One of the more accurate ways in which the different phosphoisoforms 
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can be quantified relies on the introduction of radiolabeled inositol into the membranes of 
the cell, and normalization to total levels of PtdInsP (Zolov, Bridges et al. 2012). With 
current advances in technology, this has been accomplished by culturing large plates of 
dissociated cells for several days, first starving the cells of inositol, and then introducing 
the radioactively labeled inositol for the cells to metabolize. The cells are then processed 
for their lipid content, and passed through HPLC, for comparative analysis (specific 
isoform over total PtdInsP content). When optimized with high enough signal to noise, 
these results can provide very detailed information about the entire “PtdIns phosph-ome,” 
with relative abundance of any given PtdInsP, assuming equal trafficking of the 
exogenous inositol throughout the membranes of the cell (Zolov, Bridges et al. 2012). 
Unfortunately, while there have been promising advances in treatment of primary cells 
from non-dividing neuronal cultures, our mouse models provide additional barriers, 
particularly as some of the lines do not even express Cre-recombinase until after muscle 
maturation. Additionally, these highly sensitive quantitative techniques do not provide 
information regarding subcellular localization, while being very difficult to apply towards 
mature tissue such as skeletal muscle.   
Technological advances such as Surface Plasmon Resonance (SPR), isothermal 
titration calorimetry, and vesicle sedimentation approaches allow for more precise 
quantification of binding kinetics for recognition domains of specific PtdInsPs (Narayan 
and Lemmon 2006). Probes for individual PtdInsPs, commercially available from biotech 
companies such as Echelon, are marketed as being capable of detecting levels of PtdInsP 
in solubilized lipid extracts from tissue samples by indirect approaches such as in 
enzyme-linked immunosorbent assay (ELISA) (Pierson, Dulin-Smith et al. 2012) and 
other binding assays such as lipid dot blots (Yu, Mendrola et al. 2004), or even for 
visualizing the sub-cellular location of PtdInsPs in situ using indirect immuno-
histological chemistry (IIHC) (Dowling, Vreede et al. 2009). When used as fusion 
proteins with easily identifiable or fluorescent tags, the recognition domains might 
potentially allow for visualization of the PtdInsPs and their intracellular localization in 
real time. 
There are numerous caveats to many of the detection and quantification methods, 
and some techniques require expensive systems and large quantities of lipids. Many 
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techniques rely on non-native interactions between the lipids and the probes, that might 
result in technical artifacts (Narayan and Lemmon 2006). Furthermore, precise 
quantification of PtdInsP levels requires an understanding of the individual isoforms in 
relative terms to one another and possibly to the total levels of lipids and free Ins. This is 
in part because the interconversion among the different isoforms is so dynamic, and in 
part because there is evidence of auto-regulation of some of the kinases and phosphatases 
by levels of specific PtdInsPs.  
Each detection method has its unique advantages and drawbacks, and it is 
important to bear the limitations in mind when attempting a description of the overall 
landscape of the PtdInsPs. It has been suggested that measurement of PtdInsPs should be 
performed by multiple detection methods, when possible, but certain tissues do pose 
greater barriers to some detection methods (Narayan and Lemmon 2006). 
In order to identify subcellular localization of the individual phosphoisoforms in 
skeletal muscle, there are some options that could be used to varying effects. For general 
population analysis of cell organelles, fractionation experiments have been described 
using skeletal muscle from rodents (Smith and Appel 1977, Amoasii, Hnia et al. 2013), 
and could provide additional information on where the kinases, phosphatases and effector 
proteins localize. However, this uses the assumption that these proteins will remain 
relatively affixed to their target, and that the targets remain stable long enough for 
detection. Use of proteomic approaches, such as nano-liquid chromatography-tandem 
mass spectrometry, may give false positives while excluding some of the validated 
interactors (Tsujita, Itoh et al. 2010).  
Alternative approaches to fractionation and proteomic analysis could include the 
use of labeled binding domains of proteins that specifically target individual PtdInsP 
isoforms, or what Echelon protocols refer to as “grip” proteins. Examples of these 
(sometimes proprietary) binding elements are the green fluorescent protein (GFP)-tagged 
constructs of tandem FYVE domains (labeling PtdIns(3)P), of tandem n-termini of the 
TRPML1 channel (labeling (PtdIns(3,5)P2), of PH domains (labeling PtdIns(4,5)P2), and 
others (Gillooly, Morrow et al. 2000, Lodhi, Bridges et al. 2008, Hertel, Switalski et al. 
2011, Samie, Wang et al. 2013). There is still ongoing debate as to the specificity of some 
probes, and we must take on the challenge of visualizing some of the transient products 
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of highly dynamic processes that are of low relative abundance, while they are 
surrounded by hordes of energetic protein complexes. There is an additional worry that 
using these tagged probes for the purpose of visualization could also interfere with 
endogenous processes, producing unwanted artifacts. 
While the focus of this dissertation is on muscle health, PtdInsPs regulate similar 
pathways in other environments, and are often regulated by the same enzymatic reactions. 
Many of the probes that are developed for visualization of PtdInsPs have been optimized 
in cell culture, and in organisms such as yeast. We need to optimize new, reproducible 
techniques for visualizing probes in healthy or diseased muscle, preferably in vivo, 
through transgenics and transiently expressed constructs. In addition to transfection or 
infection of fluorescent protein probes, morpholino technologies have also advanced and 
are capable of localizing to a variety of targets, although they are most useful in 
controlling expression of genes by binding RNA. 
5.6 Overall conclusions 
Enzymes that regulate or interact with PtdIns(3)P and other phosphoisoforms are 
involved in many cellular activities that directly affect muscle development and health. 
Due to the large network of proteins that interact with PtdIns(3)P it is not enough to 
simply describe diseases such as MTM or AVMs simply as displaying defective PtdInsP 
regulation, but may require a greater understanding of specificity in localization and of 
complicated protein to protein and protein complex to lipid dynamics. With advances in 
our ability to visualize and control smaller cellular elements, we will see a clearer picture 






Figure 5.1 Photograph of plt mouse with transgenic rescue of FIG4 in neurons. 
The plt;Tg(NSE-Fig4) mice do not suffer the same effects on muscle health as the 
Fig4 null mice, but are easily distinguished by the color of their coat. Clockwise from 
top: Fig4+/- (heterozygous), Fig4+/+ (wild type), Fig4+/+ (wild type), Fig4-/- (null); all 
expressing transgenic FIG4 under the enolase (NSE) promoter. Mice were photographed 







Al-Qusairi, L., N. Weiss, A. Toussaint, C. Berbey, N. Messaddeq, C. Kretz, D. 
Sanoudou, A. H. Beggs, B. Allard, J. L. Mandel, J. Laporte, V. Jacquemond and A. Buj-
Bello (2009). "T-tubule disorganization and defective excitation-contraction coupling in 
muscle fibers lacking myotubularin lipid phosphatase." Proc Natl Acad Sci U S A 
106(44): 18763-18768. 
Amoasii, L., K. Hnia, G. Chicanne, A. Brech, B. S. Cowling, M. M. Muller, Y. Schwab, 
P. Koebel, A. Ferry, B. Payrastre and J. Laporte (2013). "Myotubularin and PtdIns3P 
remodel the sarcoplasmic reticulum in muscle in vivo." J Cell Sci. 
Amoasii, L., K. Hnia and J. Laporte (2012). "Myotubularin phosphoinositide 
phosphatases in human diseases." Curr Top Microbiol Immunol 362: 209-233. 
Andrew, C. G., A. D. Roses, R. R. Almon and S. H. Appel (1973). "Phosphorylation of 
muscle membranes: identification of a membrane-bound protein kinase." Science 
182(4115): 927-929. 
Arcaro, A., S. Volinia, M. J. Zvelebil, R. Stein, S. J. Watton, M. J. Layton, I. Gout, K. 
Ahmadi, J. Downward and M. D. Waterfield (1998). "Human phosphoinositide 3-kinase 
C2beta, the role of calcium and the C2 domain in enzyme activity." J Biol Chem 273(49): 
33082-33090. 
Avila, G. and R. T. Dirksen (2001). "Functional effects of central core disease mutations 
in the cytoplasmic region of the skeletal muscle ryanodine receptor." J Gen Physiol 
118(3): 277-290. 
Avila, G., J. J. O'Brien and R. T. Dirksen (2001). "Excitation--contraction uncoupling by 
a human central core disease mutation in the ryanodine receptor." Proc Natl Acad Sci U S 
A 98(7): 4215-4220. 
Backer, J. M. (2008). "The regulation and function of Class III PI3Ks: novel roles for 
Vps34." Biochem J 410(1): 1-17. 
Balla, T., M. Wymann and J. D. York (2012). Phosphoinositides. I, Enzymes of synthesis 
and degradation. Dordrecht ; London, Springer. 
 
 107 
Banfic, H., D. Visnjic, N. Mise, S. Balakrishnan, S. Deplano, Y. E. Korchev and J. 
Domin (2009). "Epidermal growth factor stimulates translocation of the class II 
phosphoinositide 3-kinase PI3K-C2beta to the nucleus." Biochem J 422(1): 53-60. 
Bechtel, W., M. Helmstadter, J. Balica, B. Hartleben, B. Kiefer, F. Hrnjic, C. Schell, O. 
Kretz, S. Liu, F. Geist, D. Kerjaschki, G. Walz and T. B. Huber (2013). "Vps34 
deficiency reveals the importance of endocytosis for podocyte homeostasis." J Am Soc 
Nephrol 24(5): 727-743. 
Beggs, A. H., J. Bohm, E. Snead, M. Kozlowski, M. Maurer, K. Minor, M. K. Childers, 
S. M. Taylor, C. Hitte, J. R. Mickelson, L. T. Guo, A. P. Mizisin, A. Buj-Bello, L. Tiret, 
J. Laporte and G. D. Shelton (2010). "MTM1 mutation associated with X-linked 
myotubular myopathy in Labrador Retrievers." Proc Natl Acad Sci U S A 107(33): 
14697-14702. 
Berwick, D. C., G. C. Dell, G. I. Welsh, K. J. Heesom, I. Hers, L. M. Fletcher, F. T. 
Cooke and J. M. Tavare (2004). "Protein kinase B phosphorylation of PIKfyve regulates 
the trafficking of GLUT4 vesicles." J Cell Sci 117(Pt 25): 5985-5993. 
Blajecka, K., M. Marinov, L. Leitner, K. Uth, G. Posern and A. Arcaro (2012). 
"Phosphoinositide 3-kinase C2beta regulates RhoA and the actin cytoskeleton through an 
interaction with Dbl." PLoS One 7(9): e44945. 
Bodine, S. C., T. N. Stitt, M. Gonzalez, W. O. Kline, G. L. Stover, R. Bauerlein, E. 
Zlotchenko, A. Scrimgeour, J. C. Lawrence, D. J. Glass and G. D. Yancopoulos (2001). 
"Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can 
prevent muscle atrophy in vivo." Nat Cell Biol 3(11): 1014-1019. 
Bolino, A., A. Bolis, S. C. Previtali, G. Dina, S. Bussini, G. Dati, S. Amadio, U. Del 
Carro, D. D. Mruk, M. L. Feltri, C. Y. Cheng, A. Quattrini and L. Wrabetz (2004). 
"Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and 
impaired spermatogenesis." J Cell Biol 167(4): 711-721. 
Bonangelino, C. J., N. L. Catlett and L. S. Weisman (1997). "Vac7p, a novel vacuolar 
protein, is required for normal vacuole inheritance and morphology." Mol Cell Biol 
17(12): 6847-6858. 
Boss, W. F. and Y. J. Im (2012). "Phosphoinositide signaling." Annu Rev Plant Biol 63: 
409-429. 
Bridges, D. and A. R. Saltiel (2012). "Phosphoinositides in insulin action and diabetes." 
Curr Top Microbiol Immunol 362: 61-85. 
 
 108 
Brooks, S. V. and J. A. Faulkner (1988). "Contractile properties of skeletal muscles from 
young, adult and aged mice." J Physiol 404: 71-82. 
Bruning, J. C., M. D. Michael, J. N. Winnay, T. Hayashi, D. Horsch, D. Accili, L. J. 
Goodyear and C. R. Kahn (1998). "A muscle-specific insulin receptor knockout exhibits 
features of the metabolic syndrome of NIDDM without altering glucose tolerance." Mol 
Cell 2(5): 559-569. 
Buj-Bello, A., V. Laugel, N. Messaddeq, H. Zahreddine, J. Laporte, J. F. Pellissier and J. 
L. Mandel (2002). "The lipid phosphatase myotubularin is essential for skeletal muscle 
maintenance but not for myogenesis in mice." Proc Natl Acad Sci U S A 99(23): 15060-
15065. 
Cao, C., J. Laporte, J. M. Backer, A. Wandinger-Ness and M. P. Stein (2007). 
"Myotubularin lipid phosphatase binds the hVPS15/hVPS34 lipid kinase complex on 
endosomes." Traffic 8(8): 1052-1067. 
Chakrabarti, S., K. S. Kobayashi, R. A. Flavell, C. B. Marks, K. Miyake, D. R. Liston, K. 
T. Fowler, F. S. Gorelick and N. W. Andrews (2003). "Impaired membrane resealing and 
autoimmune myositis in synaptotagmin VII-deficient mice." J Cell Biol 162(4): 543-549. 
Chaussade, C., L. Pirola, S. Bonnafous, F. Blondeau, S. Brenz-Verca, H. Tronchere, F. 
Portis, S. Rusconi, B. Payrastre, J. Laporte and E. Van Obberghen (2003). "Expression of 
myotubularin by an adenoviral vector demonstrates its function as a phosphatidylinositol 
3-phosphate [PtdIns(3)P] phosphatase in muscle cell lines: involvement of PtdIns(3)P in 
insulin-stimulated glucose transport." Mol Endocrinol 17(12): 2448-2460. 
Chen, J. K. (2013). "PIK3C3/VPS34, the class III PtdIns 3-kinase, plays indispensable 
roles in the podocyte." Autophagy 9(6). 
Chow, C. Y., J. E. Landers, S. K. Bergren, P. C. Sapp, A. E. Grant, J. M. Jones, L. 
Everett, G. M. Lenk, D. M. McKenna-Yasek, L. S. Weisman, D. Figlewicz, R. H. Brown 
and M. H. Meisler (2009). "Deleterious variants of FIG4, a phosphoinositide 
phosphatase, in patients with ALS." Am J Hum Genet 84(1): 85-88. 
Chow, C. Y., Y. Zhang, J. J. Dowling, N. Jin, M. Adamska, K. Shiga, K. Szigeti, M. E. 
Shy, J. Li, X. Zhang, J. R. Lupski, L. S. Weisman and M. H. Meisler (2007). "Mutation 
of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J." 
Nature 448(7149): 68-72. 
Clague, M. J. and O. Lorenzo (2005). "The myotubularin family of lipid phosphatases." 
Traffic 6(12): 1063-1069. 
 
 109 
Codogno, P., M. Mehrpour and T. Proikas-Cezanne (2012). "Canonical and non-
canonical autophagy: variations on a common theme of self-eating?" Nat Rev Mol Cell 
Biol 13(1): 7-12. 
Daimon, M., H. Sato, T. Oizumi, S. Toriyama, T. Saito, S. Karasawa, Y. Jimbu, K. 
Wada, W. Kameda, S. Susa, H. Yamaguchi, M. Emi, M. Muramatsu, I. Kubota, S. 
Kawata and T. Kato (2008). "Association of the PIK3C2G gene polymorphisms with 
type 2 DM in a Japanese population." Biochem Biophys Res Commun 365(3): 466-471. 
Das, S., J. Dowling and C. R. Pierson (2011). X-Linked Centronuclear Myopathy. 
GeneReviews™ [Internet]. A. M. Pagon RA, Bird TD, et al. Seattle (WA): University of 
Washington, Seattle; 1993-2013. 
De Camilli, P., S. D. Emr, P. S. McPherson and P. Novick (1996). "Phosphoinositides as 
regulators in membrane traffic." Science 271(5255): 1533-1539. 
Di Paolo, G. and P. De Camilli (2006). "Phosphoinositides in cell regulation and 
membrane dynamics." Nature 443(7112): 651-657. 
Domin, J., L. Harper, D. Aubyn, M. Wheeler, O. Florey, D. Haskard, M. Yuan and D. 
Zicha (2005). "The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell 
migration by a PtdIns3P dependent mechanism." J Cell Physiol 205(3): 452-462. 
Dominguez, V., C. Raimondi, S. Somanath, M. Bugliani, M. K. Loder, C. E. Edling, N. 
Divecha, G. da Silva-Xavier, L. Marselli, S. J. Persaud, M. D. Turner, G. A. Rutter, P. 
Marchetti, M. Falasca and T. Maffucci (2011). "Class II phosphoinositide 3-kinase 
regulates exocytosis of insulin granules in pancreatic beta cells." J Biol Chem 286(6): 
4216-4225. 
Dove, S. K., F. T. Cooke, M. R. Douglas, L. G. Sayers, P. J. Parker and R. H. Michell 
(1997). "Osmotic stress activates phosphatidylinositol-3,5-bisphosphate synthesis." 
Nature 390(6656): 187-192. 
Dowling, J. J., R. Joubert, S. E. Low, A. N. Durban, N. Messaddeq, X. Li, A. N. Dulin-
Smith, A. D. Snyder, M. L. Marshall, J. T. Marshall, A. H. Beggs, A. Buj-Bello and C. R. 
Pierson (2012). "Myotubular myopathy and the neuromuscular junction: a novel 
therapeutic approach from mouse models." Dis Model Mech 5(6): 852-859. 
Dowling, J. J., S. E. Low, A. S. Busta and E. L. Feldman (2010). "Zebrafish MTMR14 is 
required for excitation-contraction coupling, developmental motor function and the 
regulation of autophagy." Hum Mol Genet 19(13): 2668-2681. 
 
 110 
Dowling, J. J., A. P. Vreede, S. E. Low, E. M. Gibbs, J. Y. Kuwada, C. G. Bonnemann 
and E. L. Feldman (2009). "Loss of myotubularin function results in T-tubule 
disorganization in zebrafish and human myotubular myopathy." PLoS Genet 5(2): 
e1000372. 
Duex, J. E., F. Tang and L. S. Weisman (2006). "The Vac14p-Fig4p complex acts 
independently of Vac7p and couples PI3,5P2 synthesis and turnover." J Cell Biol 172(5): 
693-704. 
Dyson, J. M., C. G. Fedele, E. M. Davies, J. Becanovic and C. A. Mitchell (2012). 
"Phosphoinositide phosphatases: just as important as the kinases." Subcell Biochem 58: 
215-279. 
Falasca, M. (2012). Phosphoinositides and Disease. Dordrecht, Springer Netherlands : 
Imprint: Springer. 
Falasca, M., W. E. Hughes, V. Dominguez, G. Sala, F. Fostira, M. Q. Fang, R. Cazzolli, 
P. R. Shepherd, D. E. James and T. Maffucci (2007). "The role of phosphoinositide 3-
kinase C2alpha in insulin signaling." J Biol Chem 282(38): 28226-28236. 
Falasca, M. and T. Maffucci (2007). "Role of class II phosphoinositide 3-kinase in cell 
signalling." Biochem Soc Trans 35(Pt 2): 211-214. 
Ferguson, C. J., G. M. Lenk, J. M. Jones, A. E. Grant, J. J. Winters, J. J. Dowling, R. J. 
Giger and M. H. Meisler (2012). "Neuronal expression of Fig4 is both necessary and 
sufficient to prevent spongiform neurodegeneration." Hum Mol Genet 21(16): 3525-
3534. 
Ferguson, C. J., G. M. Lenk and M. H. Meisler (2009). "Defective autophagy in neurons 
and astrocytes from mice deficient in PI(3,5)P2." Hum Mol Genet 18(24): 4868-4878. 
Fisher, S. K., J. E. Novak and B. W. Agranoff (2002). "Inositol and higher inositol 
phosphates in neural tissues: homeostasis, metabolism and functional significance." J 
Neurochem 82(4): 736-754. 
Foster, F. M., C. J. Traer, S. M. Abraham and M. J. Fry (2003). "The phosphoinositide 
(PI) 3-kinase family." J Cell Sci 116(Pt 15): 3037-3040. 
Funderburk, S. F., Q. J. Wang and Z. Yue (2010). "The Beclin 1-VPS34 complex--at the 
crossroads of autophagy and beyond." Trends Cell Biol 20(6): 355-362. 
 
 111 
Furuya, N., J. Yu, M. Byfield, S. Pattingre and B. Levine (2005). "The evolutionarily 
conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor 
suppressor function." Autophagy 1(1): 46-52. 
Futter, C. E., L. M. Collinson, J. M. Backer and C. R. Hopkins (2001). "Human VPS34 is 
required for internal vesicle formation within multivesicular endosomes." J Cell Biol 
155(7): 1251-1264. 
Gary, J. D., T. K. Sato, C. J. Stefan, C. J. Bonangelino, L. S. Weisman and S. D. Emr 
(2002). "Regulation of Fab1 phosphatidylinositol 3-phosphate 5-kinase pathway by Vac7 
protein and Fig4, a polyphosphoinositide phosphatase family member." Mol Biol Cell 
13(4): 1238-1251. 
Gibbs, E. M., E. L. Feldman and J. J. Dowling (2010). "The role of MTMR14 in 
autophagy and in muscle disease." Autophagy 6(6): 819-820. 
Gibbs, E. M., E. J. Horstick and J. J. Dowling (2013). "Swimming into prominence: the 
zebrafish as a valuable tool for studying human myopathies and muscular dystrophies." 
FEBS J 280(17): 4187-4197. 
Gillooly, D. J., I. C. Morrow, M. Lindsay, R. Gould, N. J. Bryant, J. M. Gaullier, R. G. 
Parton and H. Stenmark (2000). "Localization of phosphatidylinositol 3-phosphate in 
yeast and mammalian cells." EMBO J 19(17): 4577-4588. 
Glass, D. J. (2010). "PI3 kinase regulation of skeletal muscle hypertrophy and atrophy." 
Curr Top Microbiol Immunol 346: 267-278. 
Grounds, M. D. and T. Shavlakadze (2011). "Growing muscle has different sarcolemmal 
properties from adult muscle: a proposal with scientific and clinical implications: reasons 
to reassess skeletal muscle molecular dynamics, cellular responses and suitability of 
experimental models of muscle disorders." Bioessays 33(6): 458-468. 
Gumerson, J. D., C. S. Davis, Z. T. Kabaeva, J. M. Hayes, S. V. Brooks and D. E. 
Michele (2013). "Muscle-specific expression of LARGE restores neuromuscular 
transmission deficits in dystrophic LARGE(myd) mice." Hum Mol Genet 22(4): 757-768. 
Hakim, S., M. C. Bertucci, S. E. Conduit, D. L. Vuong and C. A. Mitchell (2012). 
"Inositol polyphosphate phosphatases in human disease." Curr Top Microbiol Immunol 
362: 247-314. 
Hamilton, D. L., A. Philp, M. G. MacKenzie and K. Baar (2010). "A limited role for 
PI(3,4,5)P3 regulation in controlling skeletal muscle mass in response to resistance 
exercise." PLoS One 5(7): e11624. 
 
 112 
Han, B. K. and S. D. Emr (2011). "Phosphoinositide [PI(3,5)P2] lipid-dependent 
regulation of the general transcriptional regulator Tup1." Genes Dev 25(9): 984-995. 
Harada, K., A. B. Truong, T. Cai and P. A. Khavari (2005). "The class II 
phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation." Mol Cell 
Biol 25(24): 11122-11130. 
Herman, P. K. and S. D. Emr (1990). "Characterization of VPS34, a gene required for 
vacuolar protein sorting and vacuole segregation in Saccharomyces cerevisiae." Mol Cell 
Biol 10(12): 6742-6754. 
Hertel, F., A. Switalski, E. Mintert-Jancke, K. Karavassilidou, K. Bender, L. Pott and M. 
C. Kienitz (2011). "A genetically encoded tool kit for manipulating and monitoring 
membrane phosphatidylinositol 4,5-bisphosphate in intact cells." PLoS One 6(6): e20855. 
Hnia, K., H. Tronchere, K. K. Tomczak, L. Amoasii, P. Schultz, A. H. Beggs, B. 
Payrastre, J. L. Mandel and J. Laporte (2011). "Myotubularin controls desmin 
intermediate filament architecture and mitochondrial dynamics in human and mouse 
skeletal muscle." J Clin Invest 121(1): 70-85. 
Hnia, K., I. Vaccari, A. Bolino and J. Laporte (2012). "Myotubularin phosphoinositide 
phosphatases: cellular functions and disease pathophysiology." Trends Mol Med 18(6): 
317-327. 
Ho, C. Y., T. A. Alghamdi and R. J. Botelho (2012). "Phosphatidylinositol-3,5-
bisphosphate: no longer the poor PIP2." Traffic 13(1): 1-8. 
Ikonomov, O. C., D. Sbrissa, K. Delvecchio, H. Z. Feng, G. D. Cartee, J. P. Jin and A. 
Shisheva (2013). "Muscle-specific Pikfyve gene disruption causes glucose intolerance, 
insulin resistance, adiposity, and hyperinsulinemia but not muscle fiber-type switching." 
Am J Physiol Endocrinol Metab 305(1): E119-131. 
Ikonomov, O. C., D. Sbrissa, K. Delvecchio, Y. Xie, J. P. Jin, D. Rappolee and A. 
Shisheva (2011). "The phosphoinositide kinase PIKfyve is vital in early embryonic 
development: preimplantation lethality of PIKfyve-/- embryos but normality of 
PIKfyve+/- mice." J Biol Chem 286(15): 13404-13413. 
Ikonomov, O. C., D. Sbrissa, R. Dondapati and A. Shisheva (2007). "ArPIKfyve-PIKfyve 
interaction and role in insulin-regulated GLUT4 translocation and glucose transport in 
3T3-L1 adipocytes." Exp Cell Res 313(11): 2404-2416. 
Ikonomov, O. C., D. Sbrissa, J. Fligger, K. Delvecchio and A. Shisheva (2010). 
"ArPIKfyve regulates Sac3 protein abundance and turnover: disruption of the mechanism 
 
 113 
by Sac3I41T mutation causing Charcot-Marie-Tooth 4J disorder." J Biol Chem 285(35): 
26760-26764. 
Ikonomov, O. C., D. Sbrissa, K. Mlak, M. Kanzaki, J. Pessin and A. Shisheva (2002). 
"Functional dissection of lipid and protein kinase signals of PIKfyve reveals the role of 
PtdIns 3,5-P2 production for endomembrane integrity." J Biol Chem 277(11): 9206-9211. 
Itakura, E., C. Kishi, K. Inoue and N. Mizushima (2008). "Beclin 1 forms two distinct 
phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG." Mol 
Biol Cell 19(12): 5360-5372. 
Itoh, T. and T. Takenawa (2002). "Phosphoinositide-binding domains: Functional units 
for temporal and spatial regulation of intracellular signalling." Cell Signal 14(9): 733-
743. 
Jaber, N., Z. Dou, J. S. Chen, J. Catanzaro, Y. P. Jiang, L. M. Ballou, E. Selinger, X. 
Ouyang, R. Z. Lin, J. Zhang and W. X. Zong (2012). "Class III PI3K Vps34 plays an 
essential role in autophagy and in heart and liver function." Proc Natl Acad Sci U S A 
109(6): 2003-2008. 
Jaber, N., Z. Dou, R. Z. Lin, J. Zhang and W. X. Zong (2012). "Mammalian 
PIK3C3/VPS34: the key to autophagic processing in liver and heart." Autophagy 8(4): 
707-708. 
Jin, N., C. Y. Chow, L. Liu, S. N. Zolov, R. Bronson, M. Davisson, J. L. Petersen, Y. 
Zhang, S. Park, J. E. Duex, D. Goldowitz, M. H. Meisler and L. S. Weisman (2008). 
"VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and 
PI(3,5)P(2) in yeast and mouse." EMBO J 27(24): 3221-3234. 
Johnson, E. E., J. H. Overmeyer, W. T. Gunning and W. A. Maltese (2006). "Gene 
silencing reveals a specific function of hVps34 phosphatidylinositol 3-kinase in late 
versus early endosomes." J Cell Sci 119(Pt 7): 1219-1232. 
Jungbluth, H., C. Wallgren-Pettersson and J. Laporte (2008). "Centronuclear 
(myotubular) myopathy." Orphanet J Rare Dis 3: 26. 
Jungbluth, H., H. Zhou, C. A. Sewry, S. Robb, S. Treves, M. Bitoun, P. Guicheney, A. 
Buj-Bello, C. Bonnemann and F. Muntoni (2007). "Centronuclear myopathy due to a de 
novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene." 
Neuromuscul Disord 17(4): 338-345. 
Katso, R. M., O. E. Pardo, A. Palamidessi, C. M. Franz, M. Marinov, A. De Laurentiis, J. 
Downward, G. Scita, A. J. Ridley, M. D. Waterfield and A. Arcaro (2006). 
 
 114 
"Phosphoinositide 3-Kinase C2beta regulates cytoskeletal organization and cell migration 
via Rac-dependent mechanisms." Mol Biol Cell 17(9): 3729-3744. 
Kihara, A., T. Noda, N. Ishihara and Y. Ohsumi (2001). "Two distinct Vps34 
phosphatidylinositol 3-kinase complexes function in autophagy and carboxypeptidase Y 
sorting in Saccharomyces cerevisiae." J Cell Biol 152(3): 519-530. 
Kukkonen, J. P. (2011). "A menage a trois made in heaven: G-protein-coupled receptors, 
lipids and TRP channels." Cell Calcium 50(1): 9-26. 
Laporte, J., F. Bedez, A. Bolino and J. L. Mandel (2003). "Myotubularins, a large 
disease-associated family of cooperating catalytically active and inactive 
phosphoinositides phosphatases." Hum Mol Genet 12 Spec No 2: R285-292. 
Laporte, J., L. J. Hu, C. Kretz, J. L. Mandel, P. Kioschis, J. F. Coy, S. M. Klauck, A. 
Poustka and N. Dahl (1996). "A gene mutated in X-linked myotubular myopathy defines 
a new putative tyrosine phosphatase family conserved in yeast." Nat Genet 13(2): 175-
182. 
Lecompte, O., O. Poch and J. Laporte (2008). "PtdIns5P regulation through evolution: 
roles in membrane trafficking?" Trends Biochem Sci 33(10): 453-460. 
Leibiger, B., T. Moede, S. Uhles, C. J. Barker, M. Creveaux, J. Domin, P. O. Berggren 
and I. B. Leibiger (2010). "Insulin-feedback via PI3K-C2alpha activated PKBalpha/Akt1 
is required for glucose-stimulated insulin secretion." FASEB J 24(6): 1824-1837. 
Lemmon, M. A. (2003). "Phosphoinositide recognition domains." Traffic 4(4): 201-213. 
Lenk, G. M., C. J. Ferguson, C. Y. Chow, N. Jin, J. M. Jones, A. E. Grant, S. N. Zolov, J. 
J. Winters, R. J. Giger, J. J. Dowling, L. S. Weisman and M. H. Meisler (2011). 
"Pathogenic mechanism of the FIG4 mutation responsible for Charcot-Marie-Tooth 
disease CMT4J." PLoS Genet 7(6): e1002104. 
Lenk, G. M. and M. H. Meisler (2013). "Mouse models with defects in PI(3,5)P2 and 
impaired endolysosome function." Methods Enzymol in press. 
Lindmo, K. and H. Stenmark (2006). "Regulation of membrane traffic by 
phosphoinositide 3-kinases." J Cell Sci 119(Pt 4): 605-614. 
Lodhi, I. J., D. Bridges, S. H. Chiang, Y. Zhang, A. Cheng, L. M. Geletka, L. S. 
Weisman and A. R. Saltiel (2008). "Insulin stimulates phosphatidylinositol 3-phosphate 
production via the activation of Rab5." Mol Biol Cell 19(7): 2718-2728. 
 
 115 
Maffucci, T. (2012). "An introduction to phosphoinositides." Curr Top Microbiol 
Immunol 362: 1-42. 
Maffucci, T., A. Brancaccio, E. Piccolo, R. C. Stein and M. Falasca (2003). "Insulin 
induces phosphatidylinositol-3-phosphate formation through TC10 activation." EMBO J 
22(16): 4178-4189. 
Maffucci, T., F. T. Cooke, F. M. Foster, C. J. Traer, M. J. Fry and M. Falasca (2005). 
"Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration." 
J Cell Biol 169(5): 789-799. 
Malicdan, M. C. and I. Nishino (2012). "Autophagy in lysosomal myopathies." Brain 
Pathol 22(1): 82-88. 
Mammucari, C., G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, S. J. 
Burden, R. Di Lisi, C. Sandri, J. Zhao, A. L. Goldberg, S. Schiaffino and M. Sandri 
(2007). "FoxO3 controls autophagy in skeletal muscle in vivo." Cell Metab 6(6): 458-
471. 
Masiero, E., L. Agatea, C. Mammucari, B. Blaauw, E. Loro, M. Komatsu, D. Metzger, C. 
Reggiani, S. Schiaffino and M. Sandri (2009). "Autophagy is required to maintain muscle 
mass." Cell Metab 10(6): 507-515. 
McCartney, A., Y. Zhang and L. Weisman (2013). "Phosphatidylinositol 3,5-bis 
phosphate: low abundance, high significance." Bioessays in press. 
Meijer, A. J. and D. J. Klionsky (2011). "Vps34 is a phosphatidylinositol 3-kinase, not a 
phosphoinositide 3-kinase." Autophagy 7(6): 563-564. 
Michell, R. H., V. L. Heath, M. A. Lemmon and S. K. Dove (2006). 
"Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions." Trends 
Biochem Sci 31(1): 52-63. 
Millay, D. P., M. Maillet, J. A. Roche, M. A. Sargent, E. M. McNally, R. J. Bloch and J. 
D. Molkentin (2009). "Genetic manipulation of dysferlin expression in skeletal muscle: 
novel insights into muscular dystrophy." Am J Pathol 175(5): 1817-1823. 
Miller, S., B. Tavshanjian, A. Oleksy, O. Perisic, B. T. Houseman, K. M. Shokat and R. 
L. Williams (2010). "Shaping development of autophagy inhibitors with the structure of 
the lipid kinase Vps34." Science 327(5973): 1638-1642. 
Nance, J. R., J. J. Dowling, E. M. Gibbs and C. G. Bonnemann (2012). "Congenital 
myopathies: an update." Curr Neurol Neurosci Rep 12(2): 165-174. 
 
 116 
Narayan, K. and M. A. Lemmon (2006). "Determining selectivity of phosphoinositide-
binding domains." Methods 39(2): 122-133. 
Nemazanyy, I., B. Blaauw, C. Paolini, C. Caillaud, F. Protasi, A. Mueller, T. Proikas-
Cezanne, R. C. Russell, K. L. Guan, I. Nishino, M. Sandri, M. Pende and G. Panasyuk 
(2013). "Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and 
lysosomal disease." EMBO Mol Med 5(6): 870-890. 
Nicholson, G., G. M. Lenk, S. W. Reddel, A. E. Grant, C. F. Towne, C. J. Ferguson, E. 
Simpson, A. Scheuerle, M. Yasick, S. Hoffman, R. Blouin, C. Brandt, G. Coppola, L. G. 
Biesecker, S. D. Batish and M. H. Meisler (2011). "Distinctive genetic and clinical 
features of CMT4J: a severe neuropathy caused by mutations in the PI(3,5)P(2) 
phosphatase FIG4." Brain 134(Pt 7): 1959-1971. 
Nicot, A. S. and J. Laporte (2008). "Endosomal phosphoinositides and human diseases." 
Traffic 9(8): 1240-1249. 
Nishida, Y., S. Arakawa, K. Fujitani, H. Yamaguchi, T. Mizuta, T. Kanaseki, M. 
Komatsu, K. Otsu, Y. Tsujimoto and S. Shimizu (2009). "Discovery of Atg5/Atg7-
independent alternative macroautophagy." Nature 461(7264): 654-658. 
Nishino, I. (2003). "Autophagic vacuolar myopathies." Curr Neurol Neurosci Rep 3(1): 
64-69. 
Nobukuni, T., S. C. Kozma and G. Thomas (2007). "hvps34, an ancient player, enters a 
growing game: mTOR Complex1/S6K1 signaling." Curr Opin Cell Biol 19(2): 135-141. 
North, K. (2008). "What's new in congenital myopathies?" Neuromuscul Disord 18(6): 
433-442. 
Payrastre, B. (2004). "Phosphoinositides: lipid kinases and phosphatases." Methods Mol 
Biol 273: 201-212. 
Pierson, C. R., P. B. Agrawal, J. Blasko and A. H. Beggs (2007). "Myofiber size 
correlates with MTM1 mutation type and outcome in X-linked myotubular myopathy." 
Neuromuscul Disord 17(7): 562-568. 
Pierson, C. R., A. N. Dulin-Smith, A. N. Durban, M. L. Marshall, J. T. Marshall, A. D. 
Snyder, N. Naiyer, J. T. Gladman, D. S. Chandler, M. W. Lawlor, A. Buj-Bello, J. J. 
Dowling and A. H. Beggs (2012). "Modeling the human MTM1 p.R69C mutation in 
murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy 
phenotype." Hum Mol Genet 21(4): 811-825. 
 
 117 
Raben, N., V. Hill, L. Shea, S. Takikita, R. Baum, N. Mizushima, E. Ralston and P. Plotz 
(2008). "Suppression of autophagy in skeletal muscle uncovers the accumulation of 
ubiquitinated proteins and their potential role in muscle damage in Pompe disease." Hum 
Mol Genet 17(24): 3897-3908. 
Raben, N., A. Roberts and P. H. Plotz (2007). "Role of autophagy in the pathogenesis of 
Pompe disease." Acta Myol 26(1): 45-48. 
Rahimov, F. and L. M. Kunkel (2013). "The cell biology of disease: cellular and 
molecular mechanisms underlying muscular dystrophy." J Cell Biol 201(4): 499-510. 
Razidlo, G. L., D. Katafiasz and G. S. Taylor (2011). "Myotubularin regulates Akt-
dependent survival signaling via phosphatidylinositol 3-phosphate." J Biol Chem 
286(22): 20005-20019. 
Reifler, A., G. M. Lenk, X. Li, L. Groom, S. V. Brooks, D. Wilson, M. Bowerson, R. T. 
Dirksen, M. H. Meisler and J. J. Dowling (2013). "Murine Fig4 is dispensable for muscle 
development but required for muscle function." Skelet Muscle 3(1): 21. 
Robinson, F. L. and J. E. Dixon (2006). "Myotubularin phosphatases: policing 3-
phosphoinositides." Trends Cell Biol 16(8): 403-412. 
Rodon, J., R. Dienstmann, V. Serra and J. Tabernero (2013). "Development of PI3K 
inhibitors: lessons learned from early clinical trials." Nat Rev Clin Oncol 10(3): 143-153. 
Romero-Suarez, S., J. Shen, L. Brotto, T. Hall, C. Mo, H. H. Valdivia, J. Andresen, M. 
Wacker, T. M. Nosek, C. K. Qu and M. Brotto (2010). "Muscle-specific inositide 
phosphatase (MIP/MTMR14) is reduced with age and its loss accelerates skeletal muscle 
aging process by altering calcium homeostasis." Aging (Albany NY) 2(8): 504-513. 
Rommel, C., B. Vanhaesebroeck, P. K. Vogt and SpringerLink (Online service) (2011). 
Phosphoinositide 3-kinase in Health and Disease Volume 1. Berlin, Heidelberg, Springer-
Verlag Berlin Heidelberg. 
Rozycka, M., Y. J. Lu, R. A. Brown, M. R. Lau, J. M. Shipley and M. J. Fry (1998). 
"cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-
kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 
12p12." Genomics 54(3): 569-574. 
Samie, M., X. Wang, X. Zhang, A. Goschka, X. Li, X. Cheng, E. Gregg, M. Azar, Y. 
Zhuo, A. G. Garrity, Q. Gao, S. Slaugenhaupt, J. Pickel, S. N. Zolov, L. S. Weisman, G. 
M. Lenk, S. Titus, M. Bryant-Genevier, N. Southall, M. Juan, M. Ferrer and H. Xu 
 
 118 
(2013). "A TRP Channel in the Lysosome Regulates Large Particle Phagocytosis via 
Focal Exocytosis." Dev Cell. 
Sandri, M. (2010). "Autophagy in skeletal muscle." FEBS Lett 584(7): 1411-1416. 
Sbrissa, D., O. C. Ikonomov, Z. Fu, T. Ijuin, J. Gruenberg, T. Takenawa and A. Shisheva 
(2007). "Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate 
synthesis and turnover that regulates the progression of endosomal transport. Novel Sac 
phosphatase joins the ArPIKfyve-PIKfyve complex." J Biol Chem 282(33): 23878-
23891. 
Shen, D., X. Wang and H. Xu (2011). "Pairing phosphoinositides with calcium ions in 
endolysosomal dynamics: phosphoinositides control the direction and specificity of 
membrane trafficking by regulating the activity of calcium channels in the 
endolysosomes." Bioessays 33(6): 448-457. 
Shen, J., W. M. Yu, M. Brotto, J. A. Scherman, C. Guo, C. Stoddard, T. M. Nosek, H. H. 
Valdivia and C. K. Qu (2009). "Deficiency of MIP/MTMR14 phosphatase induces a 
muscle disorder by disrupting Ca(2+) homeostasis." Nat Cell Biol 11(6): 769-776. 
Shin, J., M. M. Tajrishi, Y. Ogura and A. Kumar (2013). "Wasting mechanisms in 
muscular dystrophy." Int J Biochem Cell Biol. 
Smith, P. B. and S. H. Appel (1977). "Isolation and characterization of the surface 
membranes of fast and slow mammalian skeletal muscle." Biochim Biophys Acta 466(1): 
109-122. 
Soos, M. A., J. Jensen, R. A. Brown, S. O'Rahilly, P. R. Shepherd and J. P. Whitehead 
(2001). "Class II phosphoinositide 3-kinase is activated by insulin but not by contraction 
in skeletal muscle." Arch Biochem Biophys 396(2): 244-248. 
Srivastava, S., L. Di, O. Zhdanova, Z. Li, S. Vardhana, Q. Wan, Y. Yan, R. Varma, J. 
Backer, H. Wulff, M. L. Dustin and E. Y. Skolnik (2009). "The class II 
phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel 
KCa3.1 and CD4 T-cells." Mol Biol Cell 20(17): 3783-3791. 
Stack, J. H., P. K. Herman, P. V. Schu and S. D. Emr (1993). "A membrane-associated 
complex containing the Vps15 protein kinase and the Vps34 PI 3-kinase is essential for 
protein sorting to the yeast lysosome-like vacuole." EMBO J 12(5): 2195-2204. 
Stein, M. P., C. Cao, M. Tessema, Y. Feng, E. Romero, A. Welford and A. Wandinger-
Ness (2005). "Interaction and functional analyses of human VPS34/p150 
phosphatidylinositol 3-kinase complex with Rab7." Methods Enzymol 403: 628-649. 
 
 119 
Strahl, T. and J. Thorner (2007). "Synthesis and function of membrane phosphoinositides 
in budding yeast, Saccharomyces cerevisiae." Biochim Biophys Acta 1771(3): 353-404. 
Taylor, G. S., T. Maehama and J. E. Dixon (2000). "Myotubularin, a protein tyrosine 
phosphatase mutated in myotubular myopathy, dephosphorylates the lipid second 
messenger, phosphatidylinositol 3-phosphate." Proc Natl Acad Sci U S A 97(16): 8910-
8915. 
Tosch, V., H. M. Rohde, H. Tronchere, E. Zanoteli, N. Monroy, C. Kretz, N. Dondaine, 
B. Payrastre, J. L. Mandel and J. Laporte (2006). "A novel PtdIns3P and PtdIns(3,5)P2 
phosphatase with an inactivating variant in centronuclear myopathy." Hum Mol Genet 
15(21): 3098-3106. 
Touchberry, C. D., I. K. Bales, J. K. Stone, T. J. Rohrberg, N. K. Parelkar, T. Nguyen, O. 
Fuentes, X. Liu, C. K. Qu, J. J. Andresen, H. H. Valdivia, M. Brotto and M. J. Wacker 
(2010). "Phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) potentiates cardiac 
contractility via activation of the ryanodine receptor." J Biol Chem 285(51): 40312-
40321. 
Tronchere, H., J. Laporte, C. Pendaries, C. Chaussade, L. Liaubet, L. Pirola, J. L. Mandel 
and B. Payrastre (2004). "Production of phosphatidylinositol 5-phosphate by the 
phosphoinositide 3-phosphatase myotubularin in mammalian cells." J Biol Chem 279(8): 
7304-7312. 
Tsujita, K., T. Itoh, A. Kondo, M. Oyama, H. Kozuka-Hata, Y. Irino, J. Hasegawa and T. 
Takenawa (2010). "Proteome of acidic phospholipid-binding proteins: spatial and 
temporal regulation of Coronin 1A by phosphoinositides." J Biol Chem 285(9): 6781-
6789. 
Vaccari, I., G. Dina, H. Tronchere, E. Kaufman, G. Chicanne, F. Cerri, L. Wrabetz, B. 
Payrastre, A. Quattrini, L. S. Weisman, M. H. Meisler and A. Bolino (2011). "Genetic 
interaction between MTMR2 and FIG4 phospholipid phosphatases involved in Charcot-
Marie-Tooth neuropathies." PLoS Genet 7(10): e1002319. 
Vanhaesebroeck, B., J. Guillermet-Guibert, M. Graupera and B. Bilanges (2010). "The 
emerging mechanisms of isoform-specific PI3K signalling." Nat Rev Mol Cell Biol 
11(5): 329-341. 
Vergne, I. and V. Deretic (2010). "The role of PI3P phosphatases in the regulation of 
autophagy." FEBS Lett 584(7): 1313-1318. 
Volpicelli-Daley, L. and P. De Camilli (2007). "Phosphoinositides' link to 
neurodegeneration." Nat Med 13(7): 784-786. 
 
 120 
Wang, L., K. Budolfson and F. Wang (2011). "Pik3c3 deletion in pyramidal neurons 
results in loss of synapses, extensive gliosis and progressive neurodegeneration." 
Neuroscience 172: 427-442. 
Weisman, L. S. (2006). "Organelles on the move: insights from yeast vacuole 
inheritance." Nat Rev Mol Cell Biol 7(4): 243-252. 
Wheeler, M. and J. Domin (2006). "The N-terminus of phosphoinositide 3-kinase-C2beta 
regulates lipid kinase activity and binding to clathrin." J Cell Physiol 206(3): 586-593. 
Whiteford, C. C., C. A. Brearley and E. T. Ulug (1997). "Phosphatidylinositol 3,5-
bisphosphate defines a novel PI 3-kinase pathway in resting mouse fibroblasts." Biochem 
J 323 ( Pt 3): 597-601. 
Willinger, T. and R. A. Flavell (2012). "Canonical autophagy dependent on the class III 
phosphoinositide-3 kinase Vps34 is required for naive T-cell homeostasis." Proc Natl 
Acad Sci U S A 109(22): 8670-8675. 
Winters, J. J., C. J. Ferguson, G. M. Lenk, V. I. Giger-Mateeva, P. Shrager, M. H. 
Meisler and R. J. Giger (2011). "Congenital CNS hypomyelination in the Fig4 null 
mouse is rescued by neuronal expression of the PI(3,5)P(2) phosphatase Fig4." J 
Neurosci 31(48): 17736-17751. 
Workman, P. and R. L. van Montfort (2010). "Unveiling the secrets of the ancestral PI3 
kinase Vps34." Cancer Cell 17(5): 421-423. 
Yamamoto, A., D. B. DeWald, I. V. Boronenkov, R. A. Anderson, S. D. Emr and D. 
Koshland (1995). "Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal 
vacuole function and morphology in yeast." Mol Biol Cell 6(5): 525-539. 
Yan, Y. and J. M. Backer (2007). "Regulation of class III (Vps34) PI3Ks." Biochem Soc 
Trans 35(Pt 2): 239-241. 
Yu, J. W., J. M. Mendrola, A. Audhya, S. Singh, D. Keleti, D. B. DeWald, D. Murray, S. 
D. Emr and M. A. Lemmon (2004). "Genome-wide analysis of membrane targeting by S. 
cerevisiae pleckstrin homology domains." Mol Cell 13(5): 677-688. 
Zhou, X., J. Takatoh and F. Wang (2011). "The mammalian class 3 PI3K (PIK3C3) is 
required for early embryogenesis and cell proliferation." PLoS One 6(1): e16358. 
Zhou, X., L. Wang, H. Hasegawa, P. Amin, B. X. Han, S. Kaneko, Y. He and F. Wang 
(2010). "Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration 
 
 121 
by disrupting the endosomal but not the autophagic pathway." Proc Natl Acad Sci U S A 
107(20): 9424-9429. 
Zolov, S. N., D. Bridges, Y. Zhang, W. W. Lee, E. Riehle, R. Verma, G. M. Lenk, K. 
Converso-Baran, T. Weide, R. L. Albin, A. R. Saltiel, M. H. Meisler, M. W. Russell and 
L. S. Weisman (2012). "In vivo, Pikfyve generates PI(3,5)P2, which serves as both a 
signaling lipid and the major precursor for PI5P." Proc Natl Acad Sci U S A 109(43): 
17472-17477. 
 
 
